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The diverse therapeutic applications of gene therapy are only now being realised. 
One major approach in the treatment of cancer involves immunostimulation. Initial 
studies aimed to deliver vectors containing the genes encoding MHC class II molecules, 
plus the costimulatory molecule B7, to murine melanoma cells, and to establish any 
ensuing antitumour effect. The incorporation of a melanoma-specific promoter, Trp-1, 
into these vectors would confer selective gene expression.
The characterisation of vectors for gene delivery requires correlation between 
physical stability and structure, and biological activity. This study examined the in vitro 
activity of a variety of plasmid DNA-polycation formulations and their physical 
attributes. The polymers examined included a variety of homopolymers, a series of 
lysine, alanine block co-polymers and a series of PEG-polylysine block co-polymers. 
Progressive exclusion of ethidium bromide was used to monitor complexation of DNA 
by polycations using spectrofluorimetry. The charge ratio (+/-) at which condensation 
occurred was established for each polymer to be approximately 1 .0 .
Varying the formulation by using different polycations produced a rank order of 
transfection efficiency in B16 melanoma cells, although no differences were observed in 
the spectrofluorimetry. Transfection activity was shown to be dependent on the 
presence of the endosomolytic agent chloroquine. The prerequisite for chloroquine to 
produce transfection was shown to be a cell-specific effect. Transfection in the absence 
of chloroquine of formulations that produced no gene expression in B16 cells 
demonstrated activity in HEK293 cells.
A strategy was developed to incorporate an endosomolytic component into the 
polycation-DNA complex. Polymers capable of buffering the endosomal acidification 
process have previously been shown to enhance gene expression. A peptide was 
synthesised containing oligolysine for DNA binding and oligohistidine for buffering 
activity at the endosomal pH. No activity was observed after transfection into B16 or 
HEK293 cells in the absence of chloroquine.
Physical characterisation of the different formulations demonstrated that all of 
the systems served to protect the DNA from enzymatic degradation. Polycations were 
shown to exhibit reduced cellular toxicity after complexation to DNA. Analysis of 
complex size revealed no correlation between diameter and transfection activity, 
although sodium chloride was shown to affect the formation of complexes. This is 
believed to be a critical effect in determining the stability of the formulation. The 
uptake of complexes was examined at high charge ratios and in the presence of free 
polycation. Uptake remained unaffected under these conditions, indicating that the 
process was non-selective, and non saturated at these levels. Further investigations 
should concentrate on the processes occurring distal to the cell membrane.
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The understanding of the molecular biological basis of many human diseases has 
led to new therapeutic applications in clinical practice. This revolutionary approach 
arises from rapid advances in laboratory technologies and computer applications, which 
combine to provide a rational understanding of the basis of disease. Gene therapy 
provides us with the tool for treating the cause rather than the chemical or biochemical 
symptoms of a disease. There is the potential to treat both the immediate and the 
downstream effects of gene dysfunction.
Initial interest centred on the treatment of conditions resulting from single-gene 
defects such as cystic fibrosis (Curiel et a l, 1996). Subsequently, alternative 
approaches have evolved to allow the treatment of more complex conditions. These 
include attempts to down-regulate gene expression such as antigene or antisense 
strategies, and enhancement of the host’s immune response to specific cell types, as 
employed in anti-tumour therapy.
This project has concentrated on the immunostimulation of melanoma cells 
using a murine model. The aim of this project was to alter the immunogenicity of the 
melanoma cells by transfection with cDNA’s encoding cell surface molecules involved 
in the presentation of antigen and the costimulatory signal required for T cell activation.
The delivery of genes for therapeutic applications requires a high degree of 
specificity. This can be achieved at two levels: the physical delivery of the gene, and the 
cellular expression. An additional objective of this project involved the use of 
melanoma-specific promoters to drive the expression of the transfected genes. Also, the
1
formulation of non-viral vectors was studied to provide a basic understanding of the 
interactions between DNA and cationic polymers. Characterisation of the 
pharmaceutical properties of these complexes was necessary to allow the further 
development of more complicated and efficient targeted vectors for gene delivery.
1.1 Single gene defects.
The classical application for gene therapy was seen as the correction of a single­
gene disorder by the insertion of an appropriate gene, resulting in the expression of a 
defective protein. Substantial interest currently centres on the disease cystic fibrosis 
(Crystal et a l , 1994). This disease is characterised by deficient electrolyte transport 
through epithelia due to mutations in the cystic fibrosis transmembrane conductance 
regulator gene (Riordan et a l, 1989). This gene encodes a cyclic AMP-regulated 
chloride ion channel (Welsh, 1990).
The major cause of mortality in cystic fibrosis is respiratory disease, due mainly 
to repeated opportunistic lung infection which ultimately leads to fatal inflammatory 
lung disease (Curiel et a l, 1996). Hence, the airway epithelium has been the principle 
target tissue for gene therapy in cystic fibrosis, and in vitro optimisation of the best 
cationic liposome for a DNA delivery vector revealed strong dependence on cell type 
(Caplen et al, 1995b). While the initial clinical studies demonstrated an encouraging 
trend in the partial restoration of electrolyte transfer in the epithelium (Caplen et a l, 




Cancer is a disease where the cells are no longer responsive to the normal 
genetic control mechanisms. The uncontrolled cell proliferation, invasiveness and 
substrate independent growth characteristic of cancer is brought about by multiple 
mutations involving two basic routes: the production of a hyperactive stimulatory gene 
(the transformation of a proto-oncogene into an oncogene) or the inactivation of a 
tumour supressor gene (Bishop, 1991). These changes may arise from a combination of 
hereditary predisposition and as a response to external stimuli (Pike, 1987).
Knowledge regarding the biochemical basis of cancer has led to the application 
of gene therapy for the delivery of targeted cytotoxics or prodrugs to tumours 
(Deonarain et al., 1995). Additionally, gene therapy has been used to deliver genes 
capable of enhancing the host’s immunological response to the cancer cells (Pardoll 
1993; Ostrand-Rosenberg, 1994). These approaches are intended to be more efficient 
and selective than existing chemotherapeutic agents or radiation (Gutierrez et al., 1992), 
reducing the toxicity to normal cells.
Some cancers are exceptionally resistant to traditional treatment by 
chemotherapy and radiotherapy (Malpas, 1991). For example, the treatment of 
malignant melanoma is one of the least successful of all solid tumour treatments 
because of the rapid formation of distant metastases (Dalgleish, 1996). Attempts have 
been made to produce biological therapies such as the specific targeting of cytotoxic 
drugs to melanoma cells using melanocyte stimulating hormone (MSH). Due to the 
rapid degradation of the native peptide in vivo, D-analogues have been synthesised
3
which exhibit enhanced activity profiles (Sahm, 1994). This was believed to be due to a 
higher receptor-binding affinity plus increased resistance to degradation. Malignant 
melanoma was the first cancer in which gene therapy was tried in humans. This 
involved the treatment of patients with advanced cancer using cyclophosphamide, IL-2 
and tumour infiltrating lymphocytes (Rosenberg et al., 1989).
1.2.1. Malignant melanoma.
Malignant melanoma is a rapidly metastasising form of skin cancer which arises 
from the transformation of normal skin melanocytes to a malignant phenotype. Skin 
melanocytes arise from the neural crest (Boissy, 1988) and produce the pigment 
melanin, which they transfer to the surrounding keratinocytes in the epidermis. This 
helps to protect the skin from environmental ultraviolet light damage (Yaar and Gilcrest, 
1991). Increasing exposure to this radiation due to changes in life-style has been linked 
to the current rapid increasing incidence of melanoma (Sanchez and Robinson, 1993).
Transformation of melanocyte cells results in highly migratory and invasive 
cells, which rapidly metastasise to major organs within the body. Additionally, this 
rapid and highly disseminated metastatic spread and resistance of the melanoma tumour 
to most chemotherapeutic regimes is problematic for treatment, resulting in poor patient 
prognosis (Dalgleish, 1996).
There are several predisposing factors including age, exposure to ultraviolet 
radiation (UVR) and the skin type (Elwood et al., 1985). While older people exhibit a 
reduced survival rate, exposure to UVR at a young age or repeated sunburn are serious
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risk factors. Fair-skinned people constitute the majority of melanoma patients, 
especially if they have a large number of moles (melanocytic nevi) or pronounced 
freckling of the upper back (Rigel et a l, 1985). Having more than one of these factors 
significantly increases the risk of developing malignant melanoma.
1.3. Enzyme pro-drug therapy.
The potential of cancer treatments based on genes which activate prodrugs 
within the tumour cells have been discussed in a review by Deonarain et al. (1995). The 
expression of enzymes capable of activating prodrugs in the tumour cells theoretically 
lends itself to the promise of gene therapy. The increased rate of proliferation of 
neoplastic cells is accompanied by a reduction in the level of regulation of DNA 
transcription. Gene therapy by enzyme-prodrug strategies is reliant on the loss of 
control to ensure that upregulated promoters express high levels of the enzymes capable 
of intracellular activation of the prodrugs. Since the enzyme is only expressed 
intracellularly, it does not encounter the immune system; an advantage over antibody- 
directed enzyme prodrug therapy. However, this advantage is offset by the delivery 
problems associated with the presentation of the genes and prodrugs to the intracellular 
compartment.
Alternative strategies for prodrug therapy have involved the generation of 5- 
fluorouracil from 5-fluorocytosine by the enzyme cytosine deaminase (Wallace et a l, 
1994) and the release of doxorubicin from its prodrug by the enzyme (3-glucuronidase 
(Svensson et al, 1995). In both of these cases the delivery of the enzyme was directed 
specifically to the target tumour cells by fusion with antigen-specific monoclonal
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antibodies. Limitations to this approach include the unpredictable toxicity seen in 
clinical trials, and the inability of proteins to readily diffuse into tumour cells, reflected 
by the small quantities of antibodies localised in tumours in human studies.
The tumour-selective expression of a prodrug-activating enzyme was first 
demonstrated by Harris et a l  (1994). This group used the c-erbE2 promoter, which is 
often overexpressed in mammary tumour lines (Hollywood et al, 1993), to restrict 
expression of the enzyme cytosine deaminase to er6B2-positive cell lines. This enzyme 
served to convert 5-fluorocytosine to 5-fluorouracil, which disrupts both DNA and RNA 
synthesis. Many of the mammary tumours were shown to be sensitive to treatment 
using this protocol.
A strategy employing the delivery of a pro-drug to malignant melanoma cells has 
been studied by Bonnekoh et a l (1995). The herpes simplex virus thymidine kinase gene 
was delivered to established melanomas in mice, using an adenoviral vector, sensitising 
the melanoma cells to subsequent administration with ganciclovir. Ganciclovir is 
normally non-toxic, but is converted to a DNA-synthesis inhibitor by thymidine kinase. 
The reduction in growth rate observed was roughly 50%, much higher than expected 
from a parallel in vitro transfection with a reporter gene. This indicated the existence of 
a bystander effect to the treatment. In this case, the bystander effect was reliant on the 
membrane translocation of the active drug between the cells, allowing access to cells 
neighbouring those that were transfected. The adjacent cells were then susceptible to 
the cytotoxic actions of the activated drug. The access is believed to be the result of 
passage through desmosomes between cells.
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1.4. Immunotherapy.
The clinical interface between immunology and oncology has long been 
appreciated. Oncologists have used recently discovered information about the 
functional role of several cell surface molecules in attempts to enhance the endogenous 
immunity of tumours. Approaches to the immunostimulation of tumours have included 
manipulation to augment antigen presentation at the tumour cell surface (Ostrand- 
Rosenberg et al, 1990), stimulation of immunological reactivity by treatment with 
cytokines (Golumbek et al., 1991), or by expression of a costimulatory agent necessary 
for the production of an immune response (Chen et al., 1992).
In contrast to humoral immunity, where antibodies combat microbes in their 
native form in the extracellular body fluids, most of the tumour immunostimulation 
strategies rely on cell-mediated immunity. This involves the activation of T 
lymphocytes by processed antigenic proteins which are associated with the surface of a 
host cell. It is now widely accepted that T-cell responses are the primary target for 
antitumour immunisation protocols, as reviewed by Fathman (1993).
The classical cell-mediated primary immune response involves the endocytosis 
and processing of exogenous antigen by professional antigen presenting cells (APC’s), 
known as dendritic cells or Langerhans cells, or presentation of antigen by macrophages. 
These antigenic peptides are then presented in association with a major 
histocompatibilty complex II (MHC II) molecule to the T cell receptor/CD3 complex on 
the CD4+ T lymphocytes (helper T cells; TH). This interaction produces signal 1 which 
primes the T cell for activation. However, additional signals are required from a variety
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of cell surface adhesion molecules, cytokines and accessory costimulatory molecules to 
begin the cascade of communication between dendritic cells and T cells, and to activate 
the resting T cell (Mueller et a l., 1989). In the absence of costimulation the T cells may 
reach a state of clonal anergy (Jenkins et al, 1991). Activation of the helper T cell 
stimulates production of the cytokine interleukin-2 (IL-2), which causes further 
activation and proliferation of various subsets of T and B cells. Ultimately, this results 
in the initiation of a cell-mediated immune response. The critical interactions between 
dendritic cells and T cells occur in the lymph nodes and these can result in activation of 
naive T cells.
A second type of MHC molecule, MHC I, is expressed by all nucleated cells. 
MHC I molecules directly activate CD8 + T lymphocytes (cytotoxic T cells; CTL) by 
presentation of endogenously produced antigen. Many tumours express endogenously 
produced antigen, and processed viral peptides may be presented by MHC I molecules, 
allowing recognition by cytotoxic T cells. Cytotoxic T cells can also be activated by the 
production of IL-2 by helper T cells. Whereas CD8 + CTL kill their targets in an 
antigen-specific manner, CD4+ Th cells expand the immune response by releasing 
cytokines.
Tumour cells escape the normal host defences, in spite of many of them 
expressing tumour-specific antigens (Hellstrom and Hellstrom, 1991; Boon et al., 
1994). These antigens are derived from normal self-components, but are oyerexpressed 
and exhibit abnormal distribution in metastatic cells. A series of melanoma antigens 
were identified by Van der Bruggen et al. (1991), which were named MAGE and found 
to be expressed in a variety of different melanomas. This group concentrated their 
studies on MAGE-1, in an attempt to discern the level of expression of this antigen
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required to produce effective antigenic peptides. A review by Nossal (1993) described 
the capacity for immunologic tolerance that occurs during tumour progression. It was 
postulated that this could result from an absence of MHC E-restricted tumour antigens 
or from the production of a state of clonal anergy (Nossal and Pike, 1980).
1.4.1. Cancer Vaccines.
In contrast to viral vaccines, tumour vaccines involve the induction of a systemic 
immune response subsequent to the antigenic insult. Due to the patient-specific nature 
of tumour antigens, vaccines are produced using the patient’s own tumour cells. This 
involves removal of the tumour cells from the patient, and cultivation and manipulation 
of the cells ex vivo. The transfected cells are then irradiated to render them incapable of 
further proliferation, before re-introduction to the patient (Morton et al., 1993).
The aim of cancer vaccines is to render the tumour cells more immunogenic, and 
the approaches used to achieve this fall into three categories : expression of MHC-I or 
MHC-E antigens (Porgador et al., 1989; Ostrand-Rosenberg et al., 1990); expression of 
cytokines (Bannerji et al., 1994); delivery of genes coding for costimulatory molecules 
(Chen et al., 1992; Turcovski-Corrales et a l, 1995). A recent approach involved the 
pulsing of bone-marrow-derived dendritic cells with tumour-associated antigens, and 
injection into mice which were subsequently challenged with a lethal tumour burden 
(Mayordomo et al., 1995). In more than 80% of cases, tumour regression was observed 
and tumour free status was maintained.
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1.4.2. Major histocompatibility complex molecules.
If tumour cells could present their own peptides as antigen by the expression of 
MHC class II molecules, T lymphocyte activation might be enhanced. Tumour cells that 
have been transfected with MHC class II molecules demonstrated an increase in tumour 
immunogenicity (Ostrand-Rosenberg et al., 1990). It has been postulated that this effect 
was due to the direct presentation of endogenously synthesised peptides in the context of 
MHC class II molecules to memory TH cells (Topalian, 1994). This approach was based 
on the assumption that the effectiveness of CTL cells was dependent on sufficient help 
from tumour-activated CD4+ T cells to amplify the immune response by the secretion of 
cytokines. The stimulation of CD4+ T cells would also theoretically increase the 
likelihood of antitumour responses at distant metastatic sites. This study attempted to 
genetically engineer the tumour cell to act as an antigen presenting cell, as reviewed by 
Ostrand-Rosenberg (1994). The murine melanoma K1735 was adapted to allow 
presentation of endogenous tumour antigens after transfection with MHC class II genes, 
which activated CD4+ T cells (Chen et al., 1994).
Porgador et al. (1989) showed a reduction in the tumorigenicity of B16 
melanoma after transfection with class I MHC molecules, and that this also converted 
high-metastatic clones into non-metastatic tumours. It was postulated by Giovanni et al. 
(1991) that this reduction in metastatic capacity was due to steric hindrance of cell 
association, in addition to a better interaction with the immune system of the host.
An alternative approach involved the concept of associative recognition (Kenne 
and Foreman, 1982). This proposed that the minor cell surface antigenic differences
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occurring in cancer cells may be insufficient to induce an immune response. This may 
be overcome by the addition of powerful cell-surface antigens by transfection, which 
stimulate a response not only to the exogenous antigens, but also to the original tumour- 
specific antigens (Fearon et al., 1988). Foreign MHC class I genes have been 
transfected in vivo into a variety of tumours in this context, inducing a cytotoxic T cell 
response in mice sensitised to the antigen (Plautz et al, 1993). Additionally, this group 
demonstrated that lymphocytes from these mice were capable of stimulating an immune 
response against genetically unmodified tumour cells.
1.4.3. Cytokine expression.
This strategy is based on the assumption that tumour cells inherently present 
endogenously synthesised tumour peptides in the context of MHC class I molecules. As 
such, they are capable of directly stimulating class I restricted CD8 + T cells, but lack 
sufficient immunogenicity to produce an immune response. The additional expression 
of cytokines that are normally secreted by Th cells or other accessory cells may enable 
CD8 + T cells and other effector cells to be directly activated.
Several groups have analysed the immunogenicity of tumours engineered to 
secrete interleukin-2 (IL-2) (Foa et al., 1992; Bannerji et al., 1994). High levels of IL-2 
expression resulted in increased tumour rejection, and the tumours were found to exhibit 
a massive infiltrate of lymphocytic cells. While CD8 + T cells have been implicated in 
complete tumour eradication, initial tumour suppression was shown to be due to the 
local activation of natural killer cells (Hock et al., 1993). A clinical trial involving the
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use of IL-2 transfected allogeneic melanoma cells has been initiated to assess the anti­
tumour efficacy and toxicity of this kind of treatment regimen and strategy (Osanto et 
a l, 1993).
Zatloukal et a l (1995) have established a receptor-mediated, adenoviral gene 
vector capable of stimulating a systemic anti-melanoma immune response in mice. 
They demonstrated that expression of IL-2 in MHC class IYIT melanoma cells reduced 
the tumorigenicity of the cancer cells. A tumour-specific lytic activity was observed, 
and this was demonstrated to be due to the activation of CD8+ T cells. The challenged 
sites of the immunised mice contained many macrophages and granulocytes, indicating 
that other mechanisms also contributed to the tumour destruction. A long-lasting 
systemic immune response was elicited in syngeneic, euthymic mice.
The majority of studies have involved IL-2, but other cytokines have also been 
employed to stimulate antitumour immune responses. IL-4 has shown anti tumour 
activity in established renal cancer (Golumbek et a l, 1991) while interferon-y (Hock et 
a l, 1993) and tissue necrosis factor-a (TNF-a) (Yannelli et al, 1993) have shown 
similar activity profiles to the other cytokines.
1.4.4. Accessory molecules.
The multi-signal model for lymphocyte activation is now widely accepted 
(Schwartz, 1992). This describes a system where an antigen-specific signal is delivered 
via the antigen receptor, and an antigen non-specific or costimulatory signal is also 
required to determine whether engagement of the T cell receptor (TCR)/CD3 complex
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causes clonal activation or anergy. Costimulation involves several cell surface 
molecules on APC’s, which are recognised by T cell surface receptors.
The cell-surface molecule B7 (CD80) was identified as a ligand for the T cell 
receptors CD28 (Linsley et al, 1990) and CTLA-4 (Linsley et a l , 1991a). 
Subsequently, it was shown that cells transfected with B7 provided co-stimulatory 
signals for activation of T cells (Gimmi et a l, 1991). B7 is normally expressed on 
professional antigen presenting cells i.e. dendritic cells (Freeman et a l, 1989). The co­
stimulatory signal enables the generation and amplification of antigen-specific T cell 
responses (Linsley et a l, 1991b). This is as a result of the increased production of 
various cytokines that have autocrine and paracrine effects on the proliferation, 
activation and maturation of T cells to effector phenotypes. In view of the discovery of 
a second, functionally similar ligand B7-2 (Freeman et a l, 1993), the initial ligand is 
now referred to as B7-1. Several theories have been discussed regarding the differential 
functions of these two molecules, but there is currently no widely accepted mechanism 
described. It has recently been postulated that CTLA-4 and CD28 have opposing 
functions during T cell activation (Finn et a l, 1997).
Chen et a l (1992) demonstrated the capacity for tumour regression subsequent 
to co-transfection with a rejection antigen (associated with the human papillomavirus) 
and B7. Tumour cells expressing only the rejection antigen grew progressively in 
immunocompetent hosts. This rejection pattern has been mirrored in several different 
tumour types (Denfield et al, 1995; Li et a l, 1996), and has been shown to be due to 
direct stimulation of CD8+ T cells (Townsend and Allison, 1993; Iezzi et a l, 1996). In 
contrast to this, Li et a l (1994) reported that activation of CD4+ Th cells was required to
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amplify the tumoricidal response of CD8+ T cells in the immunostimulation of the 
murine melanoma K1735 (Kripke, 1979). This supports the discovery by Chen et al. 
(1994) that the inherent immunogenicity of the tumour, or the immunostimulatory 
activity of any co-transfected antigens determines the activity profile for B7 to induce 
tumour immunity.
Baskar et al. (1995) co-transfected sarcoma cells with syngeneic MHC class II 
genes plus the costimulatory molecule B7. The most efficient tumour rejection occurred 
when both the class II and B7 molecules were co-expressed on the same tumour cell, 
and this response was shown to involve CD4+ and CD8+ T cells. This combines two of 
the previous strategies in an attempt to activate class II-restricted Th lymphocytes to 
stimulate tumour-specific immunity. A recent report by Chong et al. (1996) detailed 
studies of B7 expression in CMT93 murine colorectal tumour and K1735 murine 
melanoma cells. A local antitumour effect was observed in both tumours, although no 
significant systemic immunity was elicited in either tumour. The K1735 tumour is 
mildly immunogenic, but no systemic response was generated, even with co-expression 
of B7 and interferon-y to produce high levels of surface MHC I expression.
1.5. Tissue-specific expression of genes.
Successful gene therapy requires the selective delivery and expression of a 
therapeutic gene to the target cells in vitro and in vivo. Currently available viral and non- 
viral vectors do not provide sufficient specificity for in situ use, but selective expression 
can be effected through manipulation of the transcriptional elements inherent to the
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target cell. This approach involves the use of evolving molecular biological information 
about the control of eukaryotic gene expression, and the diversity of the tissue-specific 
control elements involved in the regulation of expression.
The majority of gene therapy vectors incorporate strong viral promoters that are 
indiscriminate in their cell-line related activity, and are often referred to as promiscuous 
promoters. In contrast, tissue-specific promoters and enhancers are preferentially active 
in certain cell types. Promoters are specific sequences that initiate the contact of RNA 
polymerase with the DNA sequence. The activity of promoters can be altered by 
enhancer sequences located at a distance from the start site of transcription, and these 
enhancers are active when placed in either orientation relative to the promoter .
Huber et al. (1991) demonstrated a system where tumour-specific transcriptional 
control elements were used to regulate expression of unrelated genes. Sikora et al.
(1994) have shown that the promoter of the proto-oncogene c-erbB-2 could specifically 
express a prodrug in tumour cells.
1.5.1. Targeted expression to melanoma cells.
The production of melanin within mammalian cells occurs almost exclusively in 
melanocytes (Riley, 1977), and involves a series of chemical reactions brought about by 
a series of enzymes (Hearing and Tsukamato, 1991). Two promoters have been 
described by Jackson et al. (1991), which normally control expression of the proteins 
tyrosinase (Tyr) and tyrosinase-related protein-1 (Trp-1). Tyrosinase catalyses the 
conversion of tyrosine to dihydroxyphenylalanine (DOPA) and DOPA to dopaquinone
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(Komer and Pawalek, 1982). Trp-1 functions as an oxidase of 5,6-dihydroxyindole-2- 
carboxylic acid (DHICA), producing a carboxylated indole-quinone (Kobayashi et a l,
1994).
Lowings et a l (1992) described both positive and negative elements that 
regulated the Trp-1 promoter, conferring melanocyte-specific gene expression. It was 
postulated that this control involved a highly specific interaction between the AT-rich 
TATA box (usually found about 30 bases upstream of the transcription start site) and a 
multi-component complex comprising the TATA-binding factor and multiple-associated 
proteins. Studies by Shibata et a l (1992a) demonstrated an enhancer-like activity 
displayed by the first intron of the Trp-1 gene, but this was demonstrated not to be a 
tissue-specific effect. It was concluded that this sequence was necessary for efficient 
transcription of the Trp-1 gene in pigment cells.
Work on the Tyr promoter has identified two possible sites for a cell-specific 
enhancer. Shibata et a l (1992b) demonstrated that a sequence located approximately 
1.8 Kb upstream from the transcription start site could enhance the transient expression 
of a reporter gene specifically in melanoma cells. However, Ganss et a l (1994) 
discovered a 200 base pair sequence approximately 12 Kb upstream of the tyrosinase 
gene which displayed strong cell-specific enhancement. This group also showed, by 
protein binding, the presence of a melanoma-cell-specific complex that could contribute 
to the cell-specific activity, although the exact nature of the factor interacting with the 
binding motif has yet to be elucidated.
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Vile and Hart (1993a) have shown that the promoters Tyr and Trp-1 are 
preferentially active in melanocytic cells. Further development involved the expression 
of the herpes simplex virus thymidine kinase under the control of the tyrosinase 
promoter to established murine melanomas in vivo (Vile and Hart, 1993b). Expression 
of this gene sensitises the tumour cells to subsequent administration of ganciclovir, 
which is phosphorylated by the kinase to an intermediate capable of disrupting DNA 
synthesis. Vile and Hart (1995) have also shown successful in vitro selective expression 
of cytokine genes to malignant melanoma cells using the tyrosinase promoter. The 
intratumoural injection of a selection of cytokines under the control of the tyrosinase 
promoter showed no significant reduction in tumour growth, although RNA levels 
demonstrated that 1% of the tumour population were expressing the exogenous genes. 
Chong et al. (1996) have developed a tissue-specific expression vector where the 
murine B7 gene is driven by the 5’ promoter of the murine tyrosinase gene (Vile and 
Hart, 1993a) for expression studies in the melanoma cell line K1735.
Atruc et al. (1995) have performed similar work to Vile and Hart, demonstrating 
reporter gene upregulation in a variety of melanoma cells lines. Use of the tyrosinase 
promoter produced upregulation of approximately 21-fold, while a combination of the 
melanocyte-specific enhancer and tyrosinase promoter increased expression by up to 
154-fold. Gene expression was strongly associated with the capacity for the cells to 
synthesise melanin.
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Tissue-specific enhancers are capable of enhancing the promoter activity of an 
unrelated promoter, and this method has been used to enhance the weak tissue-specific 
expression of a gene under the control of the Tyr promoter. The Tyr enhancer has been 
linked to viral promoters to effect the strong expression of genes in a tissue specific 
manner (Dr. R. Vile, personal communication).
1.6. Gene delivery.
Pharmaceutically, the greatest challenge associated with gene therapy is the 
production of an efficient gene transfer vehicle. The aim is to maximise the therapeutic 
potential of genes, while creating a product that resembles a conventional 
pharmaceutical formulation in terms of composition, characterisation, safety and clinical 
application (Ledley, 1995). Inherent are the problems associated with the in vivo 
delivery of macromolecules and the many biological barriers that have to be overcome. 
In addition, immunogenicity and reticuloendothelial clearance must be considered 
during product development.
1.6.1. The optimal gene transfer vehicle.
The achievement of efficient in vivo gene delivery would dramatically increase 
the applications of gene therapy. A basic requirement of any such system is that the 
therapeutic gene must be reproducibly expressed in the target cells to produce 
subsequent expression of the gene in an appropriate manner (Mitani and Caskey, 1993).
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The initial step of transfection of the target cell population must ultimately result in 
efficient gene transit across several biological barriers to the interior of the nucleus to 
produce functional activity. Successful transfection requires that the gene gains access 
to the cell population. It must then transit across the plasma membrane and cytoplasm 
before gaining nuclear entry (Michael and Curiel, 1994).
Davies et al. (1993) showed that in contrast to the belief that viral promoters 
acted non-specifically in cell lines, distinct differences were observed both in the levels 
and time over which this expression was sustained. This selectivity in promoter activity 
requires consideration when designing vectors to ensure optimal transcription within the 
target population. An ideal gene therapy delivery vector would require the inclusion of 
several intrinsic characteristics combining the attributes of a marketable pharmaceutical 
product with the desired biological activity (Michael and Curiel, 1994; Smith et al., 
1996):
(i) to ensure reproducible, efficient gene delivery to the target population of cells.
(ii) to include a means of target selectivity, whether through delivery or expression.
(iii) to transit several biological barriers, delivering DNA from the exterior of the 
cell to the nucleus.
(iv) to ideally contain no viral gene sequences, hence reducing any safety issues 
intrinsically associated with viruses.
(v) to be non-toxic, non-immunogenic and biodegradable.
(vi) to be pharmaceutically acceptable : to be physically,chemically and biologically 
stable; to be reproducibly manufactured; to be well-characterised.
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1.6.2. Approaches to delivery for gene therapy.
All current vectors for gene therapy are based on either viral transduction or 
transfection using particulate or physical methods. Much research has focused on gene 
delivery using recombinant viruses, capitalising on their natural capacity to transport 
their genetic material into target cells. The attractiveness of non-viral systems compared 
with viral delivery centres around their ease of manipulation, their safety and stability on 
storage, which has led to the development of several non-viral approaches.
1.7. Viral vectors.
The work by Westphal et al. (1968) demonstrated the capacity of polyoma 
viruses to transfer viral DNA to the nuclei of transformed cells. Since then, many 
studies have involved the manipulation of this inherent property of viruses for the 
delivery of foreign DNA to eukaryotic cells. Successful gene delivery has been 
achieved with recombinant viral vectors developed using both RNA and DNA viruses, 
including retroviruses (Ferry et al., 1991), adenoviruses (Karlsson et al., 1985) and 
herpes simplex virus-1 (Geller and Breakefield, 1988). The majority of viral vectors for 
in vivo gene therapy are either retroviruses or adenoviruses, although a vector has 




Retroviruses carry their genetic information as RNA. Retroviral infection 
involves internalisation of the host cells, effected by the viral envelope protein. 
Subsequent to infection, the RNA genome is reverse-transcribed into DNA which 
integrates at a random position into the host’s genomic DNA. Retroviral vectors are 
composed of an RNA copy of the exogenous gene contained within the envelope of a 
replication deficient retrovirus, as detailed by Eglitis and French Anderson (1988).
This kind of delivery vector has several safety concerns associated with it 
(Temin, 1990). The intrinsic problems include a high rate of mutations during viral 
replication capable of inactivating the therapeutic gene; recombination to produce 
replication-competent virus; expression of viral genes with the potential to activate 
proto-oncogenes in the infected cells. Packaging cell lines have been developed which 
are replication defective (Le Gal La Salle et a l, 1993). The cells contain the pro viral 
DNA of a helper virus but the signal that normally packages the viral DNA into virions 
has been removed. This serves to reduce the expression of inherent viral genes. Further 
development of such packaging cell lines has reduced the likelihood of recombinatorial 
events to produce wild-type virus (Miller and Buttimore, 1986).
Retroviral infection is dependent on the target cells being actively replicating at 
the time of infection (Miller et a l, 1990). This may have profound effects on transfer in 
situ, where the rate of cell division is far lower than in culture. Additionally there is a
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size constraint of a maximum of 6-7 Kb (Eglitis and French Anderson, 1988) that can be 
packaged within the virion, which may restrict the applications for which this system is 
suitable.
A study by Porter et al. (1996) compared the efficiency of infection of different 
cells by a variety of retroviruses. The envelopes borne by these retroviruses were 
capable of recognising different receptors on human cells, and hence exhibited varying 
specificities for a selection of cell lines. Previously, retroviral vectors for gene therapy 
have used either envelopes from the murine leukaemia virus, MLV-A (Miller and 
Buttimore, 1986), or gibbon ape leukaemia virus, GALV (Meller et al., 1991). The 
feline endogenous virus RD114 (Takeuchi et al., 1994) was shown to be the most 
universally efficient system. Also, unlike other retroviruses, the RD114 envelope was 
shown to be stable and retain activity in serum.
Despite the safety concerns, retroviruses currently remain the most widespread 
delivery system utilised in gene therapy clinical trials, although many of the transduction 
events are carried out ex vivo. Retroviral vector producer cells have been used (Kun et 
al., 1995) for the in vivo delivery of the HSVtk gene to malignant brain tumour cells. 
This trial was designed to establish the treatment load of vector producer cells required 
to produce successful tumour regression upon injection of the prodrug ganciclovir. An 
alternative use was in a gene marking study of patients with acute leukaemia carried out 
by Cornetta et al. (1996) to determine whether transplanted marrow contributed to 
patient relapse.
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Retroviral vectors remain the most popular choice for gene therapy clinical trials 
because of the efficiency of delivery which they provide. It is however widely 
recognised that the risk of recombination of the attenuated viruses back to the wild type 
i.e. replication competent, is unacceptable. Hence, vector-producing cell lines require 
extensive testing for replication competency before use. In spite of the numerous 
mutations employed in the quest to produce safer retroviral vectors, it appears likely that 
they will eventually be replaced as in vivo gene therapy vectors by synthetic or 
particulate delivery systems.
7.7.2. Adenoviruses.
Adenoviruses are non-enveloped DNA viruses which are approximately 80-90 
nm in diameter, and have a double-stranded DNA genome of 36 Kb in length. There are 
several serotypes of adenovirus, and types 2 and 5 have been extensively studied as a 
model for eukaryotic gene expression. Infection with wild-type adenovirus commonly 
results in upper respiratory tract infections, the ‘common cold’ (Straus, 1984). Only 
replication-defective adenoviruses are deemed suitable for gene therapy, and these are 
created by deletion of the El early transcriptional region. Adenoviral vectors are 
capable of accommodating 7.5 Kb foreign DNA by deletion of the El and the E3 region 
(Berkner, 1988).
In contrast to retroviruses, adenoviruses can transfect non-dividing cells, and 
have been shown to produce high levels of expression in hepatocytes (Jaffe et al., 1992)
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and terminally differentiated neurones (Le Gal La Salle, 1993). These viruses do not 
usually integrate into the genome of the host cell, and therefore act by producing 
transient expression. Therapeutically, this necessitates repeated administration, 
increasing the risk of stimulating an immune response against the delivery vehicle (Yei 
et al., 1994). Further development by Bramson et a l (1996) has produced a double 
recombinant adenoviral vector capable of expressing the heterodimeric cytokine 
interleukin-12 in vivo and in vitro.
Adenoviruses exhibit highly promiscuous tropism, allowing widespread 
transduction after systemic in vivo delivery. Approaches to effect targeted delivery have 
involved extensive studies where the adenovirus has been coupled to transferrin- 
polylysine/DNA complexes (Wagner et a l, 1992a). This combined the delivery aspects 
of the virus with the facility to restrict uptake to cells expressing transferrin receptors, 
such as hepatocytes. An alternative approach has involved the production of a 
recombinant adenovirus vector with modified fibres (Krasnykh, 1996). These fibres 
contain cell recognition domains, and the production of chimeric fibres has been shown 
to alter the receptor recognition profile, providing a means of generating cell-specific 
targeting.
Adeno-associated vectors (AAV) were developed for clinical use as they are not 
associated with any human disease, and are able to infect a wide range of cell types 
(Flotte and Carter, 1995). This naturally defective, single-stranded DNA parvovirus 
generally requires co-infection with a helper virus for replication. In the absence of 
helper virus, the AAV genome integrates into the host chromosome. The lack of a
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strong intrinsic promoter reduces the possibility of unwanted activation of downstream 
sequences. A major disadvantage was the inefficient process of vector production, but 
an improved titre was shown by Mamounas et al (1995), involving co-infection with a 
‘helper’ adenovirus.
1. 7.3. Herpes simplex viruses.
The ability of herpes simplex virus (HSV) to infect neurones has led to initial 
gene therapy investigations for delivery to post-mitotic cells, as found in the nervous 
system, using HSV vectors. The vectors used have either been disabled to inhibit 
growth except in a complementing cell line, or to rely on a helper virus for replication 
and packaging into virus particles (Stevens, 1975). In vitro studies have involved 
delivery of a reporter gene to cultured peripheral neurones, achieving almost 100% 
transfection (Geller and Breakfield, 1988). Recent developments have included the 
delivery of HSV 1 ICP34.5 deletion mutants to the nervous systems of mice (Coffin et 
al., 1996). The infection was shown to be avirulent, yet the reporter gene was expressed 
close to the inoculation site. This was in contrast to wild-type infection where transgene 
expression was low, and found far from the inoculation site. This was an indication of 
the quick spread of the wild-type virus from cell to cell.
1.8. Non-viral delivery.
There are several advantages to the use of non-viral vectors over viral vectors for 
gene therapy. These include their resemblance to conventional pharmaceutical products
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in terms of their composition, characterisation and safety, as reviewed by Ledley (1995). 
Non-viral vectors rely on the delivery of plasmid DNA. Plasmid DNA has exhibited 
activity after intramuscular injection (Wolff et a l, 1992) and more recently in melanoma 
cells after intratumoural injection (Yang and Huang, 1996). Not all tissues are capable 
of taking up and expressing free plasmid DNA, and hence much effort has concentrated 
on the generation of carrier systems. Unlike the viral vectors, there is little or no size 
constraint on the DNA with non-viral vectors.
The main biological challenge of non-viral gene delivery is that plasmid DNA is 
negatively charged. The physical properties of a particle within the body determine 
distribution and the extent of interaction with biological membranes. Several 
formulation theories and methods that were developed for controlled delivery of small- 
molecule drugs using particulate systems have been adapted and applied to gene 
delivery to cells. These systems include the use of cationic liposomes or particulate 
systems for the complexation of DNA expression vectors to deliver therapeutic genes in 
vivo. These systems rely on cellular mechanisms for import and nuclear transport of the 
DNA. Further developments of the systems currently in use will involve a greater 
appreciation of the fate of exogenous DNA both within the body and within the cell.
1.8.1. Liposomes.
Cationic liposomes were pioneered by Feigner et al. (1987) as gene delivery 
vectors. The variety of lipids currently available for liposome formation consist of 
molecules with spacers of differing lengths and a variety of positively charged head
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groups (usually a single or multiple amine group), as reviewed by Gao and Huang
(1995). This cationic nature allows interaction with the anionic DNA. Use of excess 
cation results in the formation of positively charged complexes which can interact non- 
specifically with the negatively charged cell surface. The DNA structure has been 
shown to collapse into a condensed form at charge neutralisation (Gershon et al., 1993), 
and a further electron microscopy study of complex formation revealed a very 
heterogeneous population of complexes (Zabner et al., 1995). Differences in structure 
of the liposome have been shown not to affect the type of DNA-vesicle association 
(Gustafsson etal., 1995).
It was initially believed that uptake of liposome-DNA complexes was via fusion 
with the cell membrane (Zhou and Huang, 1994), but recent evidence has suggested that 
endocytosis is the major mechanism of entry (Zabner et al., 1995 ; Friend et al., 1996). 
The question of the fate of these complexes after internalisation has been addressed by 
several groups, and Friend et al. (1996) detailed extensive liposome-membrane 
interactions throughout the cytoplasm. It has been demonstrated that the complexes 
produced a membrane-destabilising effect, which subsequently allowed the anionic 
lipids present on the cytoplasmic edge of cellular membranes to displace the DNA from 
the liposome (Xu et a l, 1996).
Many studies have concentrated on the use of liposomes for gene therapy 
applications, as reviewed by Lasic and Templeton (1996). Initial in vitro transfection 
results produced high levels of reporter gene expression, but these levels were highly 
dependent on the DNA-liposome complex formulation and the cell type transfected
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(Caplen et al., 1995a). pH-dependent liposomes have previously demonstrated 
enhanced cytoplasmic delivery of macromolecules (Connor and Huang, 1986) due to the 
destabilisation of the liposome bilayer at acidic pH within the endosome. Legendre and 
Szoka (1992) showed that cationic liposomes were superior to pH-sensitive liposomes, 
indicating that the cationic liposomes used an alternative delivery pathway into the cell.
Clinical trials for the treatment of cystic fibrosis have used cationic liposome 
vectors for delivering DNA to the nasal epithelium (Caplen et al., 1995b). A 
comparative study of the in vitro and in vivo activity of liposome-DNA complexes for 
cystic fibrosis gene therapy has revealed that the choice of viral promoter can enhance 
the levels and duration of expression (McLachlan et a l, 1995). Evaluation of the 
aerosol delivery of this vector has shown that a more stable DNA-lipid complex is 
required than that currently in use (Schwartz et a l, 1996). The use of cationic 
liposomes as systemic vectors in vivo is restricted by their lack of stability in serum and 
as pharmaceutical entities.
1.8.2. Poly cationic polymers.
Smull and Ludwig (1962) showed that some basic proteins were capable of 
enhancing poliovirus RNA delivery to eukaryotic cells. Interest in the interactions 
between protamines and histones with DNA led to parallel studies with cationic 
homopolymers (Olins et al., 1967; 1968). These physical and chemical studies 
demonstrated that the DNA was stabilised and condensed into a toroid by the interaction 
with polycationic polymers. Binding of DNA to the cationic polypeptides
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resulted in structural phase transitions, which gave very different profiles to free DNA 
when analysed by electrophoretic sedimentation (Tsuboi et al., 1966). The interactions 
were discovered to be co-operative with 1:1 stoichiometry with respect to amine and 
phosphate groups.
Initial adsorption and uptake studies of polycation-DNA complexes were 
performed by Farber et al. (1975). It was shown that several polycationic polymers 
were able to enhance the uptake of exogenous DNA into eukaryotic cells and that 95% 
of the DNA became nuclear-associated within 15 minutes. This rapid nuclear delivery 
now seems highly misleading. This group also demonstrated that optimal activity was 
seen when sufficient basic polymer had been added to neutralise the negative charge on 
the DNA.
In contrast to liposome-DNA complexes, the mechanisms of uptake of 
polycation-DNA systems have not been elucidated. It is generally accepted that non­
specific mechanisms are used to accomplish cellular internalisation. Problems with the 
use of polycation-DNA complexes alone for gene therapy are associated with inefficient 
cellular uptake and the delivery steps distal to the cell membrane. Consequently, 
relatively low levels of expression are obtained compared with viral vectors. 
Mechanisms of overcoming these inefficiencies include the addition of a receptor ligand 
to provide a means of targeting the delivery to a specific cell type (Cotten et al., 1993), 
or the use of endosomolytic agents to enhance DNA release into the cytoplasm, such as 
inactivated adenovirus (Curiel et al., 1991) or peptides (Plank etal., 1994).
The development of more elegant vectors for gene therapy, often described as 
self-assembly vectors, involves the combination of several moieties with different
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functions: cell targeting, DNA-binding, endosomal release, nuclear delivery.
Polycationic polymers have already shown their DNA-binding capacity (Olins et al., 
1966), and they are also capable of conferring protection to the DNA from nuclease 
degradation (Chiou et al., 1994). Hence, the cationic polymers provide the DNA- 
binding moiety, and can be conjugated to molecules which will provide other functions 
in the resultant ‘artificial viruses’ for gene delivery.
This approach has been used at a basic level for cationic liposomes. The 
incorporation of polycations at appropriate ratios into cationic liposome-DNA mixes has 
been shown to alter complex formation and biological activity (Gao and Huang, 1996). 
Vitiello et a l (1996) have also shown that condensation of plasmid DNA with 
polylysine prior to formation of DNA-liposome complexes produced enhanced delivery 
and expression in muscle cells. This enhancement was found to be particularly evident 
for transfections performed in the presence of serum, as the polylysine served to both 
condense the DNA and protect it from enzymatic degradation.
1.8.3. Receptor-mediated polycationic DNA delivery.
The receptor-mediated delivery of a DNA-polycation complex was first studied 
by Wu and Wu (1987). The polycation acted as a DNA carrier while the covalently 
coupled ligand served to target the system to the receptor. Similar studies by several 
other groups (Wagner et al., 1990, 1991; Zenke et al., 1990; Gottschalk et a l, 1993) 
have shown that with a variety of ligand-receptor systems, specific receptor-mediated
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uptake was maintained after covalent attachment of the DNA-polylysine complex to the 
ligand. Once bound to the receptor, the whole complex was internalised via receptor- 
mediated endocytosis (Wagner et a l, 1994).
Asialoorosomucoid was covalently linked to a polylysine-DNA complex and 
delivered to hepatoma cells expressing asialoglycoprotein receptors in a receptor- 
dependent manner (Wu and Wu, 1988). Successful in vivo delivery was achieved 
specifically to hepatoma cells following intravenous injection (Wu et a l, 1991) The 
majority of the exogenous gene was discovered in cytoplasmic vesicles, and seen to be 
DNase resistant (Chowdhury et a l, 1993).
Receptor-mediated gene transfer of polycation-DNA complexes has also been 
successfully performed using galactose (Midoux et al, 1993), insulin (Rosenkranz et 
a l, 1992), an integrin-binding peptide (Hart et a l, 1996) and most extensively with 
transferrin (Wagner et a l, 1990). Transfection of the transferrin-polylysine-DNA 
complexes has further been enhanced several hundred-fold by the presence of glycerol 
or ethylene glycol during transfection (Zauner et a l, 1996). This effect is believed to 
arise due to the interaction of glycerol with cell membranes (Fraley et a l, 1981). This 
approach has also been applied to the cationic liposome, lipofectin. Addition of the 
receptor-ligand transferrin was able to enhance the transfection of HeLa cells from 4% 
for lipofectin alone to 98% (Cheng, 1996).
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1.8.4. Enhancing endosomal release.
The majority of gene delivery methods rely on endocytosis for entry into the cell. 
Subsequent to endocytosis, the DNA passes into the endosome, where rapid enzymatic 
degradation can occur. Methods that enhance the release of the DNA before the 
lysosome and endosome fuse (the point at which the nucleases are introduced) would 
serve to enhance nuclear delivery and gene expression.
One approach involved the use of polymers that possessed a substantial 
buffering capacity below physiological pH, and which were potentially capable of 
producing membrane disruption. The main successful examples of these include the 
polyamidoamine cascade polymers developed by Haensler and Szoka in 1993, the 
interpolyelectrolyte complexes (IPEC’s) produced by Kabanov and Kabanov (1995), 
and the organic macromolecule polyethyleneimine used by Boussif et al. (1995).
These polymers are all based on polycations, so retain the DNA-binding and 
protective properties of polylysine. Although the structures of these polymers differ, 
they all share the feature of residues that are protonatable at physiological pH. Their 
action as a network of effective ‘proton sponges’ allows them to disrupt the endosome 
(Stenseth and Thyberg, 1989). In order to ensure cellular delivery, the resulting 
polycation-DNA complexes required an overall positive charge, but in order to see an 
endosomolytic advantage, much higher polycation/DNA ratios were necessary (roughly 
4-8) than for the polylysine-DNA systems. This resulted in a high density of active 
groups within the endosome to provide the proton sponge effect, and cause membrane 
disruption.
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Adenoviruses have developed efficient mechanisms for host cell infection. 
These mechanisms have been utilised to enhance polycation-DNA complex delivery by 
the use of whole inactivated adenoviruses (Wagner et a l , 1992a) and in the 
development of fusogenic peptides mimicking the action of peptides involved in viral 
infection (Wagner et al., 1992b).
Expression studies involving the enhanced delivery of transferrin-polylysine 
gene vectors due to co-infection with adenovirus sparked an interest in the merging of 
viral and non-viral vector properties (Curiel et a l, 1991; Cristiano et a l, 1993). 
Adenoviral particles induced endosomal lysis during the process of infection 
(Blumenthal et al, 1986). Co-intemalisation of the complexes and adenoviral particles 
in the endosome allowed release of the DNA after the endosome had been lysed due to 
the viral particles. The trans delivery of adenovirus and transferrin-polylysine/DNA 
complexes used transcription- and replication-defective virus, because the gene was not 
carried within the genome of the adenovirus particle (Cotten et a l, 1992). This 
removed the size constraint on the delivery vector, as well as enhancing the safety 
profile of the system.
Rapid progress by this group produced a construct where the adenovirus was 
coupled directly to the transferrin-polylysine/DNA (Wagner et a l, 1992). Transfection 
levels of virtually 100% were achieved in both HeLa cells and murine hepatocytes. This 
vehicle contains moieties to package nucleic acids (polylysine), for cell attachment and 
receptor-mediated endocytosis (transferrin) and an endosomolytic agent (adenovirus).
34
Successful in vitro transfection of primary canine cells and epithelial cells in 
haemophilia B (Lozier et al., 1994), primary fibroblasts in haemophilia A (Zatloukal et 
al, 1993), and in vivo transfection of airway epithelium (Gao et al., 1993) have also 
been demonstrated.
It was only a small step to the use of specific fusogenic peptides in place of the 
entire virus, and initial studies involved the use of the influenza haemagglutinin HA-2 
N-terminal peptide fragment (Wagner et a l, 1992). Approximately 10% of the HeLa 
cells transfected showed expression of the reporter gene after 48 hours. Although this 
shows a reduced efficiency compared with the complete adenovirus, this system is 
favoured as an in vivo gene therapy vector for safety reasons. Further analysis of the 
adenoviral cell entry mechanism by Cotten and Weber (1995) revealed that a viral 
protease is required for the proteolytic processing of the virus capsid to ensure effective 
pH 5-induced membrane disruption in the endosome. Potentially, this shows that viral 
particles lacking the capacity to produce the viral proteases may exhibit reduced 
efficiency of gene delivery compared with full adenoviral particles.
1.9. Second generation non-viral vectors.
It is widely accepted that second generation non-viral delivery vectors will need 
to incorporate some attributes of viral particles. While the non-viral vectors are efficient 
at condensing the DNA, major shortfalls in their design centre around endosomal release 
after internalisation and uptake into the nucleus. Information regarding viral infection 
mechanisms has allowed the development of fusogenic peptides capable of conferring 
the viral uptake profile onto non-viral vectors.
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The initial studies involved the use of the HA-2 peptide (Wagner et a l,  1992b). 
This idea has been further developed by the use of synthetic endosome-disruptive 
peptides (Plank et a l, 1994). This work utilised the further knowledge gained about the 
fusogenic properties of the influenza haemagglutinin peptide. It was shown that the 20- 
N-terminal amino acids of this peptide exhibited activity only when an additional 
amphipathic helix was included.
Gottschalk et al. (1996) have designed and synthesised two peptides to emulate 
the functions of viral proteins: a DNA-condensing agent and an amphipathic, pH- 
dependent endosomal releasing agent. The replacement of the polylysine as the DNA- 
binding agent was due to the heterogeneity displayed in commercially available samples. 
Hence, its replacement was to ensure the production of more homogeneous and well- 
characterised complexes. The synthetic DNA-condensing peptide was based on the 
highly efficient DNA-condensing agent spermine. The number of lysine residues was 
varied in an attempt to discover the minimum size required for DNA binding.
The novel amphipathic peptide was designed after analysing many influenza 
fusion sequences and other fusion peptides, and using molecular modelling. The 
amphipathic peptide was a prototypic pH-dependent peptide for rupturing endosomes. 
The gene delivery system was created by stepwise self-assembly, and achieved high 
levels of gene expression in several cell lines. This system does not include a receptor 
ligand, and the inclusion of transferrin failed to increase expression by more than 8-fold.
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Fominaya and Weis (1996) have produced a recombinant fusion protein based 
on the multidomain structure of the bacterial Pseudomonas exotoxin A. This consists of 
three functional domains : a single chain antibody capable of producing target cell 
specificity, the exotoxin domain capable of endosomolysis, and a DNA binding domain 
based on a yeast protein. In this case the DNA-binding domain was unable to facilitate 
uptake alone. The DNA required condensation and compensation of the negative charge 
with polylysine. The complexes that were spontaneously formed with the fusion protein 
were shown to be capable of transfecting cells in a ligand-specific manner in vitro. This 
demonstrates the advances currently being made towards more highly characterised and 
reproducible systems, where the non-viral vectors are acquiring advantageous viral 
attributes.
1.9.1. Nuclear localisation.
Bonner (1975a) demonstrated that certain proteins were capable of entering and 
accumulating in the nucleus of frog oocytes by translocation through the nuclear pores, 
which was attributed at the time to passive diffusion. However the fact that the nuclear 
protein histone is synthesised in the cytoplasm (Borun et al., 1967) and then transported 
to the nucleus suggested the presence of a selective transport mechanism across the 
nuclear membrane (Bonner, 1975b). Moreland et al. (1987) discovered that a single 
amino acid substitution in the sequence of yeast histone 2B completely abolished
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nuclear localisation. Additionally, it was shown that there is a large degree of 
conservation of this sequence in a variety of species, and that this sequence is lysine- 
rich.
Further studies by Breeuwer and Goldfarb (1990) demonstrated that the earlier 
belief that small nucleophilic proteins like histone HI diffused into the nucleus were 
incorrect, as no transport occurred if the cells were chilled or energy depleted. This 
indicated that localisation within the nuclei occurred via a receptor-mediated process, 
and precluded the diffusion of proteins through the nuclear pores.
Recently, much work has been performed to elucidate the mechanisms of 
nuclear protein import, reviewed by Melchior and Gerace (1995). Transport across the 
nuclear envelope is mediated by large supramolecular structures which span the 
membrane, called the nuclear pore complexes. Small ions and metabolites diffuse freely 
through the nuclear pore complex, while most macromolecules are transported through 
gated channels via signal- and energy-dependent mechanisms. Nuclear localisation 
sequences of amino acids have been identified, and while there is no consensus 
sequence, they are highly enriched in basic amino acids (Dingwall and Laskey, 1991). 
Receptors for these nuclear localisation sequences have been identified, capable of 
stimulating transport of the protein into the nucleus (Adam and Gerace, 1991).
Strategies for DNA delivery have been developed incorporating this information. 
Histones, which naturally bind nuclear DNA, were galactosylated so as to act as 
asialoglycoprotein receptor-targeted DNA carriers (Chen et al., 1994). The histones 
contain their own intrinsic nuclear localisation sequences, and galactosylated histone HI
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was shown to exhibit superior transfection efficiency over other modified histone groups 
and non-nuclear proteins. Additionally, Conary et a l (1995) have shown that the use of 
synthetic peptides, containing a nuclear localisation signal, with liposome vectors can 
enhance transgene expression.
It seems clearly apparent that future developments will attempt to incorporate the 
viral attributes known to be advantageous to gene delivery and expression into the non- 
viral vectors already in use. Hence, we see development towards a synthetic virus-like 
delivery vector, some way between the current viral and non-viral vehicles.
1.10. Aims and Objectives.
The immunotherapeutic approach to tumour gene therapy has produced several 
encouraging preliminary results. Interest now centres on the production of cell- 
mediated immune responses, through the activation of T cells specific for both MHC 
class I and MHC class II restricted tumour antigens. Many of the patients presenting 
with cancer have immune systems that have become functionally tolerant to any tumour 
antigens which may be present at the tumour cell surface. Information about antigen 
processing, presentation and T cell regulation have allowed the use of approaches to 
break this tolerance by the stimulation of more potent immune responses.
Becker et al. (1993) demonstrated that a human melanoma cell line that 
expressed MHC class II induced clonal anergy in CD4+ T cells. Transfection of the 
melanoma cells with the co-stimulatory molecule B7 stimulated IL-2 production and T
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cell proliferation. Additionally, Chen and Ananthaswamy (1993) showed that the 
murine melanoma cell line K1735 required the expression of MHC class I antigen and 
either class II antigen or the presence of IL-2 to effect rejection in syngeneic mice.
The primary aim of this project was to create a tissue-specific immunotherapy 
for the treatment of melanoma. The approach to be used was that of co-expressing 
MHC class II molecules and B7-1 in the murine melanoma cell line K1735. An 
expression vector containing the B7-1 gene under the control of the tissue-specific 
promoter Trp-1 (Jackson et al., 1991) was to be used to create stable transfectants. This 
required preliminary experiments to establish the suitability of the Trp-1 promoter for 
this study using the reporter gene p-galactosidase. Further experiments are described 
aimed at selection of stably transformed clones of K1735 expressing B7-1 and MHC 
class II genes. In practice, problems were encountered in producing stable expression, 
which are discussed in Chapter 2.
The delivery of genes for therapeutic purposes requires that the vector is safe, 
efficient and well-characterised. The additional objective of this project was to further 
the physical and biological characterisation of the interaction between polycations and 
DNA. The use of cationic polypeptides for condensation of DNA has been widely 
documented (Wagner et al., 1991; Midoux et a l, 1993, Hart et al., 1996). An 
understanding of the physicochemical interactions occurring will allow the development 
of non-viral self assembly systems, composed of several functional moieties. Each 
separate component will have its own function: to deliver the DNA to target cells; to 
bind and protect the DNA from degradation; to release the DNA from the cytoplasm; to 
direct uptake into the nucleus.
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The characterisation of the DNA binding by cationic polypeptides in this study 
attempted to correlate physical attributes with biological activity. A variety of cationic 
polypeptide-DNA complexes were compared, both in their physicochemical properties, 
and their biological activities. The optimal charge-ratio (+/-) was established for each 
system. A comparison of the physical properties of the optimum systems and the 
inefficient systems was made. Measurement of such factors as the DNA condensation 
capacity, particle size, protection of the DNA from degradation, and uptake and 
association of the complexes with cultured cell lines was carried out to clarify the 
interactions involved. This study will form the basis for optimisation of the DNA- 
binding moiety for an ultimately more complicated self-assembly system containing 
several other functional components.
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CHAPTER 2. Tissue-specific expression of immunostimulants in 
melanoma cells
2.1. INTRODUCTION
The advent of gene therapy has revolutionized the approach to the treatment of 
various diseases, including cancer. Gene therapy allows alteration of the genotype of 
individual cells, hence affecting both the cell’s phenotype and interaction with other 
cells within the organism. For cancer treatment, most interest has revolved around 
immunotherapies, which rely on stimulation of the host’s immune system to recognise 
and eliminate tumour cells (as reviewed by Fathman, 1993). Several studies have 
involved the transformation of tumour cells with cytokines, MHC antigens or co­
stimulatory molecules, so that they act as antigen-presenting cells. This serves to 
activate T cells in a manner similar to the classical immune response (Ostrand- 
Rosenberg, 1994).
Malignant melanoma is one of the more difficult cancers to treat successfully 
due to the rapid formation of distant metastases. Experimental studies have shown that 
transfection of melanoma cell lines with the co-stimulatory molecule B7 (CD80) have 
resulted in antitumour responses (Chen et a l , 1992; Townsend et a l, 1994; Iezzi et a l,
1996). However, it has recently been demonstrated that this effect may be accompanied 
by a reduction in systemic antitumour immunity (Chong et a l, 1996). An alternative 
protocol used MHC class I and II antigens to stimulate tumour immunity against murine 
melanoma (Chen and Ananthaswamy, 1993). A study by Baskar et a l (1995) 
demonstrated rejection of established sarcoma tumours after transformation with both
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MHC class II plus B7 genes, and this activity was shown to be more effective than 
strategies using B7 alone.
This study aimed to examine the co-expression of MHC class II genes and B7 in 
the melanoma cell line K1735. Additionally, incorporation of a tissue-specific 
promoter, Trp-1 (Jackson et al., 1991), upstream of the B7 gene, was planned to restrict 
the expression of the B7 gene to cells undergoing melanogenesis. This would serve to 
reduce gene expression in non-target cells, increasing the therapeutic benefit to the 
patient.
2.2. MATERIALS AND METHODS
2.2.1. Bacterial strains.
General cloning procedures using the vectors pRSWlacZ, pCEXV-3 (Ak) and 
pPGKPuro (Dr. M. Welham, Department of Pharmacology, University of Bath, UK) 
were performed using the host strain E. coli XLl-Blue (Stratagene). Cloning procedures 
using the mammalian expression vector pcDNA3 (Invitrogen, San Diego, CA, USA) 
were performed using the host strain E. coli TOPI OF’ (Invitrogen, San Diego, CA, 
USA). Amplification of the vector containing the murine B7 gene (Dr. R. Vile, ICRF, 
St. Thomas’ Hospital, London), piLN-murB7 was performed using the host strain E. 
coli MC1061/P3 (Invitrogen, San Diego, CA, USA).
Bacterial growth media and other solutions are defined in appendix A. Growth 
media plates were produced by the addition of 15% Bacto Agar (Difco) to the media of 
choice prior to autoclaving. The solution was cooled to 55°C, and antibiotics were 
added (section 2.2.4) before pouring into 90 mm polystyrene petri dishes.
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2.2.2. Plasmid vectors.
The melanoma-specific expression experiments were performed using the Trp-1- 
(3-Gal vector, which was supplied by Dr. I. Hart (ICRF, St. Thomas’ Hospital, London, 
UK). This contains 4.8 kb of the Trp-1 promoter and the first Trp intron, inserted 
upstream of an SV40 splice donor/ acceptor sequence, the p-galactosidase gene, and the 
SV40 polyadenylation sequence (Fig. 2.2).
Control expression studies were carried out using the mammalian expression 
vector pRSYlacZ (7.8 kb), kindly supplied by Dr. D. Ogilvie (Zeneca Pharmaceuticals, 
Alderley Edge, Cheshire, UK.). This contains the Rous sarcoma virus long terminal 
promoter / enhancer sequence, which drives expression of the E. coli p-galactosidase 
reporter gene (Fig. 2.1).
Initially, it was planned that the Trp-1 promoter would be inserted into the 
promoterless mammalian expression vector pNASSp (Clontech). This allows cloning 
and testing of promoters using p-galactosidase expression. This vector contains an 
SV40 RNA splice site, a polyadenylation sequence and the E. coli p-galactosidase gene 
(Fig. 2.1).
The cDNA’s for the a  and p chains of the MHC I-Ak were a gift from Dr. S. 
Rosenberg (Department of Biological Sciences, University of Maryland, Baltimore, 
Maryland, USA). The genes were supplied as subcloned inserts at the EcoR I site in the 
mammalian expression vector pCEXV-n (Fig. 2.1; Miller and Germain, 1986). The 
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Figure 2.2. Plasmid maps of vectors. A:pcDNA3 after ligation of murine B7 gene; B: pPGKPuro; C: 
basic structure of construct containing the Trp-1 promoter obtained from Dr. I. Hart.
2.2.3. Preparation of electrocompetent E. coli.
A primary overnight culture of E. coli cells was diluted 1:100 in 500 ml LB 
medium and incubated until the OD600 reached 0.5 - 1.0. The cells were briefly chilled 
on ice then centrifuged at 4000 g for 10 min at 4°C using a Beckman J2-MC centrifuge. 
Extensive washing with water reduced the ionic strength of the cell suspension : 500 ml 
ice cold sterile water, 250 ml ice-cold sterile water, 10 ml sterile ice cold 10% glycerol, 
and finally resuspending into 1.0 ml of 10% glycerol. Electrocompetent cells were snap 
frozen in 40 |il aliquots in Cardice/methanol and stored at -70°C until required.
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The murine B7 gene (0.93 kb) was supplied by Dr. R. Vile (ICRF, St. Thomas’ 
Hospital, London, UK), in the vector piLN-murB7 (Fig. 2.1). This was inserted into the 
mammalian expression vector pcDNA3 (Invitrogen) at the Hind III and Xba I sites in the 
multicloning site (Fig. 2.2). The plasmid pPGKPuro (Fig. 2.2) was received as a gift 
from Dr. M. Welham (Bath University, Bath, UK). Both of these plasmids were used 
for selection of stable transformants by use of the neomycin and puromycin resistance 
markers respectively, as described in section 2.2.18.3.
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2.2.4. Transformation of E. coli by electroporation.
Prior to transformation, the electrocompetent cells were thawed slowly on ice. 
Chilled plasmid DNA (up to 1 pg in water) was added, and the mixture was pipetted 
into a sterile pre-chilled 0.2 cm electroporation cuvette (Bio-Rad Laboratories, 
Richmond, CA, USA). The cuvette was placed in the chilled cuvette holder of a Bio- 
Rad Gene Pulser and subjected to the standard conditions of 2.5 KV, 200 £2 and 25 
pFarads (Dower et al., 1988), producing a time constant of 4.8 ms. The cells were then 
allowed to recover in 1 ml of pre-warmed SOC medium (appendix A) at 37°C with 
shaking for 1 hour, allowing expression of the plasmid-coded antibiotic resistance. 
Transformants were selected by plating onto LB agar plates containing the antibiotics 
ampicillin (50 pg/ml or 30 pg/ml for MC1061/P3 cells) and tetracycline (12.5 pg/ml or
7.5 pg/ml for MC1061/P3 cells). A negative control of cells electroporated in the 
absence of DNA was plated in parallel onto selective media plates. Several single 
colonies were picked from each transformation, and grown overnight in LB broth 
containing antibiotics. Plasmid DNA was recovered by miniprep (section 2.2.5) and 
analysed by restriction endonuclease digestion.
2.2.5. Isolation and purification of plasmid.
Plasmid was initially prepared for restriction analysis by the alkaline lysis ‘mini­
prep’ method detailed by Sambrook et al. (1989), which is adapted from that of 
Bimboim and Doly (1979). The DNA was routinely resuspended in 50 pi of TE buffer 
after drying.
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2.2.6. Large scale plasmid preparation (maxipreps).
Large scale isolation was performed using Qiagen Plasmid Kits (Qiagen, Hilden, 
Germany). This involved a modified alkaline lysis step where 50 ml aliquots of bacterial 
suspension were pelleted by centrifugation at 5000 g, and the pellets resuspended in 2.5 
ml buffer PI, using a sterile Pasteur pipette, before being pooled in an ultra­
centrifugation tube. The composition of all buffers used in this procedure is described 
in appendix A. Ten millilitres of buffer P2 was added and the contents mixed by gentle 
inversion five times. After four minutes, 10 ml of buffer P3 was added to the cell lysate. 
The tube was placed on ice for 30 minutes and then centrifuged at 45,000 g at 4°C for 
45 minutes in a Beckman Ti45 rotor. The supernatant was removed promptly and 
applied onto a single-use modified silica anion-exchange resin purification column 
(Qiagen) at appropriate low salt and pH conditions. The column was pre-equilibrated 
with 10 ml buffer QBT prior to use. The column was then washed twice with 30 ml of 
buffer QC, and plasmid DNA was eluted using 15 ml of buffer QF and precipitated by 
the addition of 10.5 ml isopropanol. The tube contents were gently mixed and 
centrifuged at 45,000 g for 45 minutes at 4°C. Pelleted DNA was washed with 15 ml 
ice-cold 70% ethanol and repelleted by centrifugation. Following aspiration of the 
supernatant, residual ethanol was removed from the pellet by air drying at room 
temperature for 10 minutes. The DNA was suspended in TE buffer containing RNAase 
at 20 jag/ml. Spectrophotometric analysis (section 2.2.7) showed the plasmid samples to 
be routinely pure enough for transfection into mammalian cells. It is possible that the 
addition of RNase introduced impurities to the DNA sample, and an alternative
48
purification procedure using a cesium chloride centrifugation gradient would reduce the 
contamination.
2.2.7. Spectrophotometric determination of nucleic acid concentration.
Spectrophotometric readings at 260 nm and 280 nm (Milton Roy Spectronic 
601) were used to determine the quantity and purity of DNA. An OD of 1.0 at 260 nm 
corresponds to a solution at 50 pg/ml for double stranded DNA, 40 pg/ml for single 
stranded DNA and RNA (Sambrook et al, 1989). Contaminating phenol and protein 
absorbs at 280 nm. Nucleic acid solutions with a 260 nm : 280 nm absorbance ratio of 
less than 1.8 were considered too impure for this method of quantification, and for 
subsequent transfection into eukaryotic cells.
2.2.8. Restriction endonuclease digestion of plasmid DNA.
Plasmid DNA restrictions were performed using New England Biolab (NEB) 
restriction enzymes and buffers, according to the manufacturers directions. Complete 
plasmid digestions were performed by incubation of the reaction mixtures at 37°C for 1 
hour. Standard endonuclease restrictions for size analysis and cloning contained ~1 pg 
plasmid DNA in a total of 20 pi total reaction mix volume. Large scale restriction 
reactions used in the preparation of plasmids for mammalian cell transfections utilised 
20 pg DNA, which was subsequently purified by phenol : chloroform extraction 
(section 2.2.5) before use.
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2.2.9. Concentration of DNA by ethanol precipitation.
Precipitation of plasmid DNA from aqueous solutions was performed by the 
addition of 3 M sodium acetate (pH 5.2) to a final concentration of 0.3 M. Two 
volumes of ice-cold ethanol were added, and the solution mixed and incubated at -70°C 
for 15 minutes to precipitate. The mixture was centrifuged at 14,000 rpm for 30 
minutes at 4°C in a Jouan A14 centrifuge to pellet the DNA. The washing and drying 
procedure was as detailed in section 2.2.5, and the DNA was finally resuspended in TE 
buffer.
2.2.10. Horizontal agarose gel electrophoresis.
Routinely, 1% agarose gels were produced by dissolving electrophoresis grade 
agarose (Gibco BRL) in 0.5x TBE buffer at 100°C. The solution was cooled to about 
60°C, poured into the gel tray and allowed to set at room temperature for 45 minutes. 
The gels were then mounted in an electrophoresis tank (Bio-Rad mini-sub DNA cell) 
and submersed in 0.5x TBE. Electrophoresis was carried out at 80-200 V for sufficient 
time to produce full separation of the bands of interest. All gels were run with lanes of 
A.DNA with Hind III and EcoR I  digests as the marker (NBL Gene Sciences Ltd, U.K.; 
appendix B) and DNA samples were mixed with 0.2 volumes 5x DNA loading buffer 
(appendix A). The gels were stained with ethidium bromide in water at a concentration
50
of 0.5 Jig/ml for 10 minutes. The DNA bands were visualized using a UV light box. 
Photographs were taken using a Polaroid MP4 camera and Polaroid 637 film.
2.2.11. Purification of DNA using Geneclean.
DNA was purified from agarose gels by adsorption of the DNA to a silica matrix 
using the Geneclean II system (Bio-101, La Jolla, CA, USA). The restriction mixture 
was run on an agarose gel, and the section of gel containing the fragment of interest was 
excised (less than 0.4 g). Three volumes of Nal solution was added to the gel, and 
incubated at 55°C for 5 minutes (for TBE gels, a half volume of TBE modifier and 4.5 
volumes Nal were added to the agarose). The Glassmilk was resuspended by vigorous 
vortexing, and 5 jul was added to the agarose solution, mixed and left at room 
temperature for 5 minutes., mixing every 1-2 minutes. The silica matrix was pelleted by 
centrifugation for approximately 5 seconds, the Nal supernatant aspirated and the pellet 
washed three times with a wash buffer. The fragment of DNA was finally eluted from 
the beads into TE at 55°C for 5 minutes. Solutions of DNA were also purified by this 
method using 3 volumes Nal and proceeding straight to the addition of Glassmilk.
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2.2.12. Ligation of DNA fragments into plasmid vectors.
The plasmid vector pcDNA3 was linearised by restriction at the Hind III and the
Xba I  sites within the polylinker site, as described in section 2.2.8. The enzymes were
subsequently denatured by heat treatment, and 1 pg of vector was run on a horizontal
agarose gel, and recovered using Geneclean as described in section 2.2.11. A fragment
of approximately 900 bp was recovered from the piLN-murB7 vector and purified in a
similar fashion for ligation.. The sticky end ligation was set up as detailed in Table 2.1
and incubated at 16°C for four hours. Control ligations were performed with the vector
DNA alone, in the presence and absence of ligase. Purification involved the Geneclean
procedure, before transformation of the host cells with a 5 pi aliquot by electroporation.
Vector: pcDNA3 (5.4 Kb) 0.5 pg
Insert: murB7 (0.9 Kb) 5.0 pg
10X Ligation Buffer (NEB) 5.0 pi
T4 DNA Ligase 400,000 U/ml (NEB) 0.5 pi
Sterile Water to 50 pi
Table 2.1. Reaction conditions for ligation of murine B7 gene into pcDNA3.
The CMV promoter was removed from pcDNA3 by restricted at the Nru I  and 
Hind III sites to produce a fragment of approximately 4.6 Kb. The Hind III site was 
converted to a blunt end using Klenow fragment (NEB) prior to treatment with calf 
intestinal alkaline phosphatase (CIAP, NEB). This treatment reduces self-ligation of the 
two ends of the vector in the presence of ligation enzymes, by removal of 5’ phosphates.
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The Trp-1 PCR product (section 2.2.13) was treated with Klenow fragment to ensure 
blunt ends, and the ligation was set up as detailed in Table 2.2. The reaction mixtures 
were purified using Geneclean before transformation of the host cell by electroporation.
Vector: pcDNA3 without CMV(4.6 Kb) 0.5 jxg
Insert: Trp-1 PCR (2.1 Kb) 1.0 |ig
10X Ligation Buffer (NEB) 5.0 jul
T4 DNA Ligase 400,000 U/ml (NEB) 0.5 pi
Sterile Water to 50 pi
Table 2.2. Reaction conditions for blunt ligation of Trp-1 PCR product into pcDNA3 
(no CMV).
2.2.13. Preparation of oligonucleotides.
Synthesis of oligonucleotides for PCR amplification was kindly carried out by 
Dr. A. Wolstenholme (School of Biochemistry, University of Bath, UK). The 
oligonucleotides were eluted from their synthesis columns by drawing 1 ml concentrated 
ammonia solution through the column in 0.2 ml aliquots at 20 minute intervals. The 
eluate was placed in a 1.5 ml screw-capped eppendorf and placed in a glass universal 
containing 0.5 ml concentrated ammonia solution. This was incubated at 55°C 
overnight (to remove amino-protecting groups). The ammonia solution was removed by 
vacuum drying in a DNA Speedvac (Savant) at room temperature in a fume cupboard. 
The oligonucleotide pellet resuspended in 300 pi sterile distilled water, and the DNA 
was precipitated using ethanol (section 2.2.9) before the dried DNA was resuspended in 
1 ml sterile water. The oligonucleotide yield was determined as detailed in section
2.2.7, and diluted as necessary for the polymerase chain reaction. The typical yield was 
between 1-2 mg.
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2.2.14. Polymerase Chain Reaction (PCR) of cDNA probes for murine Trp-1 
promoter.
The cDNA of 4 kb of the Trp-1 promoter was received from Dr. I. Hart (section 
2.2.2) and used as a template for PCR using the GeneAmp PCR Core Reagent Kit 
(Perkin Elmer Cetus, Norwalk, CT, USA) according to the setting and concentrations 
detailed in the manufacturers protocol. The reaction contained lOx Buffer, 10 mM 
dNTP’s, 1 |iM oligonucleotide primers (section 2.2.13) and 2.5 units Amplitaq. To this, 
1-4 mM magnesium chloride and approximately 1-100 ng template cDNA was added. 
The reaction was exposed to cycling parameters of 94°C for 1 minute, 55°C for 1 
minute and 72°C for 2 minutes, repeated for 30 cycles using a Crocodile II temperature 
cycler (Appligene). This protocol is based on the Taq DNA polymerase method 
described by Saiki et al. (1988) . The DNA fragment from this process was purified 
using Geneclean before further use, as detailed in section 2.2.11.
2.2.15. Mammalian cell lines.
B16 murine melanoma cells (passage 6) were donated by Dr. L.R. Kelland 
(Institute of Cancer Research, Sutton), and the less metastatic murine melanoma cells 
K1735 (passage 4) were obtained from Dr. I. Hart (ICRF, St. Thomas’ Hospital, 
London). The murine fibroblast cell line NIH3T3 (passage 6), the human embryonal 
kidney line 293 (passage 50) and the SV40 transformed monkey kidney cell line were 
obtained from the European Collection of Animal Cell Cultures (ECACC, Porton 
Down, Salisbury, UK).
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2.2.16. Cell culture media.
Dulbecco's Modified Eagle's Medium (DMEM) (10X concentrate) containing 
non essential amino acids (NEAA) was obtained containing the indicator phenol red, but 
without sodium bicarbonate and L-glutamine. Sterile double distilled, deionised water 
was used to dilute the concentrated solutions and the medium supplements L-glutamine 
(2 mM), penicillin (100 IU/ml) and streptomycin (100 pg/ml) (pen/strep), and the 
medium was buffered by the addition of 25 ml sterile 7.5% NaHCOs solution. Foetal 
bovine serum was supplemented (10%) in all cases. The final pH was corrected to 7.4 
with sterile 1 M NaOH solution. All components were obtained from Gibco. Tissue 
culture flasks were obtained from Becton Dickinson Labware, USA and 6-well and 96- 
well plates from Nunc, Denmark.
2.2.16.1. Cell line maintenance and routine culture.
Routinely, cultures were seeded into 175 cm^ flasks, maintained in a humidified 
5% CC>2 atmosphere and incubated at 37°C in a LEEC anhydric incubator. The medium 
was changed on alternate days to maintain a pH of 1.2-1 A, and the cells were 
subcultured just prior to reaching confluence. Subculture involved washing the 
confluent monolayer twice with calcium and magnesium free phosphate buffered saline 
(PBS, Oxoid, UK) and incubating with a suitable volume of Trypsin-EDTA solution for 
10 minutes at 37°C. The resulting cell suspension diluted to 10 ml with culture medium 
and counted. Cell numbers were established using a grid haemocytometer after staining 
with 0.1% trypan blue (Sigma) in PBS as described in the Sigma biochemicals catalogue
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(1996, p i702-3). Cells were visualized on an M40 inverted biological microscope 
(Wiold Heerbrugg Ltd). Flasks were seeded at a density of 2xl06 cells per 175 cm2.
2.2.16.2. Storage and freezing of cell lines.
Stocks of cells were routinely frozen for long-term storage. Cells were removed 
from the flasks prior to confluence, centrifuged in a MSE Micro centaur microfuge at 
10000 g for 2 minutes, the medium aspirated, and washed with PBS. The cell pellet was 
resuspended in DMEM-FBS (10%) supplemented with 10% DMSO. The cell 
suspension (1.8 ml) was pipetted into polypropylene ampoules (Coming, USA) and 
cooled at a rate of l°C/minute using a biological freezer unit (Union Carbide BF6 ). 
Once the cells were uniformly frozen at -70°C, they were transferred to a Union Carbide 
LR-40 liquid nitrogen refrigerator for long term storage at approximately -148°C.
2.2.16.3. Recovery of frozen cells.
Frozen cells were rapidly thawed in a water bath at 37°C, resuspended in 10 ml 
of complete pre-warmed medium. The cells were then centrifuged at 10000 g for 10 
minutes to remove the cryoprotectant. The supernatant was removed, and the cells 
resuspended in complete medium and transferred to a 175 cm2 flask. Cells were 
incubated at 37°C in 95% air / 5% CO2 .
2.2.17. Calcium phosphate mediated transfection.
B16 melanoma cells were transfected using a method adapted from that of 
Graham and van der Eb (1973) and Chen and Okayama (1987) of co-precipitation of the
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DNA with calcium phosphate. B16 cells were harvested and seeded at a density of 
lxlO 5 cells per well in 60 mm tissue culture dishes and incubated at 37°C for 24 hours 
prior to transfection. Separate tubes were prepared containing 500 jul aliquots of 15 |LLg 
DNA in 0.248 M calcium chloride solution, and 2x HBS. The DNA/CaCl2 mixture was 
added dropwise to the HBS, and the reaction incubated at room temperature for 30 
minutes. The calcium phosphate-DNA suspension was added dropwise to the medium 
in the wells along with chloroquine to a final concentration of 100 pM. The cells were 
incubated at standard conditions for 24 hours and the medium containing the calcium 
phosphate-DNA co-precipitate was removed. The cells were washed three times and 
overlaid with complete culture medium, and incubated for a further 24 hours at 37°C. 
Cell extracts were prepared (section 2.2.20.1) and the cells were assayed using the 
ONPG assay (section 2.2.20.2).
2.2.18. Electroporation of eukaryotic cells.
The initial expression studies using electroporation to compare promoter activity 
used a protocol modified from that described by Chu et al. (1987) and Potter (1988). 
This protocol involved using lower voltage and higher capacitance settings than that 
described in the initial electroporation studies by Neumann et al (1982). The cells were 
removed from 175 cm2 tissue culture flasks at 70% confluence, washed three times with 
ice cold PBS, and resuspended at a density of 5xl06 cells in 500 pi PBS. These were 
then placed in 0.4 cm electroporation cuvettes (Bio-Rad), and 20 pg plasmid (prepared 
using Qiagen plasmid preparation column, section 2.2.6) added. The parameters on the 
Gene Pulser and the Capacitance Extender (Bio Rad) were set to those established as
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optimal for the particular cell line used. Cells were then incubated for 15 minutes on ice 
after electroporation, before re-seeding into tissue culture flasks. Electroporated cells 
were incubated at 37°C and 5% CO2 before assaying for p-galactosidase activity using 
the spectrophotometric ONPG assay (section 2.2.20.2).
2.2.18.1. Optimisation o f electroporation parameters using FITC labelled dextran.
The optimal conditions for efficient transfection by electroporation vary for each 
cell line. FITC labeled dextran (Sigma, average MW 71,200) was used to establish the 
optimal parameters for each cell line, using a method adapted from that of Andreason 
and Evans (1989) and Graziadiel et al. (1991). An aliquot of 50 pi of FITC-dextran (10 
mg/ml stock) was added to lxlO6 cells in a total volume of 500 pi of PBS. 
Electroporation was performed at a variety of capacitance and voltage values, producing 
a range of time constants between 4-12 msecs. They were then reseeded into tissue 
culture flasks, and incubated at 37°C for four hours. The cells were trypsinised, washed 
with PBS and resuspended into 500 pi PBS and analysed by fluorescence activated cell 
sorting (FACS, section 2.2.21) for fluorescence associated with uptake of the FITC- 
dextran. Cells were additionally labelled with 100 ng/ml propidium iodide to establish 
the percentage of cell death associated with each set of electroporation parameters. The 
parameters used for electroporation are summarised for each cell line in Table 2.3.
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Cell line No. cells Volume Buffer Capacitance Voltage
B16 5xl06 500 j l l I PBS 125 pF 350 V
NIH3T3 5xl06 500 |il PBS 125 pF 350 V
K1735 2 x l0 7 800 pi Ficoll-Hepes 250 pF 400 V
Table 2.3. Summary of electroporation parameters used for each cell line.
2.2.18.2. Optimisation o f electroporation parameters using a reporter gene.
Transfection of the plasmid pRSWlacZ (section 2.2.2) containing the reporter
gene p-galactosidase in parallel to the FITC-dextran was performed. This allowed an 
estimation of the efficiency of gene transfer at each set of parameters. The cells were 
electroporated as detailed in section 2.2.17 with 20 fig of the plasmid pRSVlacZ and 
reseeded into tissue culture flasks before incubation at 37°C for 24-96 hours. Cells were 
washed with PBS, fixed with 1% glutaraldehyde and stained with the histochemical 
stain X-Gal (2.20.4) before visualisation using a Nikon Diaphot light microscope.
2.2.18.3. Production o f stable transfectants.
Electroporation to produce stable transfection of K1735 melanoma cells 
involved a modified protocol using an adapted Hepes-buffered saline electroporation 
buffer containing Ficoll, supplied by Dr. M. Welham
, University of Bath (appendix A). Cells were removed from the tissue culture plates 
and washed twice with HBS, before resuspending at a concentration of 2xl07 in 0.8 ml
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HBS. Cells were placed in the cuvette with 10 jig of the linearised plasmid 
pcDNA3mB7 (section 2.2.2) containing the selection marker geneticin (G418, Gibco). 
Another cuvette contained cells plus 10 jug each of the linearised plasmids pCEXV-3-Ak 
(a  and P chains) plus 1 jig of linearised pPGKPuro containing the selection marker 
puromycin (Gibco). Cells were then electroporated at a capacitance of 250 p,F and a 
voltage of 400 mV, producing time constants of 4.8 and 4.9 msecs respectively. The 
cells were left at room temperature for 2 0  minutes before reseeding into tissue culture 
flasks with complete culture medium. Culture medium was replaced after 48 hours with
1.5 mg/ml G418 and 1 |ig/ml puromycin respectively. Selection medium was replaced 
every 48 hours, and colonies were plated out as a polyclonal population and grown in 
preparation for sorting by FACS.
2.2.19. Determination of cell number using the MTT assay.
The MTT assay as described by Mosmann (1983) was used in a modified form 
to establish cell number in survival and toxicity assays. Cells were plated into 96-well 
tissue culture plates over a range of densities. After treatment and sufficient incubation, 
the medium was removed by inversion and the cells washed twice with serum free 
DMEM. A 200 jil aliquot (1 mg/ml) of l-[4,5-dimethylthiazol-2-yl]-3,5- 
diphenylformazan (MTT formazan, Sigma) was added to each well, and the plate 
incubated at 37°C for 3-5 hours. The MTT solution was carefully removed by gentle 
inversion of the plates, and the resultant crystals of formazan blue were solubilized with 
200 |il DMSO and agitation on an orbital mixer for 10 minutes. Dead cells would have
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detached from the plate, and been removed by the washing procedure. Cell number was 
established by reading the optical density of the wells (Titertek plate reader) at 540 nm, 
with a reference wavelength of 690 nm. The optical density in wells containing treated 
cells were compared with that of control wells containing untreated cells to allow the 
percentage viability to be established.
2.2.19.1. Optimisation o f antibiotic selection o f stable iransfectants.
K1735 cells were seeded at a density of 3xl03 cells/well and allowed to adhere 
in complete medium for 4 hours before the addition of 0-2 mg/ml G418, or 0-40 |Lig/ml 
puromycin. Cells were then cultured for three days under standard conditions before 
assaying using the MTT assay as detailed in section 2.2.19 to establish the number of 
surviving cells. This number was calculated according to the calibration curve for cell 
number, displayed in appendix C.
2.2.20. Analysis of (3-galactosidase expression.
The efficiency of gene transfer was determined in vitro using the plasmid 
pRSYlacZ  (section 2.2.2). Reporter genes are routinely used to evaluate delivery 
efficiency, and the (3-galactosidase gene is of particular use because of the diversity of 
assays available of varying sensitivity: histochemical, spectrophotometric, fluorimetric 
and FACS (MacGregor et al, 1991). The spectrophotometric assay allows the total 
enzyme activity in the cell extracts to be established, while the distribution of expression 
within the cell population can be determined by histochemical staining. Quantification
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of gene expression was normalized by determining p-galactosidase activity of the 
samples per milligram of soluble protein.
2.2.20.1. Preparation o f cell extracts.
The culture medium was removed from the cells, and the cells were washed 
three times with 5 ml of PBS. Each well was overlaid with 1.0 ml of PBS, and the cells 
removed by scraping with a cell scraper. The cell scraper was washed with 70% 
ethanol, rinsed with water and dried between samples. The resulting suspension was 
transferred to a 1.5 ml microcentrifuge tube and pelleted by centrifugation. Supernatant 
was aspirated and the pellet was resuspended in 250 jxl of 0.1 M sodium phosphate 
buffer (pH 7.4). Cells were then freeze-thawed three times in a dry ice-ethanol bath, 
with thawing at 37°C, and centrifuged at 10,000 rpm for 2 minutes. Supernatant was 
then removed for immediate analysis.
2.2.20.2. Spectrophotometric assay for/5-galactosidase in cell extract.
The galactoside derivative o-nitrophenol-p-D-galactoside (ONPG) formed the 
basis of the spectrophotometric assay to quantify transient P-galactosidase expression 
post-transfection. Cells were harvested 48-96 hours after transfection, washed, and cell 
extracts prepared by freeze-thawing three times in 250 p.1 0.1M sodium phosphate buffer 
pH 7.2 (appendix A). Aliquots of the cell extract solutions were incubated at 37°C with 
2X ONPG buffer (appendix A) for 30 min, and the reaction was stopped by the addition
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of 1 M Sodium Carbonate. A blank reaction, containing no cell extract, was prepared in 
parallel. Absorbance was read at 420 nm in a Milton Roy 601 spectrophotometer.
A calibration curve was prepared for this assay using purified E. coli p- 
galactosidase (Promega), displayed in appendix C. Cell extracts were assayed for 
soluble protein to provide a measure of P-galactosidase expression relative to the protein 
content of the samples.
2.2.20.3. Quantification o f soluble protein in cell extracts.
The soluble protein content of the cell extracts was quantified using the method 
established by Lowry et al. (1951). Soluble protein was assayed using a method adapted 
from that of Lowry et al. (1951). The sample was diluted to 500 |il with water and 500 
p,l 0.5M NaOH added. The sample was heated to 100°C for 10 minutes, then allowed to 
cool to room temperature. Lowry C reagent was freshly prepared by the addition of 2 
ml Lowry B to 48 ml Lowry A (appendix a), and a 2.5 ml volume added to the sample, 
with shaking. After 10 minutes, 0.5 ml Folin and Ciocalteu’s phenol Reagent (Sigma 
UK) was added and the solution vortexed. The sample was incubated at room 
temperature for 30 minutes, before determining the absorbance at 750 nm (Milton Roy 
Spectronic 601). A blank which contained no cell extract was also prepared in parallel. 
A standard curve for this assay was prepared using purified E. coli p-galactosidase 
(Promega) and is presented in appendix C.
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2.2.20.4. Histochemical assay for p-galactosidase.
The efficiency of P-galactosidase expression was determined by in situ 
histochemical staining using 5-bromo-4-chloro-3-indolyl-p-D-galactosidase (X-Gal) 
obtained from Melford Laboratories Ltd, Ipswich, England. Cell monolayers were 
washed thoroughly with PBS and fixed with 1% glutaraldehyde solution (BDH Ltd, 
UK) at 4°C. The cells were washed again with PBS, overlaid with X-Gal solution 
(appendix A) and incubated at 37°C overnight. Cells expressing p-galactosidase 
hydrolyse the chromogenic dye to produce an insoluble indigo, which shows up as a 
blue colour against an unstained background. Photographs were taken using a Nikon F- 
301 camera attached to a Nikon Diaphot light microscope.
2.2.21. Fluorescence activated cell sorting (FACS) of cells.
2.2.21.1. Antibodies
R-Phycoerythrin (R-PE) conjugated hamster anti-mouse CD80 (B7-1) 
monoclonal antibody (IgG; 16-10A1) was obtained from Pharmingen (Sorrento Valley 
Road, San Diego, USA). Purified unconjugated mouse anti rat I-A antigen (IgGi; 
MCA46G) was obtained from Serotec (Oxford, England). This antibody exhibits cross­
reactivity with MHC class II haplotypes k and s (McMaster and Williams, 1979). 
Fluorescein isothiocyanate (FITC) conjugated anti-mouse polyvalent immunoglobulins 
(IgG, IgA, IgM; F-1010) was obtained from Sigma Immunochemicals, and used as the 
secondary reagent against the IgGi MCA46G antibody. Mouse IgGi isotype control was 
obtained from Dako (Glostrup, Denmark).
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2.2.21.2. Cell labelling for FACS analysis.
Cells were removed from culture plates by trypsinisation and washed twice in 
ice-cold PBS. Cells were then counted and 5x10s cells resuspended in 50 pi PBS with 
an optimal concentration of primary antibody. Generally, this involved a 1:100 dilution 
of the 1 mg/ml stock antibody. Samples were incubated at 4°C for 30 minutes, with 
periodic agitation, then washed once with PBS. Cells were then resuspended into 50 pi 
PBS with 0.1% BSA and incubated for 15 minutes at 4°C. One further wash with PBS 
was performed prior to resuspension into 50 pi PBS containing a sufficient excess of 
FITC-labelled secondary antibody (1 pi stock solution diluted to 50 pi). The sample 
was washed three times with 1 ml PBS to remove excess antibody, before analysis on a 
FACS Vantage analyzer (Becton Dickinson). Cell viability was estimated by the 
addition of propidium iodide (100 ng/ml), and samples were measured in the FL-1 
emission spectrum (530 ±15 nm) to detect fluoresceinated components, or in the FL-2 
emission spectrum (575/26) for PE-derived samples.
For cell sorting, all samples were prepared and maintained in a sterile 
environment throughout the procedure. Generally, a population of 5xl06 cells were 
sorted into 6 ml sample tubes (Becton Dickinson) containing 500 pi DMEM. Cells 
were then seeded into 25 cm2 culture flasks and maintained in G418 or puromycin- 
supplemented culture medium for two weeks, before subculture of the polyclonal 
population prior to further rounds of cell-sorting.
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2.2.22. Preparation of spleen cells as positive control for MHC II genes.
Spleen cells from adult C3H-HEN (Harlan, Surrey, U.K.) mice were prepared as 
a positive control for the transfection of the I-Ak gene into the K1735 melanoma cells. 
The spleens of two mice were dissected out of freshly culled animals, and washed with 
lx serum-free medium to remove the connective tissue. The spleens were emptied of 
the blood cells, and the cells were pelleted by centrifugation at 15000 g for 5 minutes. 
The supernatant was removed, and the pellet resuspended in lx medium. The red blood 
cells were separated from the lymphocytes using pre-warmed Lymphoprep (Nycomed, 
Oslo, Norway), and centrifugation at 15000 g for 30 minutes. A lymphocyte band was 
carefully removed with a pipette, washed twice with lx medium and counted, before 
labeling with antibody for FACS (section 2.21.1).
2.3. RESULTS
2.3.1. Transfection of B16 cells using calcium phosphate co-precipitation.
Transfection efficiency was shown to be dependent on the promoter driving gene 
expression (Fig. 2.3). The plasmid containing the viral promoter pRSV driving the 
expression of the reporter gene produced levels of activity of roughly 130 milliunits per 
mg of soluble protein. No detectable levels of p-galactosidase activity were observed in 
the cells transfected with the plasmid containing the tissue-specific promoter Trp-1. 
The negative control involved the treatment of cells with all of the transfection reagents 
except the DNA.
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pRSV T rp-1 Control
Promoter Driving Expression
Figure 2.3. Expression o f  P-galactosidase activity in B 16  m elanom a cells, assayed 48  hours post­
transfection by calcium  phosphate co-precipitation. C ells were assayed using the spectrophotometric 
O N PG  assay. C ells were transfected with 15fig pRSVlacZ  in 0 .124M  C a P 0 4 solution in H BS and 
chloroquine (100  |xM). The control represents cells incubated with 15 p g  pRSVlacZ  w ithout C a P 0 4 and 
chloroquine. C ells were incubated with the precipitates for 24 hours, before replacem ent w ith com plete  
culture m edium, and incubation for a further 24 hours at 37°C. The data points represent the mean ±  SEM  
(n=3).
It was decided to change the DNA delivery method to electroporation to allow 
optimisation of expression due to the flexibility of the parameter settings. Additionally, 
a larger population of cells could easily be subjected to the transfection procedure using 
electroporation than for co-precipitation. Prior to transfection with DNA, an 
optimisation procedure was performed to determine the parameter settings producing 
the best trade-off of cell permeability with viability. This was important to establish, as 
variability between cell lines can often occur.
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2.3.2. Optimisation of electroporation of mammalian cells.
Establishment of the optimal conditions for electroporation required comparison 
of the uptake and cell viability profiles in parallel. This procedure was only carried out 
once, but the data (Fig. 2.4) suggested a correlation between voltage and cell death. The 
graphs displayed in Fig. 2.4 represent a measure of cell permeability (shown as 
fluorescence associated with dextran-FITC uptake) and the cell viability over a range of 
parameters. At the two resistance values studied, a voltage of 150 V produced relatively 
low levels of uptake as represented by lower cell fluorescence, but consequently higher 
levels of cell viability were observed. At higher voltages, for both of the resistance 
values, increased fluorescence levels were accompanied by large reductions in cell 
viability. At a capacitance of 125 pF, a linear decrease in viability (from 5%-100%) was 
observed above a voltage of 150 V , and this was accompanied by an increase in 
fluorescence to a maximum of 50%. For the voltages at a capacitance of 250 pF, the 
cell death reached a maximum of almost 100% at a voltage of 350 V, but this was 
accompanied by high levels of uptake. A representative two colour FACS analysis at 
the optmised parameters of 350 V and 125 pF is displayed in Figure 2.5.
The electroporation parameters 350 V and 125 pF were established as optimal 
from the viability and cell permeabilization experiments since these conditions provided 
high levels of fluorescence plus favourable levels of viability. These were used for all 
future transfections using B16 cells. Electroporation was carried out using pRS V/acZ, 
containing the P-galactosidase reporter gene, and the photographs in Figure 2.6 show the 
levels of reporter gene expression routinely obtained at these optimized electroporation 
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F ig u re  2 .4 . Optimisation o f  electroporation parameters for B 16 m elanom a cells. Dextran uptake was 
m onitored in parallel to propidium iodide staining at the various com binations o f  voltage and capacitance. 
lx lO 6 cells  w ere electroporated with dextran-FITC (1 m g/m l) in PBS at a capacitance o f  125 |iF  (plate A ) 
or 2 5 0 |iF  (plate B ) over a range o f  voltages. Propidium iodide (100  ng/m l) was added to the sam ples 
im m ediately prior to FAC S analysis (FACS Vantage, Becton D ickinson) to establish cell viability.
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Figure 2.5. Representative two colour FACS analysis used to optimise electroporation parameters for 
B16 melanoma cells. Analysis was performed by monitoring dextran-FTTC uptake in parallel with 
propidium iodide staining over a variety o f  voltage and capacitance settings. lxlO 6 cells were 
electroporated with dextran-FITC (1 mg/ml) in PBS at over a range o f  voltage and capacitance. 
Propidium iodide (100 ng/ml) was added to the samples immediately prior to FACS analysis (FACS  
Vantage, Becton Dickinson) to establish cell viability. BT2301001 displays control cells exhibiting no 
dextran uptake; BT2301004 displays cells exhibiting dextran uptake. Live control cells were gated, and 
this gate was applied to the electroporated samples.
A B
f . ; v
F igure 2.5. Photographs showing B16 cells fixed and treated with X-Gal solution overnight 48 hours 
after electroporation. Plate A shows the negative control o f B16 cells electroporated in the absence o f  
plasmid DNA, and plate B shows cells electroporated with 20 pg pRS\la cZ .  Electroporation was 
performed at 350 V and 125 pF, in line with the optimized parameters for this cell line. Cells were 
photographed at magnification x300. Cells positive for p-galactosidase activity appear blue after X-Gal 
treatment.
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constant of between 4-5 milliseconds, and values out of this range often gave lower 
levels of transfection and viability.
The optimisation procedure was repeated using the K1735 cell line over the 
same range of parameters as for B 16 cells. A lack of ability to optimize the parameters 
was observed: at lower voltages, the cells showed no enhancement of fluorescence, 
while at the higher voltages cell viability was reduced to very low levels (data not 
shown). Discussion with Dr. M. Welham led to the use of a modified electroporation 
protocol, using a Hepes buffer containing Ficoll to reduce the osmotic shock to the cells 
during electroporation, and the parameters 250 |iF and 400 V.
2.3.3. Control expression studies in mammalian cells post-electroporation.
The expression of p-galactosidase in mammalian cells post-electroporation was
studied in two cell lines - the B 16 melanoma cell line and the NIH3T3 fibroblast line. 
Comparative transfection efficiencies were established using the pRSVlacZ and the Trp- 
1 plasmids (section 2.2.2). The data displayed in Fig. 2.7. demonstrates that expression 
was observed with both the pRSV/flcZ and the Trp-1 plasmids in the B16 melanoma 
cells to levels of activity of 1400 and 900 milliunits of enzyme activity per mg soluble 
protein respectively. The pRSVlacZ plasmid induced high levels of activity of about 
1900 milliunits per mg soluble protein in the fibroblast cell line NIH3T3, but the Trp-1 
plasmid was unable to stimulate gene expression above background levels. These levels 
and profiles of expression were highly unreproducible. Figure 2.6 depicts the data 
collected from two replicate experiments, but three further replicates demonstrated no
72
activity of the Trp-i plasmid and only low levels (approximately 80 milliunits/mg 
protein) of the pRSVlacZ  plasmid in the B16 melanoma cells. The negative control in 
this experiment involved the electroporation of cells in the absence of plasmid DNA.
■ I  B16 
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Promoter Controlling Expression
F igure 2.7. Expression o f  (3-galactosidase in B16 melanoma cells and NIH3T3 fibroblast cells driven by 
the viral promoter RSV or the tissue -specific promoter Trp-1. Cells were transfected by electroporation 
with 20 pg plasmid D NA  at 350 V, 125 |iF  in 500 pi PBS to produce time constants o f 4-5 m illisecs. 
C ells were assayed 48 hours post-transfection using the ONPG assay. The data points represent mean ±  
SD  (n=2).
2.3.4. Engineering of Trp-1 promoter-B7 construct.
Initially, it was planned to engineer restriction sites into PCR primers, specific 
for the Trp-1 promoter, allowing ligation into the promoterless expression vector 
pNASS|3 (section 2.2.2). A pair of PCR oligonucleotide primers were generated 
(section 2.2.13) using sequences generated by Jackson et al. (1991) and Lowings et al. 
(1992). The specific primers described below were used with a standard PCR protocol 
(section 2.2.14) and the Trp-1 -p-Gal vector supplied by Dr. I. Hart (section 2.2.2).
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Ts 5 * -GGGCTCG AGATGCTGCTCTTTGC ATGGAG A-3 *
Ta 5 ’ -CCCCTCGAGTTTC AG ACC AGC AG ACT AC A A-3 ’
Primer Ts was designed to amplify the 1.4 Kb sequence at the 3’ end of the Trp- 
1 promoter which has displayed tissue-selective activity (Vile and Hart, 1993a). Primer 
Ta was designed to incorporate the first Trp-1 intron (0.7 Kb) into the PCR fragment, as 
this region of the human Trp gene has previously been shown to enhance the transient 
expression of a reporter gene (Shibata et a l ,  1992). Restriction sites were incorporated 
at the 5 ’ ends of each oligonucleotide for the enzyme Xho I, which are highlighted in the 
sequences. This was to allow ligation into the promoterless mammalian expression 
vector pNASS(3. Subsequently, it was decided to change the vector to pcDNA3 to allow 
use of the neomycin resistance markers, allowing selection of stable transfectants in the 
presence of the antibiotic G418.
M84966
15 970
Trp-1 promoter | j
1
F igure 2.8. Diagrammatic representation o f the overlapping sequences obtained from Genbank for the 
Trp-1 promoter and first intron o f Trp-1 (accession numbers M 84966 and X 59513 respectively). PCR 
primers were designed specific for the region 15 bp o f M 84966 and 1181 bp o f X 59513. This allowed  
amplification o f  a 2.1 Kb fragment, incorporating 1.4 Kb o f the 3 ’ end o f  the Trp-1 promoter plus 0.7 Kb 
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This restriction of pcDNA3 with Nru I and Hind m  is displayed in Figure 2.9. 
Lane 2 contains pcDNA3 restricted with both Nru I and Hind EL The two fragments of 
approximately 0.6 Kb and 4.8 Kb represent the CMV and pcDNA3 without the 
promoter respectively. Lane 3 represents uncut pcDNA3; lanes 4 and 5 represent 
pcDNA3 linearised with either Nru I or Hind ID; lanes 1 and 6 contain the molecular 
weight marker X Hind TH/EcoR I. The fragment from lane 2 of approximately 4.8 Kb 
was excised from the gel and purified (section 2.2.11), the Hind IE site blunted using 
Klenow and then dephosphorylated with alkaline phosphatase (section 2.2.12)
PCR using these primers with ~1 ng cDNA template and 2 mM magnesium 
chloride generated a single band approximately 2.1 Kb (Fig 2.10 ). Approximately 1 p,g 
of the PCR fragment was removed from a 1% horizontal TBE gel using Geneclean 
(section 2.2.11), restricted with Xho I before blunting the ends using Klenow (section 
2.2.12). Blunt end ligation of the PCR fragments into the phosphorylated vector was 
performed as detailed in section 2.2.12. The ligation was performed five times. Low 
levels of background were observed on the control plates, but any colonies picked from 
the experimental plates had no inserts. Figure 2.9 (lane 3) demonstrates that this 
plasmid preparation contained very little supercoiled plasmid DNA, and also contained 
impurities, possibly accounting for the inability to ligate the vector and insert.
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F igure 2.9. Restriction o f  pcD N A 3 with the enzymes Hind III and Nru I to remove the CM V promoter. 
Lanes 1 and 6 contain the molecular weight marker X Hind III/EcoR I; lane 2 contains pcD N A 3 restricted 
with both Hind III and Nru I; lane 3 contains unrestricted pcD NA 3; lanes 4 and 5 contain pcD NA 3  
restricted with Hind III or Nru I respectively. Electrophoresis was performed at 120 V for 30 minutes.




F igure 2 .10. 1 % TBE agarose gel stained with 0.5 |ig/m l ethidium bromide showing PCR product 
derived from Trp-1 promoter template and specific oligonucleotide primers (section 2.3.5). Lane 1: the 
control with no template; lanes 2 and 3: reactions containing 1:100 and 1:10 template dilutions 
respectively; lane 4: X Hind IIIIE c o R  I markers.
2.3.5. Analysis of the pcDNA3-B7 vector.
The murine B7 gene was removed from piLN-murN7 (section 2.2.2) by 
restriction with the enzymes Hind EH and Xba I. The restricted sample was run on a 1 %
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agarose gel (as shown in Fig. 2.11), and the fragment of approximately 0.9 Kb was 
excised and purified (section 2.2.11). Lane 1 contains the molecular weight markers; 
lane 2 contains the plasmid restricted with Hind HI and Xba I; lane 3 contains the uncut 
plasmid; lane 4 contains the plasmid linearised with Hind ID. Lane 5 contains pcDNA3 
restricted with Hind III and Xba I for ligation of the murB7 fragment.
F igure 2.11. Restriction analysis o f  piLN-murB7 on 1% agarose gel. Lane 1 contains the molecular
linearised with Hind III. Lane 5 contains pcD NA 3 restricted with Hind III and Xba I for ligation o f  
murB7 fragment. Electrophoresis was performed at 120 V for 30 minutes.
The vector pcDNA3 was restricted with the enzymes Hind III and Xba I, run on a 
1% agarose gel, excised and purified (section 2.2.11). The two purified fragments of 
DNA were mixed at a ratio of 10:1 insert:vector, and ligated (section 2.2.12). An 
aliquot of the reaction mixture was transformed into E. coli TOPI OF’ (section 2.2.1) by 
electroporation, amplified and prepared by alkaline lysis (section 2.2.5). Samples were 
restricted with Hind III and Xba I , and run on a 1% horizontal agarose gel (Fig. 2.12). 
Ten colonies were picked, eight of which contained inserts of approximately 0.9 Kb. 
Samples of the plasmid DNA were restricted with the enzymes Hind IH and Xba I




weight markers. Lane 2 contains the plasmid restricted with Hind III and Xba I, demonstrating two bands 
o f approximately 0.9 Kb and 2.7 Kb. Lane 3 contains the uncut plasmid. Lane 4 contains the plasmid
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separately (lanes 3 and 4 respectively), and a double restriction was performed using 
both of these enzymes together (lane 5). An unrestricted sample of the plasmid DNA 
was run in Lane 2, and molecular weight markers were run in lanes 1 and 6.
The samples restricted with either the enzyme Hind El or Xba I have been 
linearised, while the sample that was restricted with both of these enzymes produced 
two fragments of approximately 0.9 Kb and 5 Kb.
1 2 3 4 5 6
4268
F igure 2.12. Restriction analysis o f  pcD NA 3 on 1% agarose gel after insertion o f  the murine B7 gene at 
the Hind III and Xba I sites in the multiple cloning site. Lanes 1 and 6 contain ^.DNA with Hind  III and 
EcoR I digests as the molecular weight marker. Lane 2 contains unrestricted pcD N A 3. Lanes 3 and 4 
contain pcD N A 3-B 7 singly restricted with the enzymes Hind III and Xba I respectively. Lane 5 contains 
the plasmid restricted with both o f the enzym es Hind III and Xba I. Electrophoresis was performed at 120 
V for 30 minutes.
2.3.6. Generation of control B7-expressing K1735 cells.
K1735 melanoma cells are a preferable cell line model for therapeutic 
applications than B16 cells because they exhibit a reduced metastatic profile. This is 
believed to provide a better model for comparison with the natural disease state. It was
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decided to produce a line of control K1735 cells stably expressing the murine B7 gene 
under the control of the viral CMV promoter.
K1735 cells were electroporated, using the modified protocol (section 2.3.2), 
with pcDNA3-mB7. Subsequent treatment with G418 allowed selection of a resistant 
polyclonal population . The polyclonal population was sorted using FACS three weeks 
after electroporation, and the antibiotic pressure was maintained on the cells for this 
period.
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F igure 2.13. FACS data for K1735 melanoma cells transfected with pcD N A 3-m B 7. The transfected 
cells were grown in G418 for selection o f stable transfectants for two weeks, then labelled with R-PE  
hamster anti-mouse C D 80 antibody (Pharmingen, section 2 .21.1) against murine B 7-1. The unsorted 
population is displayed as shaded (A) with transfected cells labelled with a mouse IgGj isotype control 
(Dako, section 2.21.1). B shows the positive population after sorting from the gated region marked M l in 
A.
Standard FACS labelling assays were used with the monoclonal antibodies 
described in section 2.2.21.1. The antibody was used at a concentration of 1:100 (10 
jig/ml) for sorting the B7-expressing cells (shaded region, Fig. 2.13 ). The unshaded 
region represents transfected cells labelled with the mouse IgGi isotype control (section 
2.2.21.1). Figure 2.13A represents the polyclonal population (shaded area) and the
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negative control (unshaded area). The sorting parameters were gated to select the cells 
with the largest increase in fluorescence (about 40% population). Figure 2.13B 
represents the fluorescence profile associated with the sorted population, providing an 
indication of the efficiency of the sorting procedure.
2.3.7. Expression of MHC class II genes by K1735 melanoma cells.
Initially, the K1735 cells were transfected with the two pCEXV-3-Ak plasmids, 
each containing the gene for either the a  or p chain of the MHC II molecule. The cells 
were labelled with the antibody MCA46G 48 hours post-electroporation, to test for 
transient expression using FACS analysis. This process was repeated three times. No 
expression was observed during any of these investigations.
It was decided to electroporate the K 1735 cells with the same two plasmids plus 
pPGKpuro (all linearised) to attempt to select a polyclonal cell line with stable 
expression of the MHC II genes. Subsequent treatment with puromycin (1 pg/ml) 
produced an antibiotic-resistant population of cells, which was subcultured after two 
weeks, and then prepared for sorting. The cells were labelled with MCA46G followed 
by F-1010 (section 2.2.21.1) at 1:100 dilutions for FACS analysis. A positive control 
population of cells expressing MHC class II I-Ak was prepared from spleen cells of C3H 
HEN mice and labelled as described above. The control produced significant 
fluorescence in the FL1 region, represented by the shaded area (Fig. 2.14A). The 
unshaded area in A represents the isotype control, which is also superimposed on the 
population of puromycin-resistant cells shown in B. There was no significant difference
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observed between the antibiotic-selected population and the isotype control, indicating 
that the population was not expressing the MHC II genes.
A B
F igure 2.14. FACS data for K1735 after stable selection in puromycin (1 M-g/ml). Figure A shows spleen  
cells o f  C3H HEN mice (shaded area) labelled with M CA46G (IgG i; Serotec), and the FITC conjugated 
antibody F1010 (Sigma) as the secondary label. The unshaded region represents cells stained with the 
isotype control. Figure B represents the K1735 cells grown in the puromycin selection medium after 
transfection (shaded) and the isotype control, labelled as for the spleen cells.
2.4. DISCUSSION
2.4.1. Comparative transfection studies.
The initial priority was to determine the relative strengths and specificities 
exhibited by the viral promoter (RSV) and the tissue specific promoter (Trp-1). The 
melanoma cell line B16 formed the basis of the preliminary expression studies, with the 
plan to use the less invasive melanoma cell line K1735 for future stable gene expression 
studies. This cell line was chosen due to its less invasive nature, which is believed to 
provide a better model for comparison with the natural disease state.
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2.4.1.1. Co-precipitation using calcium phosphate.
Transient expression studies were performed in B16 cells, using calcium 
phosphate co-precipitation as the method of transfection. The RSV promoter routinely 
produced detectable levels of p-galactosidase activity. The Trp-1 promoter however 
produced no detectable levels of activity, comparable with the negative control. This 
problem could have been due to inefficient delivery or inefficient translation. An 
alternative method of transfection was performed to establish whether the problem was 
one of delivery or not.
2.4.1.2. Transfection o f mammalian cells using electroporation.
The process of electroporation was optimized for B 16 cells in the studies using 
dextran-FITC uptake compared with cell viability over a variety of parameters. 
Additionally, transfections over the range of parameters were performed using the 
plasmid pRSYlacZ, and stained with the histochemical stain X-Gal (section 2.2.20.4) to 
determine the relative percentages of cells expressing the reporter gene under the 
different conditions.
The parameters established as those optimum for the melanoma B16 cells were 
125 |iiF and 350 V. Although the level of viability was reduced to 40% under these 
conditions, and dextran uptake produced relative fluorescence levels of roughly 50% of 
the maximum under any conditions. The uptake of the FITC-dextran was closely 
mirrored by an increase in cell death, and these parameters were seen to create the best 
compromise between permeabilization and cell death. These conditions produced 30% 
cells expressing the reporter gene, which was seen to be the optimum from the
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histochemical staining (Fig. 2.6). Viability was observed over a longer period of time 
during the X-Gal experiments. Recovery from the electroporation procedure was shown 
to be reduced with increasing voltage, in line with the short-term viability results. The 
results confirmed the parameters of 125 |iF and 350 V as optimum for this process for 
longer term studies.
The permeabilization of the cells, demonstrated by the dextran uptake studies 
could only be used as an indication of the quantity of material taken up by the cells. It 
is postulated that the degree of DNA uptake under these conditions would be of similar 
levels to that observed with the dextran, as this is a non-selective process. The 
percentage of cells expressing the reporter gene were lower than the percentage of cells 
exhibiting fluorescence at identical parameter settings. This may have been a result of 
cell division without plasmid replication, causing a diluting effect of the reporter gene 
within the population. Alternatively, the DNA would be susceptible to enzymatic 
degradation and methylation in the cytoplasm of the cell. Both of these mechanisms 
would serve to reduce DNA delivery to the nucleus for subsequent translation.
An identical optimisation process was performed using the melanoma cell line 
K1735. The conditions tested proved unsuitable for transfection of this cell line, as the 
cells either withstood uptake of the dextran, or were fragmented completely beyond 
repair, by the passage of electrical current through the cell suspension. The preliminary 
expression studies therefore concentrated completely on the B 16 cell line. The modified 
protocol suggested by Dr. M. Welham (Bath University) involved the use of a Hepes 
buffer containing Ficoll, to reduce the osmotic shock to the cells. These conditions were
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not optimized due to shortness of time, but were used to electroporate the K1735 cells 
for selection of stable transformants.
The development of melanoma-specific promoters is necessary for the high 
levels of selectivity required for gene expression at target sites in vivo. The cell lines 
chosen for the tissue-selective expression studies reflected the target cell-type 
(melanoma cells) plus non-target cells that were likely to grow in close proximity to the 
melanoma cells in vivo. It is postulated that the initial transfection studies using the 
Trp-1 promoter in B16 cells may not have been carried out over a long enough time 
course. Several cell-type specific promoters have been shown to bind factors specific to 
that cell type, such as the endometrial-specific factor which binds the uteroglobin 
promoter (Misseyanni et al., 1991). Lowings et al. (1992) have postulated that the Trp- 
1 promoter is controlled by the combination of non cell-type specific upstream factors 
plus cell-type specific TATA-binding protein-associated factors. These factors are 
likely to be present at differing levels throughout the cell cycle.
It has been suggested that the lack of reproducibility demonstrated during the 
comparative expression experiments in B16 and NIH3T3 cells could be due to a cell- 
cycle effect. The cells were always harvested prior to confluence, but it was not 
possible to determine the percentage of cells that had already reached stationary phase. 
Cells that were still rapidly dividing would be expected to recover from electroporation 
and resume rapid growth faster than stationary cells. Cells in log phase produce more 
protein than those in stationary phase. This may affect the rate of melanogenesis, and 
hence the production of initiation and binding factors for the Trp-1 promoter. This may 
explain why Vile and Hart (1993a) monitored activity 72-96 hours after transfection
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when studying expression of the reporter gene p-galactosidase driven by the tyrosinase 
promoter in B16.F1 melanoma cells. This modification was adopted for any further 
expression experiments using the Trp-1 promoter.
As detailed in section (2.3.4), the initial strategy involved ligating a 2.1 Kb PCR 
product of the 3’ end of the Trp-1 promoter plus the first intron (section 2.2.27) into the 
promotorless mammalian expression vector pNASSp. Due to the requirement for 
selection of stable transfected cell lines, it was decided to use the vector pcDNA3 
(section 2.2.2). Transfection of this vector into cells confers geneticin (G418) resistance 
to the cells.
It was decided to replace the viral CMV promoter inherent to pcDNA3 with the 
Trp-1 promoter sequence produced using PCR. This would allow assessment of the 
promoter activity using the reporter gene p-galactosidase. Subsequent to this, it was 
planned to additionally incorporate the murine B7 gene into the modified vector 
containing the Trp-1 promoter. The advantage of using a melanoma-specific promoter 
such as Trp-1 is that for gene therapy applications, it is advisable to restrict gene 
expression to the target cell population. This may be achieved either via selective 
delivery or selective expression.
Problems were encountered with the ligation of the PCR product of the Trp-1 
promoter into pcDNA3. If there had been more time, it would have been sensible to 
redesign the PCR primers, to create restriction sites specific for those used to remove 
the CMV promoter. With sufficient time, expression studies would have been 
performed to compare the activity using the original pcDNA3 containing the CMV 
promoter and the modified vector with the Trp-1 promoter. These studies would have
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been performed in the B16 and K1735 cell lines in parallel, to ensure that low levels of 
expression were not simply a cell-line specific effect. Although initial studies by Vile 
and Hart (1993a) involved the use of both the Trp-1 and the Tyr promoters, further work 
concentrated on the Tyr promoter (Vile and Hart, 1995; Chong et a l, 1996). Personal 
communication with Dr. R. Vile indicated that the Trp-1 promoter had exhibited a lack 
of reproducibility, leading to preferential use of the Tyr promoter for all further work.
2.4.2. Expression of genes for immunostimulation in control K1735 cells.
Problems were encountered using electroporation to transfect K1735 cells 
(section 2.3.2). The use of a modified buffer for electroporation containing Hepes to 
reduce the osmotic shock to the cells enhanced cell survival compared with the use of 
PBS. The initial transient transfection studies using PBS demonstrated no expression of 
either the B7 gene or the MHC II genes. It was decided to attempt the stable 
transfection of these genes separately in K1735 cells, using antibiotic selection. K1735 
cells were successfully transfected with pcDNA3 containing the murine B7 gene (Fig. 
2.13), a stable expressing cell line was established and frozen stocks were produced.
A population of K1735 cells were selected in antibiotic medium after 
transfection with the two MHC class II genes plus a puromycin selection vector. These 
cells did not express the class II genes, in spite of acquiring antibiotic resistance from 
the puromycin vector, which was transfected at a tenth of the concentration of the class 
II plasmids. The control spleen cells demonstrated that the antibody was active. The 
lack of expression could have been due to inefficient transcription or translation of the 
class II genes in the K1735 cells, or that the proteins were not being expressed correctly
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at the cell surface. Since there was a requirement for two genes to be incorporated into 
the genome, it would probably have been necessary to screen many more colonies to 
discover a stable transformant. It would have been interesting to perform SDS-PAGE to 
discover whether any MHC class II proteins were present intracellularly. Unfortunately, 
there were no cell samples remaining to do this.
The MHC class II genes have successfully been expressed from the same vectors 
in the melanoma cell line K1735 by Chen et al. (1994) after transfection via calcium 
phosphate co-precipitation. It therefore seems most likely that the problem is one of 
delivery. Although electroporation is generally deemed a more efficient transfection 
method than co-precipitation, it seems that we either needed to test more clones, or 
maximise the efficiency of the vector and transfection method.
Widespread use of viral vectors has allowed increased efficiency of delivery to 
several cell lines, as reviewed by Miller and Vile (1995). Developments within the viral 
vector field have led to the production of retroviral vectors capable of efficiently co­
expressing two genes simultaneously from the same vector, known as internal ribosome 
entry site (IRES) vectors (Ghattas et al., 1991). This approach attempts to overcome the 
problems associated with multiple gene expression. These include regulated splicing of 
a single primary transcript to produce separate mRNAs, where one gene often produced 
expression at the expense of the other. Also, systems where the upstream gene was 
expressed from the viral promoter in the LTR while the downstream gene was expressed 
from an internal promoter often produced competitive interference between the 
promoters. The IRES vectors use the viral LTR to express a single polycistrionic 
transcript, from which several gene products can be translated. This avoids differential
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expression of the separate genes. This technology would provide an alternative vector 
system for the transfection of the K1735 cells with the MHC class II genes.
2.5. SUMMARY
The lack of reproducibility of reporter gene expression driven by the tissue- 
specific promoter Trp-1 in B16 melanoma cells was not encouraging for its further use 
for restricting the expression of the costimulatory molecule B7 in melanoma cells. 
Efforts concentrated on establishing cell lines capable of stable expression of both the 
MHC class II genes and the costimulatory molecule B7. The melanoma cell line K1735 
was used to produce a line exhibiting stable expression of B7, but no expression of the 
MHC class II genes was determined throughout the study. This meant that no 
immunostimulatory analysis was performed to substantiate the theory underlying the 
project.
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CHAPTER 3. Evaluation of the transfection efficiency of poly(amino 
acid)-DNA complexes.
3.1. INTRODUCTION
The ability of polycationic polymers to deliver DNA to eukaryotic cells was 
studied by Farber et a l (1975) and shown to be dependent on the ratio of polycation to 
DNA. It is now widely accepted that cationic polypeptides form particulate systems 
with DNA, and early work by Olins et a l (1967) established that several basic 
polypeptides were able to stabilise DNA against thermal denaturation. More recently, 
Zenke et a l (1990) showed that chloroquine was able to elevate the gene transfer 
efficiency of polycation-DNA complexes in vitro by several orders of magnitude, and 
this technique has been widely used to promote transfection of cultured cells. The work 
presented here attempts to correlate the formation of complexes between cationic 
polymers and DNA with in vitro transfection efficiency in eukaryotic cells.
3.2. MATERIALS AND METHODS
3.2.1. Deoxyribonucleic Acid (DNA).
Plasmid pRSNlacZ (section 2.2.2) was used for all polycationic-DNA 
complexation and transfection studies. This construct contains the Eschericia coli p- 
galactosidase reporter gene under the control of the Rous sarcoma virus long terminal 
promoter/enhancer sequence, which allowed determination of gene transfer efficiency to 




All cationic polypeptides were obtained from Sigma, and their individual 
characteristics are described below. The cationic polypeptide solutions were prepared 
under clean laboratory conditions, using sterile Hepes buffered saline (HBS; appendix 
A). The lysine-alanine co-polymers used in this study contained different molar ratios 
of lysine:alanine, reflected in the abbreviations used.
Polymer DPn Mol. Wt. (salt) Mol. Wt. per Unit 
Charge
Mw/Mn
Poly-L-lysine.HBr 219 45700 208.9 1.1
Poly-D-lysine.HBr 240 50200 208.9 1.28
Poly-L-omithine.HBr 260 50700 194.9 1.1
Poly-L-arginine.HCl 217 41800 192.5 1.2
Poly (Lys.HBr, Ala) 1:1 355 50000 280.1 N/A
Poly (Lys.HBr, Ala) 2:1 323 52700 259.3 N/A
Poly (Lys.HBr, Ala) 3:1 178 31000 238.8 N/A
(DPn - degree o f  polym erisation; N /A  - not available)
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F igu re  3 .1 . Chemical structures o f  the hom opolym ers and random co-polym ers. A ll polym ers w ere 
prepared from the corresponding N “-carboxy anhydrides, providing a straight polypeptide backbone. The 
positive charge o f  polym ers was the result o f  protonation o f  the amino group on the side chains at the 
experim ental pH conditions.
3.2.3. Calculation of Polymer to DNA charge ratio.
Complexation of the plasmid pRSVlacZ with cationic polymers was determined 
as a function of both the mass of constituents and the molar charge ratio (+/-).
Charge Ratio (+/-) Total number of Positive charges (mols) 
Total number of Negative charges (mols)
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3.2.3.1. DNA.
The calculation of negative charge provided by the DNA was determined on the 
basis that each nucleotide in the DNA sequence is associated with a single negative 
charge. A mean value of 330 was used as the molecular weight of a 
monophosphorylated nucleotide, as established from data given by Sambrook et al. 
(1989) for dAMP, dCMP, dGMP and dTMP.
3.2.3.2. Cationic homopolymers.
The effective molecular weight with which one positive charge is associated was 
calculated. Compensation was made for those polymers supplied in salt form.
3.2.3.3. Cationic co-polymers.
The molar ratio of charged to neutral polymer had to be taken into account with 
the co-polymers. The molecular weight associated with one charge was calculated 
(Table 3.1), compensating for salts or assuming complete ionisation of the side-chain 
amino terminal groups in those polymers not supplied as salts. Dissociation of the salts 
under appropriate conditions produced a protonated amino group (NH3+) and an anion 
(Br or C1‘).
3.2.4. Complexation of DNA with cationic polymers.
The DNA solution comprised 6 jig of DNA in 250 j l l I  HBS, while the polymer 
was prepared at the concentration of interest also in 250 p,l HBS. The separate solutions 
were allowed to equilibrate at room temperature before adding the polymer solution to
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the DNA solution. The mixture was gently mixed by inversion three times and the 
complexes were incubated at room temperature for 20 minutes before use.
3.2.5. Ethidium bromide as a fluorescent probe.
The intercalation of ethidium bromide (Fig. 3.2) between DNA base pairs and 
the resulting fluorescence of the complex has allowed it to be used as a probe for nucleic 
acids both in agarose gels and for quantification by spectrofluorimetry (Sharp et al., 
1973). Ultraviolet radiation is absorbed by the DNA and the bound dye, and the energy 
is re-emitted in the red-orange region of the visible spectrum (Sambrook et a l, 1989).
Figure 3.2. Structure o f  ethidium bromide : 2:7 d iam ino-9-phenyl-10-ethyl phenanthridinium bromide.
3.2.5.1. Fluorescence studies o f polymer-DNA complexes.
The polymer-DNA complexes were prepared as described in section 3.2.4. and 
complexation was analysed using a method adapted from that of Gershon et al. (1993). 
The 500 jil of complex suspension was diluted to 3.0 ml with HBS and immediately 
prior to analysis, 3 fil of ethidium bromide was added (0.5 fig/ml). The molar ratio of 
ethidium to nucleotide under these conditions was 0.42. All samples were vortexed and
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the fluorescence measured using a Shimadzu RF-450 spectrofluorophotometer (XqX 260 
nm; 600 nm). A 1-cm light path cell with excitation and emission slits of 5 nm was 
used. The degree of complexation was measured as the percentage of the fluorescence 
of a control sample containing 6 jag of uncomplexed plasmid DNA. The fluorescence of 
the control sample was normalised to 100%. A reduction of fluorescence was seen 
relative to the control as the intercalation of ethidium bromide between the DNA base 
pairs was prevented by complexation with the cationic polymers.
3.2.6. Transfection of eukaryotic cells with polymer-DNA complexes.
Cells were seeded in 6-well plates at a density of 1x10s cells per well 16-20 
hours before transfection. One hour before transfection, the medium was removed and 
replaced with 1.5 ml complete, pre-warmed medium or the reduced-serum transfection 
medium opti-MEM (Gibco). The complexes were prepared as detailed in section 3.2.4, 
then added dropwise around the wells immediately after the addition of chloroquine at a 
concentration of 100 p,M. The cells were incubated with the complexes at 37°C and 5% 
CO2 for four hours. The transfection medium was then removed and the cells were 
washed twice in ice-cold complete medium, before replenishing each well with 2 ml of 
complete medium. The cells were then incubated for a further 44 hours at 37°C before 




3.3.1. Complexation of pRSVlacZ with cationic polypeptides.
The capacity for polycations to complex the DNA was initially determined using 
the ethidium bromide exclusion assay. The complexes were prepared over a range of 
charge ratios (polymer : DNA) from 0 - 3.0, which was equivalent to mass ratios 
between 0-1.0, and the quenching effect monitored accordingly. This assay allows 
determination of the ratio of polymer / DNA which is required for complexation 
conditions, but it does not provide an indication of the strength of interaction between 
the different polymers and the plasmid DNA. Additionally, conformational differences 
between complexes formed using the various polycations and DNA cannot be inferred 
from variations in the fluorescence quenching profiles of the different polymers, and 
exclusion of ethidium is not necessarily an indication of condensation. Thus, this assay 
is only of value in establishing the ratios of constituents required for complexation, but 
little other information can be deduced or extrapolated from the results.
3.3.1.1. Homopoly(amino acid)-DNA complexation.
Complexation exhibited by mixtures of homopoly(amino acid)s with pRSVlacZ 
were examined by ethidium bromide exclusion. Fluorescence was quenched when the 
DNA was complexed with polycations in agreement with Feigner et al. (1987).
The fluorescence intensity exhibited a linear decrease from a charge ratio of 0 - 
1.0, as complex formulations with higher ratios of polymer / DNA were produced. At 
charge ratios greater than 1.0, a constant minimum background level was reached (Fig.
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3.3a). When the complex formulations were expressed as mass ratios (Fig. 3.3b) similar 
profiles were observed for the fluorescence quenching since the molecular mass per unit 
charge was similar for these homopolymers. The decrease in fluorescence occurred 
between mass ratios of 0 - 0.4, above which the constant minimum background 
fluorescence was maintained. Poly-L-arginine appeared to deviate slightly from the 
profile displayed by the other homopolymers, with a slightly shallower gradient during 
the linear decrease, reaching the minimum at a mass ratio of 0.6. This difference was 
not so noticeable in the charge ratio curve.
3.3.1.2. Co-poly(amino acid)-DNA complexation.
The lysine, alanine co-polymers showed similar complexation patterns to the
homopolymers with respect to the charge ratio required to provide fluorescence 
quenching (Fig 3.4.a). The profile exhibited was essentially the same as for the 
homopolymers, with a curve split into two clear regions: the initial linear decrease in 
fluorescence reaching a minimum at a charge ratio of 1-1.5, above which, a fairly 
constant minimum was maintained. The plots of fluorescence quenching versus mass 
ratios of the co-polymers (Fig 3.4.b) showed a shift to the right, compared with those of 
the homopolymers. The increased mass ratio (polymer / DNA) required to produce a 
similar level of fluorescence exclusion reflected the neutral component (alanine) 
contained within each co-polymer. An increase in the ratio of cationic lysine : neutral 
alanine produced a resultant decrease in the mass of co-polymer associated with each
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positive charge. Consequently, a mass ratio of 1:1 for poly-lysine / DNA was 
equivalent to mass ratios of 1.34:1, 1.24:1 and 1.14:1 for the co-polymers lysine-alanine 
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F ig u re  3 .3 . C om plexation o f  plasmid D N A  using increasing quantities o f  cationic hom opolym ers and 6
\ig pR SV lacZ  plasmid. After m ixing, the com plexes were incubated for 20 minutes at room  temperature,
and ethidium  bromide was added (0.5 pg/m l) im m ediately prior to the fluorescence reading. T he data is
expressed in terms o f  the polym er:D NA  charge ratio (A ) and the mass ratio (B ). The data points represent
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F igu re  3 .4 . Com plexation o f  plasmid D N A  using increasing quantities o f  lysine-alanine co-polym ers and
6 p g  pR SV lacZ  plasmid. Ethidium bromide (0.5 |ig /m l) was added after 20  minutes incubation at room
temperature, and the fluorescence measured im mediately The com plexation data for poly-L -lysine is also
included. The data are expressed in terms o f  the polym er:D NA  charge ratio (A ) and the mass ratio (B ).
The data points represent the mean o f  three replicate evaluations.
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3.3.2. Transfection of B16 murine melanoma cells.
3.3.2.1. Standardisation o f transfection ofB16 melanoma cells.
The activity of p-galactosidase in cell extracts assayed 48 hours post-transfection 
with different polymer-DNA complexes was shown to vary considerably between 
experiments (Fig 3.5). This problem was overcome by the introduction of a standard 
complex as a positive control in each experiment. The majority of transfection studies 
in the literature have used polylysine for complexation of DNA (Zatloukal et al., 1992). 
The profile for transfection of B16 cells using polylysine-DNA complexes of varying 
charge ratios (+/-) in the presence of 100 |iM chloroquine is shown in figure 3.6. The 
optimum charge ratio (+/-) for transfection was shown to be 1.5. All further transfection 
experiments included polylysine-DNA complexes at a charge ratio of 1.5 with 
chloroquine as a positive control.
3.3.2.2. Influence o f polypeptide-DNA complex composition on transfection efficiency. 
Initial transfection efficiency studies involved determination of the optimum
polymer : DNA ratio required for the transfection of each different polymer. Complexes 
were prepared at increasing polymer/DNA (+/-) ratios, and concurrent transfection with 
poly-L-lysine at a charge ratio of 1.5 was used as the positive control for each 
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F igure 3.5. Effect o f the charge ratio o f  poly-L-ornithine (A) and poly-L-arginine (B )-D N A  com plexes 
on the transfection efficiency into B 16 melanoma cells. Transfections were performed using 6 pg  
pRSVlacZ  and polymer as described in section 3.4, in the presence o f  100 pM  chloroquine. The cells 
were harvested and assayed for (3-galactosidase activity 48 hours later using the ONPG assay (section  
2.20.2). Transfection using com plexes o f poly-L-lysine and pRSWlacZ ( 0  ) was used as the positive  
control. The data presented represent the mean +  SEM (n=3).
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In order to compare experiments more easily, the positive control was 
normalised to 100% (Figs. 3.7 and 3.8). P-galactosidase activity above basal levels was 
only routinely observed at or above a charge ratio of 1.0 (+/-) for all polymer-DNA 
complexes, and a maximum transfection efficiency was observed near a charge ratio of
1.5. At higher charge ratios, usually a decline in transfection capacity was observed, 
although detectable levels of expression were still obtained within the ranges studied 
(generally up to a charge ratio of 2.0). It is likely that some cells were transfected at 
charge ratios below unity, and these could be visualised by staining with X-gal, but the 
ONPG assay used was insensitive unless the proportion of cells transfected was greater 
than approximately 0.1%. The ONPG assay required 109 enzyme molecules present to 




F ig u re  3 .6 . Charge-ratio (+/-) effect o f  po lylysine-D N A  com plexes on transfection effic ien cy  in B 16  
m elanom a cells. Transfections were performed using 6 p g  pRS YlacZ  and various quantities o f  poly lysine 
(section  3 .4), in the presence o f  100 pM  chloroquine. The cells were harvested and assayed for |3- 
galactosidase activity 48 hours later using the ON PG  assay (section 2 .20 .2 ). The data presented represent 
the mean ±  SEM  (n=3).
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F igure 3.7. Optimisation o f the polymer:DNA ratio for gene transfer. Each point represents the mean 
value from three replicate transfections. Com plexes were formed with 6 pg plasmid D NA , and using 
increasing quantities o f  poly-L-ornithine (A), poly-L-arginine (B), and poly-L-lysine (C). All 
transfections utilised 100 pM chloroquine and the cells were assayed 48 hours post-transfection using the 
ONPG assay (section 2.20.2). Each point was calculated as a percentage o f transfection using poly-L- 
lysine-D N A  at a charge ratio o f 1.5 with chloroquine (100 pM ) as the positive control (H  ) and represent 
the mean ±  SEM (n=3).
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F igure 3.8. Optimisation o f  the co-polym er:DNA ratio for gene transfer. Each point represents the mean 
value from three replicate transfections. Complexes were formed with 6 p.g plasmid D N A , and using 
increasing quantities o f  the lysine-alanine 1:1(L,A 1:1), 2:1 (L,A 2:1) and 3:1 (L,A 3:1) co-polym ers 
(shown in A, B and C respectively). All transfections included 100 pM  chloroquine and the cells were 
assayed 48 hours post-transfection by the ONPG assay (section 2.20 .2). Each point was calculated as a 
percentage o f transfection using poly-L-lysine with chloroquine (100 pM ) as the positive control ( CD ), 
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F igu re  3 .9 . Influence o f  polymer used for com plexation o f  D N A  on the transfection efficiency. 
C om plexes w ere formed with 6 jig pR SV lacZ at a charge ratio (+/-) o f  1.5. A ll transfections were carried 
out in the presence o f  100 jiM  chloroquine, and activity was assayed 48 hours post-transfection using the 
O N PG  assay for P-galactosidase activity (section 2 .2 .20.2). Data points represent the mean ± SEM  (n=3).
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3.32.3. Comparative transfection efficiency of complexes.
A direct comparison of the transfection efficiencies for the different polymers 
was performed at a charge ratio of 1.5 (+/-). This allowed a rank order for transfection 
efficiency to be established (Fig. 3.9) : poly-L-ornithine »  poly-D-lysine ~ poly-L- 
lysine > Lys:Ala (2:1) « poly-L-arginine > Lys:Ala (3:1). The co-polymer Lys:Ala 
(1:1), which had a lower charge density than all the other polypeptides studied, failed to 
increase gene expression above background levels.
The activity of the complexes was also determined in situ using the 
histochemical stain X-gal. This provided an indication of the number of cells being 
transfected by each complex. A by-stander effect has been observed with a pro-drug 
treatment of melanoma (Bonnekoh et al., 1995), but the majority of gene therapy 
applications require that the maximum number of target cells possible should be 
transfected with the therapeutic gene. For this reason, delivery systems should be 
adapted to enhance delivery to the target cell population. There were few positively 
stained blue cells in all cases (1-5%). Poly Lys, Ala (1:1) showed no staining, in line 
with the ONPG assay results. Figure 3.10 shows representative photographs of cultured 
cells treated with pRSVlacZ complexed with poly-L-lysine, poly-L-ornithine, poly Lys, 
Ala (1:1) and poly Lys, Ala (3:1).
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A B
F igure 3.10. B16 melanoma cells transfected with com plexes prepared with 6 |ig  pRSVlacZ  plasmid and 
the polymers poly-L-lysine (A), poly-L-ornithine (B ), poly Lys,Ala (1:1) (C) and poly Lys,Ala (3:1) (D). 
Transfections were performed at a charge ratio o f 1.5 with 100 (iM  chloroquine, and the cells treated 
with X-Gal 48 hours post-transfection. Cells positive for (3-galactosidase activity stain blue with X-Gal 
treatment. Cells were photographed at magnification x300. The fields shown are representative o f  the 
expression levels detected over the plates, with three w ells transfected per formulation.
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3.4. DISCUSSION
The association of eukaryotic nucleic DNA with cationic polypeptides such as 
histones and protamines stimulated investigation into the interaction of a variety of 
basic polymers with DNA. Physical characterisation by Olins et a l (1968) of 
complexes of linear DNA with various polycations led to the deductions that such 
interactions were stoichiometric and co-operative. The motivation for the present study 
was to determine whether this similarity between complexation of DNA and a range of 
polypeptide systems correlated with transfection efficiencies.
3.4.1. Complexation of plasmid-DNA using cationic polypeptides.
All of the polymers tested produced complete exclusion of ethidium bromide at 
electroneutrality, and for the homopolymers this equated to a polypeptide / DNA mass- 
ratio of approximately 0.4:1. All of the homopolymers were a-amino acids, and the 
positive charge was hence provided by the amino group on the side-chain. While a 
similar charge-ratio profile was exhibited by the co-polymers, the mass-ratio profile 
differed, accounting for the neutral alanine component contained within the polymer 
chain.
Studies by Leng and Felsenfeld (1966) demonstrated that fragments of calf 
thymus DNA could be partially precipitated by polylysine. This involved
ultracentrifugation of systems produced under strictly controlled ionic reaction 
conditions. At a charge ratio of 1.0, all of the DNA was precipitated, but at any point
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below this the majority of the polylysine added to the system was found in the 
precipitate. This indicated that under tightly regulated reaction conditions, a co­
operative reaction could be produced.
The precipitation of DNA and polylysine at the charge ratio of 1.0 has also been 
described by Carroll (1972). It was shown in these experiments that the ionic 
concentration of the reaction solution could determine the characteristics of the 
complexes formed, consistent with the observations of Tsuboi et a l (1966). 
Additionally, Shapiro et al. (1969) described a selective interaction, where a well- 
ordered complex was produced under optimal conditions. A nucleotide selectivity for 
A-T-rich DNA was displayed by the polylysine, although this could be affected by 
altering the reaction conditions. The relatively sharp decrease in fluorescence that 
occurred during this assay supports the theory of a co-operative interaction during 
charge neutralisation of DNA molecules (Manning, 1980).
The presence of the alanine within the polymer had little effect on the 
complexation capacity of the charged lysine. This was a likely result of the 
derivatisation of the co-polymer occurring via the a-amino groups, leaving the amino 
groups on the side-chains to interact with the DNA. Hence, the backbone of the 
polymer consisted of a straight chain of amino acids, with the side-chains providing the 
only protrusions. Moreover, alanine residues provided little steric hindrance to the 
charge association, and the co-polymers exhibited similar stoichiometric behaviour to 
the homopolymers, with one positive unit interacting with each theoretical negative 
charge. Hence the stoichiometry of the interaction was apparently unaffected by the 
presence of the neutral alanine within the co-polymeric chain.
3.4.2. Correlation between charge ratio and transfection activity.
In contrast to the complexation data, the polymers displayed different 
transfection profiles, although those that successfully transfected cells all exhibited a 
similar pattern of activity. All of the polymers demonstrated little or no expression of 
the reporter gene if complexes were prepared below the critical point of charge 
neutralisation. This observation is at odds with the reports of a co-operative interaction 
between cationic polymers and DNA (section 3.4.1).
If the system was co-operative, transfection activity would have been observed 
at the charge ratios (+/-) below electroneutrality. This is because during co-operative 
binding the initial interaction between two molecules favours further binding to the host 
molecule. Therefore, the population of complexes would have contained some DNA 
molecules that had been completely neutralised by polymer, and some that had 
experienced little interaction with the cationic polymer. The transfection results argue 
that complexes produced by ‘flash’-mixing were not produced in a co-operative manner. 
In view of this, the fluorescence profiles could only be used to demonstrate the optimum 
ratios for interaction of the polymer and the DNA, and not to infer co-operativity of the 
reaction.
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Beyond electroneutrality, there was an increase in gene expression to a 
maximum at a charge ratio (+/~) around 1.5. This suggested that the complexes required 
an overall positive charge before they could overcome the repulsion of the DNA by the 
negatively charged cell surface, and interact non-specifically with it. This hypothesis 
was suggested by Bond and Wold (1987), who studied transfection of cell lines with 
polyomithine-DNA complexes. They showed that there was an optimum charge ratio 
for transfection, with a net overall positive charge, and that above this, the 
transformation efficiency decreased. Additionally, charge neutralisation is required to 
induce DNA collapse, producing the characteristic ‘doughnut’ or toroid structures 
(Olins et al., 1971; Laemmli, 1975).
At charge ratios greater than 1.5, the transfection ability of the complexes 
declined. One hypothetical factor which may account for this is the structure of the 
complexes in the presence of excess polylysine, and whether the extra polymer 
continues to be incorporated into the complex. Carroll reported (1972a) that above 
electroneutrality, DNA-polylysine complexes produced a high level of unregulated 
aggregation, and a precipitation was observed at electroneutrality. At higher charge 
ratios (+/-), the solubility of the complexes increased, probably due to the binding of 
more excess polylysine (Carroll, 1972b). The excess positive charge was believed to 
serve to separate the complexes by charge repulsion.
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An alternative theory to account for the reduction in transfection capacity 
involves the belief that the excess polycation does not associate with the DNA-polymer 
complex. In this situation, the free polymer would be capable of competing for uptake 
into the cell with the complexes. Additionally, at the point of dissociation of the 
polycation and the DNA inside the cell, any free polymer in the vicinity would compete 
to bind the recently released DNA. This would theoretically provide a reduction in 
quantity of free DNA potentially available for transfer to the nucleus. Free polylysine 
would also be expected to have toxic effects on the cells in culture which could explain 
the lower efficiency observed at high charge ratios. This is discussed further in Chapter 
6 .
3.4.3. Comparative transfection activity of polymers in B16 melanoma cells.
Uptake of the complexes after association with the cell surface is believed to 
occur by endocytosis into lysosomes, which is supported by the prerequisite for 
chloroquine in the transfection medium. Luthman and Magnosson (1983) demonstrated 
the enhancement of transformation efficiency of polyoma cells with the use of 
chloroquine. Chloroquine serves as a lysomotropic agent, although its mode of action is 
under some discussion. The concentrations of chloroquine necessary to effect increased 
transfection levels are relatively high (25-100 pM), as determined by Zenke et al. 
(1990). These concentrations of chloroquine are cytotoxic, and this is a limiting factor 
in the transfection contact time of the complexes with the cells.
i l l
The original hypothesis for the mechanism of action of chloroquine was that as a 
weakly basic molecule, chloroquine was capable of increasing the pH within the 
lysosomes. This would serve to reduce nuclease activity and hence protect the DNA 
from degradation. Dean et a l (1984) demonstrated that a concentration of 10 |iM was 
sufficient to inhibit nuclease activity, leading to an alternative hypothesis for the action 
of chloroquine in enhancing gene expression in transfected cells.
Zatloukal et a l (1992) postulated that accumulation of the chloroquine caused 
osmotic changes within the lysosome, producing membrane disruption and release of 
the contents into the cytosol. Studies by Sipe et al. (1991) demonstrated that the 
endosomes of K-562 cells were devoid of Na+K+-ATPase regulation of the pH gradient 
across the endosomal membrane. Hence there was no regulation of endosomal 
acidification observed. Therefore, chloroquine was shown to accumulate in the 
endosomes, and without the pH gradient regulation, the interior of the endosome 
became highly acidic.
There are several factors that may account for the varying transfection efficiency 
observed between the different polymer-DNA complexes. The complexes may exhibit 
a diversity in size. The postulated methods of uptake for complexes of a similar nature 
involve adsorptive endocytosis (Legendre and Szoka, 1992) also known as absorptive 
pinocytosis (Ryser and Shen, 1978). This involves the ingestion of fluid containing 
solutes or macromolecules via small vesicles (< 150 nm diameter). This is a process 
that most eukaryotic cells are continually performing at different rates, dependent on
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cell-type (Watts and Marsh, 1992). The vesicles may endocytose molecules 
indiscriminately, or the more specific process of receptor-mediated endocytosis may 
occur via clathrin-coated pits. Cellular uptake by particles of roughly 100 nm routinely 
occur (Wagner et al., 1991), and it can be assumed that any particles which deviate from 
this to a large extent may suffer selective or restricted uptake.
An alternative argument to account for the variation in transfection efficiencies 
of the polymers is that the polymers may be providing different stabilising effects on the 
DNA due to the chemical nature of the side chains. It was reported by Olins et al. 
(1967) that a decreasing order of stability towards melting was exhibited by poly-L- 
omithine > poly-L-lysine > poly-L-arginine, which corresponds to the rank order of 
efficiency of transfection for the homopolymers shown in these studies. This would 
indicate that the complexes with reduced transfection efficiency are likely to be less 
stable in the transfection medium.
The release from the endosome of all the complexes is primarily a result of the 
presence of chloroquine, as determined by the inability of cells transfected without 
chloroquine to express the reporter gene. Distal to this process, differences in 
transfection effectiveness may be introduced by variations in the dissociation of the 
DNA from the polymer, transfer to the nucleus, and uptake and transcription within the 
nucleus. Transcription has been shown to be reduced by methylation of the DNA and 
additionally affected by the local concentration of histone HI (Johnson et a l, 1995). 
Different expression efficiencies may be related to the degree of protection of the DNA 
from methylation conferred by the various polymers.
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3.4.4. Histochemical staining of transfected cells.
The histochemical staining revealed very little difference in the percentage of 
cells within the population that expressed the reporter gene ( 1-5%). This was in 
contrast to the spectrophotometric assay, where the levels of expression were shown to 
vary within orders of magnitude from one polymer to another. This suggests that 
individual positively stained cells transfected with one system were expressing higher 
levels than similar cells which had been transfected with a different polymer-DNA 
complex.
3.5. SUMMARY
The complexation of plasmid DNA by a variety of polycationic polymers was 
demonstrated using spectrofluorimetry. All of the polymers appeared to bind the DNA 
in a similar manner, such that the DNA was completely complexed at a 1:1 ratio of 
positive / negative units. A co-operative reaction has been reported for such complexes, 
although this contrasted with the transfection activity profile, where no expression was 
observed below electroneutrality. The polymer-DNA systems exhibited an optimum of 
expression between a charge ratio of 1-1.5, and different transfection abilities were 
observed with the selection of polycations. The rank order of efficacy was poly-L- 
ornithine »  poly-D-lysine « poly-L-lysine > Lys:Ala (2:1) * poly-L-arginine > Lys:Ala 
(3:1). The co-polymer Lys,Ala (1:1) did not transfect B16 melanoma cells. 
Histochemical staining with X-Gal did not reflect the variation seen with the 
spectrophotometric assay.
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CHAPTER 4. Characterisation and biological activity of complexes 
formed by DNA and polyethylene glycol-poly-L-lysine block co­
polymers.
4.1. INTRODUCTION
Polymer conjugation has been used extensively to alter the biodistribution, 
elimination and rate of metabolism of covalently bound drugs. Conjugation of polymers 
to biologically active protein drugs has been used as a method to increase efficacy and 
reduce toxicity. Polymers have also been utilised in the design of polymer-drug 
conjugates to facilitate controlled release and targeting of low molecular weight drugs.
Hydrophilic polymer-protein conjugates can exhibit increased solubility and 
stability, reduced proteolytic degradation, lower immunogenicity, and a prolonged 
protein plasma elimination half-life. For these reasons, a variety of polymers have been 
utilised as drug carriers, including poly(hydroxyethylglutamate) (PHEG; De Marre et 
a l, 1994), hydroxypropylmethacrylamide (HPMA; Kopecek et al., 1987) and 
polyethylene glycol (PEG; Abuchowski and Davis, 1979).
PEG has been used extensively for the modification of therapeutic proteins, 
conferring a decrease in the toxicity and immunogenicity of the protein, whilst both 
increasing the water solubility and plasma half-life (Katre, 1993; Fuertges and 
Abuchowski, 1990). PEG is believed to alter the properties of the conjugated protein 
due to the formation of a PEG mantle around the protein molecule (Lee et al., 1981).
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It has been postulated that PEG sterically hinders reaction with cells of the 
immune system (Tomiya et al, 1985), and PEG itself has been shown to be non- 
immunogenic (Abuchowski et al., 1977). PEG-protein conjugates exhibit varying 
degrees of reduced immunogenicity which differ for each protein and with the amount 
of PEG attached to the protein surface (Ashihara et a l , 1978). PEG also protects the 
conjugated moiety from proteolytic degradation (Wieder et al, 1979) and reduces the 
biological activity of the protein. This loss of activity is more than offset by the 
concomitant increase in plasma circulation, which is often augmented from a few 
minutes to several hours or even days.
A similar strategy could be utilised to modify the properties of condensed DNA 
particles. In this study this has been investigated using PEG-polylysine co-polymers. 
The core of such a complex would consist of the polylysine-DNA complex, and the 
PEG chains would be expected to extend into the aqueous solution (Fig. 4.1). PEG is an 
extremely hydrophilic polymer, and the establishment of a water shell around the 
peptide core would be expected to result in a colloid with enhanced lyophilic character.
PEG has been used to modify the surface properties of other colloidal systems. 
PEG has been used to coat the surface of liposomes (Woodle and Lasic, 1992), 
producing an increase in hydrophilicity. Liposomes are normally cleared from the 
circulation by the reticuloendothelial system (RES), and circulation time is related to 
vesicle size and phospholipid or cholesterol content (Senior, 1987). The RES 
constitutes mononuclear phagocytes which engulf ‘foreign’ macromolecules, and they 
are particularly concentrated in the lung, in the liver (as the Kuppfer cells ) and in the 
spleen (Poste, 1983). PEG coating of these liposomes reduces the rate of RES-mediated
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clearance, a phenomenon which has also been observed when polystyrene particles were 
coated with polymeric glycols (Ilium et al., 1986). This phenomenon is thought to be 
due to the polymers on the liposome surface exerting a long-range mutual repulsion 
between adjacent bilayers, inhibiting the interaction of macromolecules and cellular 
surfaces in the blood with the PEG-coated liposomes (Wu et al., 1993).
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Figure 4 .1. Schematic diagram o f  the putative structure o f PEG-pLL-DNA com plexes in aqueous 
systems, showing the PEG mantle expected to form around the hydrophobic core o f  com plexed pLL- 
DNA.
PEG-coated liposomes have become known as ‘stealth’ liposomes, and have 
been demonstrated to preferentially accumulate in tumours (Gabizon and 
Papahadjopoulos, 1988). The rationale for the use of these vehicles to deliver 
anthracycline anticancer agents preferentially to tumours was due to the belief that this 
characteristic resulted from the increased circulating time (Gabizon, 1992). However, 
Wu et al. (1993) demonstrated that a higher intrinsic vascular permeability of PEG- 
coated liposomes helped to effect preferential accumulation in tumours.
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Traditional gene therapy vectors require development for future in vivo 
applications. This will involve alteration of the current vectors to overcome the 
problems related to toxicity, degradation and inefficient DNA delivery. The rationale 
for the production of a polylysine-PEG co-polymer for DNA delivery is to attempt to 
utilise the beneficial properties of PEG-protein conjugates, which result in reduced 
toxicity, reduced immunogenicity and reduced degradation of the drug. The polylysine 
moiety is necessary for DNA-binding, while the PEG could serve to enhance the 
performance of the system as a viable delivery vector for gene therapy. Studies on block 
co-polymers of this nature by Katayose and Kataoka (1996) have demonstrated that 
complexes of different polylysine chain length exhibited different stoichiometry of 
interaction. This group has also shown that the complexed DNA could be displaced 
from the co-polymers by excess poly-aspartic acid. This indicated that under 
appropriate conditions, the complexed DNA could be released from the vector to 
ultimately produce gene expression.
This chapter describes the investigation of complexation properties and 
transfection efficiencies of a selection of synthesized co-polymers. The synthesis of 
these block co-polymers was strictly controlled, so that accurate mass ratios of poly­
lysine : PEG were established. The co-polymers have well-defined structures, with little 
polydispersity. These studies attempt to determine how the co-polymers compare with 
the poly(amino acid)s investigated in Chapter 3, and whether the presence of PEG in the 
structure affects the interaction with DNA and the efficiency of gene delivery and 
expression.
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4.2. MATERIALS AND METHODS.
4.2.1. Structure of block co-polymers.
All of the polyethylene glycol-poly-L-lysine (PEG-pLL) co-polymers were 
kindly donated by Professor E. Schacht (University of Gent, Belgium). The block co­
polymers were formed by linkage via the alpha amino group, and their general structure 





Figure 4.2. General structure of co-polymers.
Polymer Mol. Wt. 
(PEG : pLL)
Mol. W t.: per unit 
charge
Effective molar ratio 
(PEG : pLL)
96-7 5,000:5,000 322.58 3:1
96-8 5,000:10,000 192.31 1.5:1
96-9 5,000:20,000 160.26 0.7:1
96-10 12,000:5,000 548.39 7:1
96-11 12,000:10,000 282.05 3.5:1
96-12 12,000:20,000 205.13 1.7:1
96-13 20,000:5,000 806.45 12:1
96-14 20,000:10,000 384.62 6:1
96-15 20,000:20,000 256.41 3:1
Table 4.1. Mass and molar ratios of co-polymers. (pLL - polylysine)
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4.2.2. Calculation of charge ratios for complexation.
The mass ratios of charged lysine to neutral PEG were documented by the 
supplier for each co-polymer. The effective molecular weight for each charged and 
uncharged monomer unit was calculated, and the ratio of charged-to-neutral component 
calculated for each polymer. The effective mass of polymer associated with one 
positive charge was calculated (Table 4.1). Complete ionisation of the lysine side-chain 
amino group was assumed at the experimental pH of 7.4.
The liposome DOTAP (N-[l-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl 
ammonium methylsulfate; Boehringer Mannheim, Germany) was used as a positive 
control in transfection experiments. The effective mass associated with one mole of 
positive charge was 774.21 g, and complexes were routinely prepared at a charge ratio 
of 2.5, according to the manufacturers’ directions. This charge ratio has been 
established as optimum for the B16 cell line (A. Uduehi, personal communication).
4.2.3. Ethidium bromide exclusion assay.
Complexes were formed using increasing masses of PEG-pLL and 6 fig 
pRSVlacZ to produce the charge range 0 - 2.5 (+/-), as detailed in section 3.4. DNA 
complexation was analysed using a spectrofluorimeter (section 3.2.5.1).
4.2.4. Fluorometric assay for p-galactosidase.
In cases where expression of p-galactosidase was low, a more sensitive assay 
using 4-methylumbelliferyl-p-D-galactoside (MUG) as the substrate for the enzyme was 
used (Macgregor et al., 1991). Cells were removed from the culture plates by gentle
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scraping, and cell extracts were prepared by freeze-thawing three times in 250 pi Z 
buffer (appendix A).
An aliquot of cell extract supernatant (10-105 pi) was added to the well of a 
microtitre dish (Nunc). The volume was made up to 150 pi with 30 pi of 3 mM MUG 
and the remainder with Z buffer. The plate was incubated at 37°C for 90 minutes, then 
75pl of STOP buffer (app. A) was added. Fluorescence was measured using a 
Fluoroskan II (A** 350 nm; Aem 450 nm), and the results calculated relative to the soluble 
protein content of the samples.
4.2.5. Protein assay of cell extracts.
Cell extracts were prepared in 250 pi Z buffer, and a 50 pi aliquot used for 
protein quantification. The soluble protein was assayed as detailed in section 2.2.20.3, 
and the standard curve for the assay is presented in appendix C.
4.3. RESULTS
4.3.1. Complexation studies using the ethidium bromide exclusion assay.
The fluorescence exclusion profiles of the various co-polymers are displayed in 
Figures 4.3, 4.4 and 4.5. The maximum exclusion for all of the co-polymers was 
reached at a charge ratio of approximately 1.25. These profiles were similar to those 
exhibited by the homopolymers and lysine-alanine co-polymers studied in Chapter 3. 
The linear decrease up to a charge ratio of 1.25 exhibited very little displacement from
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that observed with polylysine. At charge ratios above this, no further quenching 
occurred and a minimum background level of fluorescence was maintained.
As expected the profiles for the mass ratio-related fluorescence quenching 
exhibited distinct translocation from the polylysine exclusion profile. Within each 
series of co-polymers, where the mass of PEG remained constant, and an increasing 
mass of polylysine was present a trend was observed. As the quantity of polylysine was 
increased, the profile shifted left, towards that of the polylysine. Hence, the co-polymer 
within each series containing the lowest charge density was displaced furthest to the 
right, and the co-polymer with the highest charge density the furthest to the left (i.e. 
closest to the polylysine profile). This was useful verification of the composition of the 
co-polymers.
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Mass Ratio (Polymer / DNA)
F igu re  4 .3 . Ethidium bromide exclusion assay for PEG-pLL co-polym ers. The com plexes w ere prepared 
using 6 |ig  plasm id D N A  and increasing quantities o f  each co-polym er to produce the required charge 
ratio. Ethidium bromide (0.5 (ig/m l) was added im m ediately prior to the measurement o f  the 
fluorescence. This series o f  co-polym ers contains a constant quantity o f  PEG (5000), with varying ratios 
o f  polylysine (50 0 0 , 10000 and 20000). The exclusion  profile for polylysine is also show n for 
com parison. T he data points are expressed in terms o f  the polym er /  D N A  charge ratio (A ) and the mass 
ratio (B ). A ll data points are calculated as a percentage o f  a control containing 6 (Xg plasm id D N A , and 
represent the mean o f  three replicate evaluations.
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F igu re  4 .4 . Ethidium bromide exclusion  assay for PEG-pLL co-polym ers. The com plexes w ere prepared 
using 6 fig plasmid D N A  and increasing quantities o f  each co-polym er to produce the required charge 
ratio. Ethidium bromide (0.5 |ig /m l) was added im m ediately prior to the measurement o f  the 
fluorescence. This series o f  co-polym ers contains a constant quantity o f  PEG (12000), with varying ratios 
o f  polylysine (5000 , 10000 and 20000). The exclusion profile for polylysine is also show n for 
com parison. The data points are expressed in terms o f  the polym er /  D N A  charge ratio (A ) and the mass 
ratio (B ). A ll data points are calculated as a percentage o f  a control containing 6 fig  plasm id D N A , and 
represent the mean o f  three replicate evaluations.
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F igu re  4 .5 . Ethidium bromide exclusion  assay for PEG-pLL co-polym ers. The com plexes were prepared 
using 6 fig plasm id D N A  and increasing quantities o f  each co-polym er to produce the required charge 
ratio. Ethidium bromide (0.5 fig/m l) was added im m ediately prior to the measurement o f  the 
fluorescence. T his series o f  co-polym ers contains a constant quantity o f  PEG (20000), with varying ratios 
o f  polylysine (5000 , 10000 and 20000). The exclusion  profile for polylysine is also show n for 
com parison. The data points are expressed in terms o f  the polym er /  D N A  charge ratio (A ) and the mass 
ratio (B ). A ll data points are calculated as a percentage o f  a control containing 6 pig plasmid D N A , and 
represent the m ean o f  three replicate evaluations.
125
4.3.2. Comparative transfection capacities in B16 melanoma cells.
The various co-polymers form three subsets, where for one subset the amount of 
PEG is maintained at 5000, and the mass of polylysine conjugated to it increased from 
5000 to 10000 to 20000. This pattern is repeated for other subsets prepared with PEG 
masses of 12000 and 20000. All of the co-polymers exhibited the capacity to generate 
reporter gene expression levels above the background levels in B16 melanoma cells, 
when transfection was carried out in the presence of chloroquine (Fig. 4.6A). 
Transfections were performed at a charge ratio of 1.5, assuming that the co-polymers 
demonstrated similar charge-related transfection profiles to the homopolymers and 
lysine-alanine co-polymers. The levels of p-galactosidase activity were determined 
using the fluorescence-based MUG assay (section 4.2.4).
The dependency of the co-polymer-DNA complexes on chloroquine to produce 
effective transfection is shown in Figure 4.5B. Co-polymer complexes were active in 
the presence of chloroquine but produced no expression in B16 melanoma cells in the 
absence of chloroquine. At best, the co-polymers in the presence of chloroquine 
produced one third of the activity of polylysine-DNA complexes. The co-polymers 
containing a high PEG:polylysine ratio produced the lowest levels of expression. The 
co-polymers containing the most polylysine in all three subgroups exhibited slightly 













96-7 96-8 96-9 96-10 96-11 96-12 96-13 96-14 96-15 C pLUC D
PEG-pLL Co-polymer
F igu re  4 .6 . Comparison o f  transfection efficiency o f  PEG -pLL-D N A  com plexes using B 16  m elanom a  
cells. A ll com plexes contained 6  |ig  pR SV /acZ  plasmid and were prepared at a charge ratio o f  1.5. 
C hloroquine (lOOpM) was added to the transfection m edium  in A, but was excluded in B . T he positive  
control in A  and B consisted o f  poly-L -lysine-D N A  plus chloroquine (pLL+C). D O T A P (D ) w as included  
as a positive control in B , as an agent that successfully transfects cells without chloroquine. T he negative 
control (C) in both cases consisted o f  free D N A  added to the transfection medium. The cells w ere assayed  
after 48 hours using the M U G  assay. Each point represents the mean ±  SEM  (n=3).
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4.3.3. Comparative expression studies in HEK293 cells.
Encouraging reports from Dr. L. Seymour (personal communication) regarding 
the transfection efficiency of particulate complexes in HEK293 cells resulted in the use 
of this cell line for comparative transfection studies in parallel to B16 cells. The PEG- 
pLL co-polymers were all shown to produce gene expression above background levels 
in HEK293 cells, both with and without chloroquine. Transfections were performed at a 
polymer / DNA charge ratio (+/-) of 1.5 for comparative purposes, and the levels of p- 
galactosidase activity determined using the fluorescence-based MUG assay (section 
4.2.4). The three subsets of co-polymers, containing three masses of PEG, each with 
three different quantities of poly lysine exhibited no trend in transfection efficiency.
The efficiency of transfection produced in the presence of chloroquine (Fig. 
4.7A) was higher than the efficiency of polylysine and chloroquine in all but one case 
(polymer 96-7, containing PEG:pLL 5000:5000). In several cases, the efficiency was 
comparable to that of the liposome DOTAP without chloroquine. It was difficult to 
assign any trend relating efficiency with increasing PEG or polylysine content.
Transfection of HEK293 cells with the various complexes of co-polymers and 
plasmid DNA in the absence of chloroquine was shown to be successful in all cases. 
The positive controls within this experiment were complexes of plasmid DNA with the 
liposome DOTAP or polylysine, both without chloroquine. DOTAP routinely generated 
levels of P-galactosidase expression around 1500 millunits/mg protein, whilst polylysine 
in the absence of chloroquine resulted in levels around 50 milliunits/mg protein. The 
co-polymers all exhibited greater activity than polylysine alone, although the optimum 
formulation produced approximately 14% of the levels of gene expression observed
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with DOTAP. Once again, there appeared to be little trend relating efficiency with
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F igu re  4 .7 . Transfection o f  H EK 293 cells with PEG-pLL com plexes. C om plexes w ere prepared with 6 
p g  pRSVlacZ  and the corresponding mass o f  polym er to provide a charge ratio (polym er /  D N A ) o f  1.5. 
Transfection was performed with 100 pM  chloroquine (A ), and without chloroquine (B ). The ce lls  were 
incubated in com plete m edium  for 48 hours post-transfection, before assaying for P-galactosidase activity  
using the M U G  assay (section 4 .4). Expression was measured per m illigram  o f  protein to account for cell 







F igure 4 .8. Comparative transfection efficiencies o f plasmid D N A  and chloroquine, D N A -polylysine and 
D N A -polylysine com plexes with chloroquine. The transfections were performed in the two cell lines : 
HEK293 and B 16 melanoma cells All systems contained 6 pg pRSVlacZ, and com plexes were prepared 
at a charge ratio o f  1.5. Where necessary, chloroquine was present in the transfection medium at a 
concentration o f  100 pM. The data points represent the mean activity ±  SEM (n=3).
4.3.4. Requirement of chloroquine for transfections.
The transfection efficiency for polylysine-DNA complexes with and without 
chloroquine were compared in the two cell lines used for the co-polymer complex 
transfections i.e. HEK293 and B16 melanoma cells (Fig. 4.8). Transfection of both cell 
lines with free plasmid DNA alone produced no activity, while transfection of the cells 
with polylysine-DNA complexes in the presence of chloroquine produced measurable 
levels of activity in both cases. The activity in the HEK293 cells was approximately 
five times greater than that observed in the B16 melanoma cells. Transfection of cells 
using polylysine-DNA complexes in the absence of chloroquine produced no 
measurable levels of activity in the B16 cell line. In the HEK293 cells, levels of p-
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galactosidase expression in transfections without chloroquine were about 1 0 % of those 
seen with transfections in the presence of chloroquine. Hence it is clear that the 
prerequisite for chloroquine to effect transfection is a cell-line dependent parameter.
4.4. DISCUSSION
4.4.1. Ethidium bromide exclusion by PEG-pLL co-polymers.
Co-polymers containing polylysine conjugated to PEG retained the capacity for 
inhibiting the intercalation of ethidium bromide into plasmid DNA. This indicated that 
all of the polymers were capable of interaction with the negatively charged DNA. The 
relationships between exclusion profiles and charge ratio were similar to those of the 
homopolymers and lysine-alanine co-polymers examined in Chapter 3. The maximum 
ethidium exclusion was reached at charge ratios near electroequivalence. This 
suggested that the presence of the PEG component within the co-polymer presented 
little steric hindrance to the interaction between the cationic polylysine and the anionic 
DNA molecules.
The co-polymer was prepared by conjugation via the a-amino group, and hence 
the side-chain amino groups would remain available for interaction with the nucleotides 
of the DNA molecules. It would appear that the neutral PEG component of the co­
polymer did not prevent the positively charged amines from interacting with the plasmid 
DNA with a similar stoichiometry to that observed with polylysine (Tsuboi et a l, 1966).
131
The profiles relating ethidium exclusion to the mass ratios of co-polymer / DNA 
showed differences between the co-polymers in accordance with expectation. The co­
polymer containing the highest PEG : pLL ratio in each subgroup produced a profile 
shifted furthest to the right away from that of polyiysine. As the ratio of PEG : pLL 
decreased, so the profile shifted to the left, approaching that of polylysine more when 
the PEG content was lowest. This phenomenon was clearly a function of the mass 
associated with each unit charge, which varied according to the ratio of neutral / cationic 
components within each co-polymer.
The minimum molecular weight of a repeating unit of polylysine contained in 
any of the co-polymers was 5000, which was equivalent to 38 lysine units. This chain 
length appeared to be sufficient to condense the DNA. Studies with various chain 
lengths of polylysine by Lucas (1995) indicated that for a short chain length polymer 
(DPn = 13), the interaction no longer exhibited a 1:1 stoichiometry; much higher lyine / 
phosphate ratios were required to produce maximum ethidium exclusion. Leng and 
Felsenfeld (1966) established that the interaction of polylysine with DNA was affected 
by the size of the polylysine used, but that between chain lengths of 7-200 the observed 
interactions appeared fairly uniform. This is at odds with the data reported by Lucas
(1995) although the material used by Lucas (1995) was not sufficiently well 
characterised to allow firm conclusions to be drawn.
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4.4.2. Transfection of B16 melanoma cells.
The prerequisite for chloroquine to effect transfection of co-polymer-DNA 
complexes in B16 melanoma cells suggested similar mechanisms of uptake and eventual 
expression to those used by polylysine / DNA complexes. The levels of expression 
were lower for the complexes produced using the co-polymers than for polylysine 
systems, which may be a result of the PEG component. The PEG mantle may serve to 
reduce the interaction of the positively charged core of polylysine-DNA with the 
negatively charged cell membrane.
As discussed in section 4.4.1, the ethidium exclusion profiles for the co­
polymers were not significantly displaced from that of polylysine, indicating little steric 
hindrance of the polycation-DNA interaction. The differences in transfection 
efficiencies may therefore have been the result of the co-polymers forming complexes of 
a different size to the polylysine-DNA complexes, which would modify the rate of 
absorptive endocytosis. Polylysine has been shown to condense DNA, forming toroid­
like structures with a diameter of about 80-100 nm (Wagner et a l, 1991) which are 
small enough to be contained in endocytic vesicles of < 150 nm (Watts and Marsh,
1992). Recently, Wolfert and Seymour (1996) have shown that the complex size and 
polydispersity is determined by the molecular weight of the cationic polylysine used for 
complexation of the DNA. It was demonstrated that lower molecular weight polylysine 
molecules produced smaller more homogeneous complexes with DNA.
It has been demonstrated by Chiou et a l (1994) that complexation of plasmid 
DNA with polylysine confers resistance to nuclease degradation compared with the
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rapid degradation of uncomplexed DNA. Hence, the DNA could be protected from 
nuclease degradation to a lesser degree by complexation with different polymers. 
Alternatively, the complex components could be interacting more strongly, hence 
reducing release of the DNA from the co-polymer inside the cell.
4.4.3. Transfection of HEK293 cells.
The levels of p-galactosidase expression after transfection with many of the co- 
polymer-DNA complexes in the presence of chloroquine were comparable to that 
obtained with DOTAP. In all but one case, the transfection efficiency observed was 
greater than for polylysine-DNA complexes in the presence of chloroquine. This 
indicated that the presence of PEG either served to enhance endosomal release in this 
cell line, or conferred a greater degree of protection on the DNA from enzymatic 
degradation.
A study by Maggio et a l (1976) demonstrated that poly(ethylene glycol) was 
capable of reducing the surface potential of phospholipid monolayers, and that lower 
concentrations of polymer reduced the surface potential as the molecular weight 
increased. This would theoretically encourage the passage of PEG-polylysine-DNA 
complexes across the plasma membrane and their release from the endosomes. If this 
was the sole reason for the activity seen with these co-polymers, increased levels of 
activity would have been observed as the PEG content increased from 5000 to 12000 to 
20000. One practical use of the reduction in phospholipid surface potential caused by 
polyethylene glycol was described by Okada and Rechsteiner (1982), who delivered 
macromolecules to mammalian cells by the osmotic lysis of pinocytic vesicles. It is
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possible that certain cells are more susceptible than other cell lines to the osmotic effects 
of polyethylene glycol, which would account for the different activity profiles observed 
in the two cell lines. Enhancement of transfection by chloroquine could be explained if 
the polyethylene glycol operated by a different mechanism of action than chloroquine. 
Alternatively, it is possibly that there was a threshold concentration of osmotically 
active component, and that the chloroquine and PEG had an additive osmotic effect on 
the membranes.
Another hypothesis which would account for this activity profile is that the 
presence of the PEG could result in complexes with different morphologies to those 
produced with polylysine alone. This could allow the polymer and DNA to be separated 
inside the cell more easily, making the process of nuclear delivery, and hence 
expression, more efficient. This is not supported by the data for transfection of B16 
cells in the presence of chloroquine.
The co-polymers 96-10 (5000:10000) and 96-13 (5000:20000) were the most 
efficient in their sub-groups at transfection with chloroquine. This may be as a result of 
two interacting factors: the compactness of the polylysine-DNA complex; the formation 
of a complete PEG-mantle around the DNA-polylysine complex. Wolfert and Seymour
(1996) observed that polylysine-DNA complexes of increasing size were formed as the 
polylysine chain length increased. Hence, the complexes formed by polymers with a 
polylysine mass of 5000 would have formed smaller complexes. This would make it 
easier for a complete PEG mantle to form around the DNA-polylysine complex, hence 
better protecting the DNA from nuclease degradation than polylysine alone.
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The complexes formed with co-polymers with a small mass of polylysine would 
be expected to form the most compact structures. The activity of the complexes formed 
by polymers with a polylysine mass of 5000 fall into two categories: either they 
produced the highest levels of expression in the sub-groups (96-10, 96-13), or the lowest 
levels (96-7). If enhanced activity was due to the protective effect of a complete PEG 
mantle in addition to good complexation of the DNA with polylysine, then this may 
explain the low levels of expression observed with co-polymer 96-7. This is a 
dangerous assumption since other PEG (5000) polymers produced high levels of 
transfection.
4.4.4. Transfection activity without chloroquine.
Comparative transfections of polylysine complexes in B16 melanoma cells and 
HEK293 cells showed that the HEK293 cells exhibited greater activity than B16 cells, 
both with and without chloroquine. The fact that activity was observed in the HEK293 
cells for polylysine-DNA complexes in the absence of chloroquine indicated that there is 
a difference in the integrity of the endosome of the HEK293 cells compared with the 
B16 cells. Release of active DNA from the endosome did not rely on the activity of 
chloroquine, although the inclusion of chloroquine for transfections with the HEK293 
cells showed a further increase in expression levels. This showed that although there 
was some reason why endosomal release was achieved easier in HEK293 cells than in 
B16 cells, the endosome was still sensitive to the actions of chloroquine, which further
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enhanced gene expression. It has been demonstrated that certain cell lines exhibit 
anomalous endosomal characteristics, such as the erythroleukaemic cell line K-562, 
which lacks the normal regulation over endosomal acidifcation observed in other cells. 
The unexpected transfection activities observed in the HEK293 cells may be due to a 
similar abnormal characteristic.
4.5. S U M M A R Y
The experimental data presented in this chapter show primarily that in vitro 
transfection studies are highly cell line specific. The activity of complexes formed from 
PEG-polylysine complexes all exhibited activity in B16 melanoma cells and HEK293 
cells, although no trend was observed relating the structure of the co-polymer to 
biological activity. The co-polymer complexes exhibited lower activity than polylysine 
complexes in the B 16 cells, but this was reversed in the HEK293 cell. Additionally, all 
of the complexes produced gene expression in HEK293 cells when the transfections 
were performed in the absence of chloroquine, a phenomenon that was not repeated in 
B16 cells. Fluorescence quenching studies showed little difference between the 
behaviour of all of the co-polymers during complex formation.
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CHAPTER 5. Adaptation of polycations to allow endosomal release.
5.1. INTRODUCTION
The adaptation of polymers to facilitate the release of complexed DNA from 
endosomes is not a new concept. Non-linear polycationic polymers (polyamidoamines) 
have been developed which are capable of binding DNA and also of disrupting the 
endosome in a manner commonly observed with weak bases (Stenseth and Thyberg, 
1989). Polyamidoamines were shown to mediate high levels of reporter gene 
transfection in a variety of cell lines and this efficiency could be further enhanced by the 
covalent attachment of an amphipathic peptide to the polymer (Haensler and Szoka,
1993). Studies using the cationic polymer polyethyleneimine (PEI) for gene delivery 
were based on a similar premise of endosomolysis combined with a DNA-binding 
capacity at neutral pH (Boussif et ai, 1995).
The polymers discussed above all contain residues which are protonated at the 
acidic pH found within the endosomes (Maxfield, 1932). It is this capacity that appears 
to explain their endosomolytic action. The branched polymeric network of PEI contains 
a secondary or tertiary amino group every third atom of the polymeric chain, producing 
what has been described as a proton sponge. This buffering capacity is believed to 
protect the DNA from nuclease degradation, and to stimulate lysosomal swelling and 
membrane rupture, consequently allowing release of the complexed DNA from the 
lysosome.
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The approach taken in the present study involved the synthesis of a block co­
polymer containing a cationic element plus an element capable of protonation at 
lysosomal pH. It was proposed that this would produce a more controlled condensation 
of DNA than in PELDNA complexes. The cationic component of the co-polymer was 
provided by polylysine and polyhistidine provided the amino groups capable of 
protonation at the pH within the lysosome. The pKa’s of the ionising side chain for 
lysine and histidine are 10.53 and 6.0 respectively. Initial attempts to construct such a 
block co-polymer involved carbodiimide coupling of polylysine and polyhistidine. This 
proved to be a difficult coupling due to the paucity of carboxyl groups available for 
coupling. After several unsuccessful attempts to purify a co-polymer product, a solid 
phase synthetic strategy was adopted. This allowed the synthesis of a pure polypeptide 
H 2 0 K 2 5 .
5.2. MATERIALS AND METHODS
5.2.1. Peptide synthesis.
A Millipore 9050 pepSynthesizer (Millipore corp., Milford, MA, USA) was used 
for peptide assembly using solid phase synthesis (Atherton-Sheppard, 1989). The solid 
support resin used was polyethylene-glycol-polystyrene (PEG-PS) (Perspective 
Biosystems UK Ltd., Hertford, UK), which was pre-derivatised with a linker group and 
the first amino acid residue of the desired peptide sequence to be synthesized. Amino 
acids, protected at the primary end with N-(9-fluorenyl)methoxycarbonyl (Fmoc) and 
activated as O-pentafluorophenyl (Opfp) esters (Perspective Biosystems), were used in 
coupling reactions for 30 minutes in situ using 0.3 M 1-hydroxybenzotriazole (HOBT)
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(Aldrich, Dorset, UK) in N,N, Dimethylformamide (DMF, Peptide synthesis grade; 
Rathburn Ltd, UK). The side chain protection group for both of the amino acids was 
Boc. Deprotection of the a-amino groups resulted from washing the resin with 20% 
piperidine in DMF for 5 minutes, then rinsing away the piperidine with DMF for 10 
minutes, prior to each coupling step. After the final coupling and deprotection step, the 
resin was washed with DMF, then dichloromethane (DCM), and finally with 
diethylether, before drying with nitrogen gas. The peptides were cleaved from the resin 
and the side chain protecting groups were removed by treating 1 g of the resin with 5 ml 
Trifluoroacetic acid (TFA)/thioanisole/ethanedithiol/anisole (90:5:3:2) for 4-6 hours. 
The TFA was evaporated under vacuum, and the peptides were precipitated by the 
gentle addition of three 2 0  ml aliquots of ether and the liquid was decanted to remove 
the thioanisole/ethanedithiol/ anisole. The crude peptide was dissolved in distilled 
water and lyophilised
5.2.2. Peptide purification.
Peptides were purified using reverse phase high performance liquid 
chromatography (HPLC). The crude peptide mixture was dissolved in 0.1% acetic acid, 
5% acetonitrile, distilled water to 100%, and the pH adjusted to 9.6 with ammonia 
solution. This was then applied to a self-packed 2.5 x 25 cm POROS column 
(Perspective Biosystems), and eluted with a linear gradient between 0.1% trifluoroacetic 
acid, 5% acetonitrile, distilled water to 100% (pH 9.6), and 0.1% trifluoroacetic acid, 
5% distilled water and acetonitrile to 100% (pH 9.6). The POROS columns are polymer 
based, and are suitable for pH ranges between 2-12.
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F ig u re  5 .1 . C hem ical structure o f  the peptide synthesised by solid phase methods (section 5 .1). T his co ­
polym er contained 20 histidine residues (m = 20) and 25 lysine residues (n = 25) . The pKa o f  the side- 
chain am ino group was 10.53 and 6 .0  for lysine and histidine respectively.
5.2.3. Cationic polymers.
The peptide (L-His)2o-(L-Lys) 25 (H20K25) was synthesised as described in section
5.1. Polyethyleneimine was obtained as a 50% (w/v) solution (Fluka) and used to 
prepare a 10 mM aqueous solution (with respect to the monomer) for complexation 
studies. Polyhistidine was obtained as the hydrochloride salt (MW 18400) from Sigma.
5.2.4. Complexation of DNA with synthetic peptide, polyhistidine and PEI.
Complexes were prepared with 6  jig of plasmid DNA and polyhistidine (Sigma), 
H20K25 and PEI at the concentrations of interest, to produce a range of charge ratios from 
0 - 3 . 0  (section 3.4). A stock solution of 10 mM monomer PEI was prepared as 
described by Boussif et al. (1995). Briefly, 9 mg of the commercial PEI solution (50% 
w/v) was diluted to 1 0  ml with water, neutralised with hydrochloric acid, and filter 
sterilised (0.2 Jim filter). This stock solution contained 10 nmol of amine nitrogen per 
microlitre of solution.
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The charge ratio was calculated using the cationic lysine residues, assuming that 
the histidine residues did not contribute any charge at the pH of preparation (pH 7.4). 
The complexes were prepared in a total volume of 500 jllI of HBS, and incubated for 20 
minutes at room temperature after mixing.
The polyhistidine complexes were prepared in a series of citrate-phosphate 
buffers at pH 4, 5, 6 , 7 and 8  (appendix A). The same mass ratios (polymer / DNA) 
were prepared at each pH.
5.2.5. Ethidium bromide exclusion assay.
DNA complexation by polyhistidine was studied over the mass ratio range 0 -
1.5, in the pH range 4 - 8 .  The changes were investigated using the ethidium exclusion 
spectrofluorimetic technique (section 3.2.5.1). The exclusion of ethidium bromide was 
also monitored for complexes of DNA with H20K25 and PEI over the charge ratio (+/-) 
range 0 - 2.5.
5.2.6. Transfection studies in eukaryotic cells.
Complexes were prepared in a total volume of 500 pi HBS as detailed in section
3.2.4. The complexes were incubated at room temperature for 20 minutes, and then 
added to the culture medium for four hours, either in the presence or absence of 100 pM 
chloroquine (section 3.2.6). The transfection medium was then replaced with complete
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culture medium, and the cells incubated for a further 44 hours before assaying for (3- 
galactosidase expression, using the MUG assay (section 4.2.4). The total protein 
content was also determined (section 4.2.5).
5.3. RESULTS
5.3.1. Ethidium exclusion assay.
5.3.1.1. The effects o f pH on polyhistidine.
The effect of pH on the ionisation of the side-chain amino group of histidine was 
examined using the ethidium bromide exclusion assay. The interaction between plasmid 
DNA and the ionised side-chain served to exclude ethidium as more polymer became 
associated with the DNA. The profile for ethidium exclusion at pH 4 was similar to that 
observed with polymers that were completely ionised at the experimental pH (section 
3.3.1). There was a decrease in fluorescence up to a mass ratio of 1.0, beyond which 
low background levels were maintained. Increase in pH to 5.0 produced a profile that 
was displaced to the right, indicating lower availability of protonated amines. At pH 6,7 
and 8  very small degrees of exclusion were observed. Even at pH 6 , 80% fluorescence 
was preserved at a mass ratio of 1.5.
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F ig u re  5 .2 . Ethidium bromide exclusion assay with poly-histidine-pR SV /acz com plexes over the pH  
range 4 -8 . C om plexes were prepared from 6 pg pRSWlacZ and varying quantities o f  polyhistidine, flash  
m ixed and incubated at room  temperature for 20  minutes. Ethidium bromide (0.5 |ig /m l) was added 
im m ediately prior to the measurement o f  fluorescence. A ll data points are calculated as a percentage o f  a 
control containing 6 1i g  plasm id D N A , and each point represents the mean (n=3).
5.3.1.2. Polycation-DNA interactions.
DNA complexation by each of H2oK25, PEI and polylysine was established using 
the ethidium bromide exclusion assay. The charge ratio for the synthetic peptide H2oK25 
was calculated using only the polylysine component, assuming that the polyhistidine 
was completely unionised at the experimental pH of 7.4. The profile for H2oK25 was 
almost identical to that exhibited by polylysine, with an initial linear decrease to a 
charge ratio of 1 .0 , beyond which a minimum background fluorescence level was 
maintained. The profile for PEI displayed a translocation to the right, reaching a 
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F ig u re  5 .3 . Ethidium  bromide exclusion assay for com plexes formed with plasm id D N A  using H2oK25 , 
PEI or p olylysine. The com plexes were prepared using 6  (ig pRSWlacZ and increasing quantities o f  the 
respective polym er, to create the required charge ratio (+/-). Ethidium bromide (0 .5  pg/m l) was added 
im m ediately prior to measurement o f  the fluorescence. The exclusion  for polylysine is show n for 
com parison. T he data points were calculated as a percentage o f  a control containing 6  p g  plasm id D N A , 
and each point represents the mean (n=3).
5.3.2. Transfection with PEI-DNA complexes.
B16 melanoma cells were transfected with PEI-DNA complexes both in the 
absence and the presence of the endosomolytic agent chloroquine at a concentration of 
IOOjiM (Figs. 5.4 and 5.5 respectively). The charge ratios used for the transfections 
were high relative to those used for previous polymers for two reasons. Firstly, the 
ethidium exclusion assay had indicated that charge ratios of approximately 2 .0  were 
required to produce similar exclusion levels to polylysine at a charge ratio of 1 .0 . 
Additionally, the proposed mechanism of endosomal release for PEI-DNA complexes
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Figure 5.4. Transfection o f  B 16 m elanom a cells with P E I-D N A  com plexes. The com plexes were 
prepared with 6 |ig  pRSVlacZ  and varying quantities o f  the PEI polym er, to produce a range o f  charge 
ratios (+/-). A ll transfections were carried out in the absence o f  chloroquine. The cells w ere assayed after 
48 hours for (i-galactosidase activity using the fluorescence-based M U G  assay. T he data were 
standardised per m g protein. T w o positive controls were included: po lylysine/D N A  with chloroquine, and 
the liposom e D O T A P /D N A  com plexes without chloroquine, as system s routinely used for successful 
transfection o f  B 16  m elanom a cells. Background levels w ere established with polylysine without 
chloroquine. A ll data points represent the mean ±  SEM  (n=3).
The transfection activity of PEI-DNA complexes in B16 cells without 
chloroquine were comparable at charge ratios of 2.25 and 4.5 with the activity of 
polylysine-DNA complexes in the presence of chloroquine. The other charge ratios 
studied showed little or no elevation of activity above the background levels seen for 
polylysine-DNA complexes without chloroquine. An additional positive control of 
DNA-DOTAP (+/- = 2.5) complexes was included as a liposome system known to be
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capable of transfection of B16 melanoma cells without chloroquine. The maximum 
activity for PEI-DNA complexes reached levels of 25% that observed with the liposome 
system.
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F ig u re  5 .5 . Transfection o f  B 16 melanoma cells with PEI-pR SV /acZ com plexes. The com plexes w ere 
prepared with 6 p g  D N A  and varying amounts o f  the cationic polym er, to produce the required range o f  
charge ratios. Transfections were performed in the presence o f  100 (iM  chloroquine. C ell extracts were 
prepared 48 hours post-transfection, and assayed for |3-galactosidase activity using the M U G  assay. The 
protein content o f  the sam ples was determined, and the levels o f  expression calculated per unit m ass o f  
protein. Data points represent the mean ±  the SEM , (n=3).
The activity profile for transfections using PEI-DNA complexes in the presence 
of 100 jiM chloroquine showed significant expression levels only at a charge ratio of
2.25 (Fig. 5.5). All of the other charge ratios tested showed levels that were similar to 
control levels. The control levels were established by transfection of plasmid DNA with 
chloroquine, and this is labeled as a charge ratio of zero on the diagram. The activity of 
the complexes at a charge ratio of 2.25 was equivalent to approximately 60% the
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F ig u re  5 .6 . Transfection o f  H EK 293 cells with PEI-D N A  com plexes. Varying quantities o f  the cationic 
polym er were m ixed with 6  jig pRSVlacZ  plasmid, to produce the range o f  charge ratios. Transfections 
w ere perform ed in the absence o f  chloroquine. Positive controls included polylysine-D N A  com plexes in 
the presence o f  chloroquine and D O T A P/D N A  (+/- 2 .5). The cells were assayed 48  hours after the 
transfection using the M U G  assay, for detection o f  (3-galactosidase activity. Data points represent the 
mean ±  SEM  (n=3).
PEI-DNA complexes were also tested in HEK293 cells in the absence of 
chloroquine (Fig. 5.6). The profile showed activity over a wider range of charge ratios 
than observed in the B16 cells, either with or without the inclusion of chloroquine. The 
highest levels of activity were produced at charge ratios of 2.25 and 4.5, which were 
approximately 75% of the levels seen with polylysine and chloroquine, and 25% of the 
activity with DOTAP-DNA complexes. All of the PEI-DNA complexes at different 
charge ratios produced activity levels greater than those observed with polylysine in the
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absence of chloroquine. The polylysine system produced activity levels approximately 
1 0 % of those observed for polylysine with chloroquine.
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F igu re  5.7 . Transfection o f  B 16 melanoma cells with com plexes o f  H 2oK25 with D N A . Various 
quantities o f  the peptide were mixed with 6  Jig pRSVlacZ  plasmid, to produce the range o f  charge ratios. 
T ransfections were performed in the absence o f  chloroquine. P ositive controls used for com parison  
included polylysine-D N A  com plexes (charge ratio 1.5) plus chloroquine and P E I-D N A  com plexes  
(charge ratio 2 .25) in the absence o f  chloroquine. The cells were assayed for fl-galactosidase activity 48  
hours post-transfection using the M U G  assay. Data points represent the mean ±  SEM  (n=3).
Transfections were performed using complexes formed over a range of charge 
ratios using H2oK25 and plasmid DNA. The activity levels were tested in both B16 and 
HEK293 cell lines, and transfections were performed in the absence of chloroquine in 
both cases. The positive controls used in the experiments included polylysine-DNA 
complexes at a charge ratio of 1.5 in the presence of chloroquine, and PEI-DNA 
complexes at a charge ratio of 2.25 without chloroquine. Polylysine-DNA complexes
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(charge ratio 1.5) were also used in the absence of chloroquine as a marker for 
background activity levels.
The p-galactosidase activity levels observed in the B16 melanoma cells (Fig. 
5.7) were comparable with the background levels observed with plasmid DNA alone, or 
polylysine-DNA complexes in the absence of chloroquine. The expression levels 
detected in the HEK293 cells after transfection with H20K25-DNA complexes in the 
absence of chloroquine (Fig. 5.8) showed a little enhancement over background levels, 
producing only 36% activity compared with polylysine-DNA complexes alone. This 
was equivalent to 10% of the activity of polylysine-DNA complexes plus chloroquine, 
and only 4% of the activity of PEI-DNA complexes.
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F igu re  5 .8 . Transfection o f  H EK 293 cells with com plexes o f  the H 20K 25 with D N A . Various quantities 
o f  H 2oK25 were m ixed with 6  p g  pRSWlacZ plasmid, to produce the range o f  charge ratios. Transfections 
w ere performed in the absence o f  chloroquine. Positive controls used for comparison included polylysine- 
D N A  com plexes (charge ratio 1.5) plus chloroquine and P E I-D N A  com plexes (charge ratio 2 .25 ) without 
chloroquine. The cells were assayed for p-galactosidase activity 48 hours post-transfection using the 
M U G  assay. Data points represent the mean ±  SEM  (n=3).
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5.4. DISCUSSION
The development of more efficient non-viral vectors for gene therapy is reliant 
on improving the transport of the DNA from the extracellular matrix to the nucleus of 
the target cell. Oligonucleotides have been shown to enter cells by endocytosis (Akhtar 
and Juliano, 1992), and most have been shown to pass through the endosome (Shoji, 
1991). The use of chloroquine to enhance plasmid DNA delivery and resultant 
expression (Zatloukal et a l 1992) is routine for polycation-DNA delivery systems in 
vitro. Alternative approaches to overcome the use of chloroquine for development of in 
vivo vectors have included the use of synthetic viral fusogenic peptides which have 
endosomolytic activity (Gottschalk et a l, 1996), or the use of amphipathic 
polyamidoamines (Kukowska-Latallo et a l, 1996). These polymers are postulated to 
buffer the pH change in the lysosome, hence reducing the nuclease activity. The 
buffering activity is also believed to enhance lysosomal swelling and membrane rupture 
because of osmotic effects. The approach used here involved the synthesis of a 
polypeptide combining a DNA-binding moiety (oligolysine), and a component capable 
of buffering the pH of the endosome (oligohistidine). For comparison the studies 
involved evaluation of the transfection capacity of polyethyleneimine, a polymer with 
reported lysosomal buffering capacity (Boussif et a l,  1995).
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5.4.1. Ethidium exclusion assays.
The exclusion assay was initially used to establish the effect of pH on the 
ionisation of the side-chain amino group of the polyhistidine. The pKa of this side- 
chain amino group is 6.0, and hence at pH 4.0, 99% of the amino groups would 
theoretically have been ionised. This was reflected by the similarity of the ethidium 
exclusion profile for polyhistidine compared with the polylysine profile. As the pH was 
increased from 4 to 5, 6 , 7 and 8 , the theoretical degree of ionisation at the side chains 
were reduced to values of 90%, 50%, 10% and 0.99% respectively. This was reflected 
by a reduction in the capacity of the polyhistidine to exclude the ethidium from 
interaction with the plasmid DNA, as observed by the maintenance of high levels of 
fluorescence with increasing mass ratios of polymer : DNA. This test demonstrated that 
the polyhistidine would not complex DNA at pH 7.4, but would be capable of a 
buffering action at acidic pH values, as found within the endosomes (Maxfield, 1982).
The exclusion assay for the synthetic peptide H20K25 showed that if it was 
assumed that only the lysine residues would be charged at pH 7.4, the exclusion profiles 
for H2oK25 and polylysine were very similar. Precise estimation of the degree of 
polyhistidine ionisation showed that 3.8% of the histidine residues would be ionised at 
pH 7.4, indicating that there was a very slight underestimation of the positive charge 
within the system. This was not expected to cause a significant problem in the 
interpretation of data.
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The profile for PEI displayed some irregularity compared with the exclusion 
patterns seen with polycations such as polylysine. Although there was a reduction in 
fluorescence associated with an increase in charge ratio (+/-), the decline was not of the 
characteristic sharpness, nor was a minimum background level reached and maintained 
until a charge ratio of 2.0 was used. This was likely to be due to the actual mass ratios 
of the polymer / DNA present in the mixing environment. A charge ratio (+/-) of 1.0 
was equivalent to mass ratios of 0.44, 0.72 and 0.13 for polylysine, H20K25 and PEI 
respectively. The PEI molecule would have a high charge density, which could possibly 
cause steric problems for the interaction of the negatively charged nucleotides. Twice as 
much charge was required to reach the background fluorescence levels observed for 
polylysine. The charge ratio was calculated from the amine nitrogen content of the PEI. 
At pH 7.4, only half of the nitrogen atoms would be expected to be protonated, in line 
with the capacity for PEI to accept protons as the pH decreased.
5.4.2. Transfection with PEI-DNA complexes.
The comparative activities of the various PEI-DNA formulations after 
transfection into B16 cells both in the presence and absence of chloroquine 
demonstrated distinct differences to the polylysine-DNA complex activity profile. Since 
the levels of activity were higher than the positive controls in the absence of 
chloroquine, it was possible that the chloroquine was destabilising the PEI/DNA 
complexes. Alternatively, the PEI could have effected endosomal release by the same
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mechanism as the chloroquine, and this process may have already been maximised so 
that no further increase in DNA release could be produced. The optimum charge ratio 
for transfection of PEI/DNA complexes without chloroquine using B16 cells was 
established. These conditions were used as a positive control when examining 
complexes believed to facilitate endosomal release by buffering endosomal acidity, a 
similar mechanism to PEI.
PEI-DNA complexes were transfected into HEK293 cells without chloroquine. 
The experiment was not repeated with chloroquine since HEK293 cells have previously 
shown that they are capable of detectable expression levels in the absence of 
chloroquine for polylysine-DNA complexes. These cells demonstrated activity 
comparable with polylysine and chloroquine at the optimal charge ratios of PEI/DNA of
2.25 and 4.5. For the majority of charge ratios studied, the PEI-DNA complexes 
exhibited greater activity than polylysine-DNA complexes in the absence of 
chloroquine, demonstrating some advantage due to the formulation. It can be postulated 
that this is due to increased sensitivity to a buffering action of the polymer within the 
endosome. The theory that the integrity of the endosomes in the HEK293 cells exhibits 
distinct differences to the endosomes found in B16 cells has already been discussed 
(section 4.4.4).
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5.4.3. Transfection with H2 0 K2 5 .
Transfection of complexes using H20K25 and plasmid DNA produced no 
detectable levels of activity in B16 cells, and very low levels of expression in the 
HEK293 cells. At the optimum formulation, 36% of the level of activity of transfection 
observed with polylysine-DNA complexes in the absence of chloroquine was obtained. 
This demonstrated no enhancement over polylysine for complexation and delivery of the 
DNA.
A possible explanation for this is that the mass of unprotonated amine delivered 
to the endosome was too low to disrupt the endosomal membrane. PEI is often used at 
higher charge density, which may be necessary to promote escape of the plasmid. Also, 
the early endosome maintains an internal environment at pH 6.2, and these conditions 
would induce ionisation of approximately 39% of the histidine side-chain amino groups. 
At the pH in the lysosomes (5.2), roughly 8 6 % of the histidine residues would be 
ionised, and although this provides more buffering capacity to effect the escape 
mechanism, DNA would be exposed to lysosomal enzymes to some extent. This 
process has been studied by Hughes et a l (1996) who compared the fate of a lipid that 
becomes fusogenic at the pH within the early endosome with a pH sensitive polymer 
that had previously shown membrane activity with phospholipid vesicles (Tirrell et al., 
1985).
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An alternative theory to explain the lack of enhancement using this system for 
DNA delivery is that the decrease in pH as the complex enters the endosome and 
possibly the lysosome affects the polyhistidine amino groups. Since the pKa of the 
polyhistidine amino groups is 6.0, more of the groups become ionised as the pH 
becomes more acidic. These ionised amino groups are then able to contribute to the 
cationic charge supplied by the co-polymer in the system. This factor would affect the 
overall cation / anion ratio, hence affecting the interaction of the polymer with the DNA. 
It has previously been demonstrated that above a threshold charge ratio, the activity 
profile decreases (section 3.3.2.2), so the endosomal environment may be altering the 
charge ratio of the complexes to more cationic systems than has been calculated. This 
could theoretically produce a system where the complexes were more strongly held 
together, and the reduced activity profile may be due to less of the DNA being released 
from association with the co-polymer after release from the endosome. This would 
serve to reduce nuclear delivery and hence resultant transcription and expression.
Due to time limitations, no transfections using H20K25-DNA complexes were 
performed in the presence of chloroquine. Enhancement of activity with the use of 
chloroquine would have confirmed that the polyhistidine component was incapable of 
effecting endosomal release of the DNA. Alternatively, if the chloroquine produced no 
increases in activity, it would have indicated that the polyhistidine was capable of 
causing endosomal release, but that the DNA was not reaching the nucleus for 
subsequent transcription, or that transcription itself was being inhibited.
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5.5. SUMMARY
Plasmid DNA can be complexed using polycations, even if they contain 
endosomolytic components. Polymers with a very high charge density appear to require 
larger quantities of polymer to completely complex DNA, as determined by the 
ethidium exclusion assay. Polymers with extensive buffering capacity in acidic pH 
conditions can enhance endosomal escape mechanisms for DNA. Polyhistidine acts as a 
buffer at low pH values, and conjugation of polyhistidine to polylysine did not appear to 
affect the DNA-binding capacity. Detectable levels of p-galactosidase activity were not 
observed in either B16 or HEK293 cells after transfection with peptide H20K25-DNA 
complexes in the absence of chloroquine.
157
CHAPTER 6. Physical characterisation of polycation-DNA 
complexes.
6.1. INTRODUCTION
The previous chapters have concentrated on characterisation of the interaction 
of polycations and plasmid DNA using the ethidium exclusion assay combined with in 
vitro biological transfection data. The combination of these two experimental 
procedures has revealed basic information about the attributes of complexes which 
rendered them active for transfection, but a more detailed study into the physical 
characteristics of each complex was deemed necessary. The stability of these 
complexes in different environments was also an important issue with a view to 
production of a pharmaceutical product. A clearer understanding of the uptake 
mechanisms associated with each complex, and the affect of the physical composition 
and structure of the complexes on gene delivery and expression were other areas 
identified as crucial to the development of non-viral vectors for in vivo use.
6.1.1 Particle sizing by photon correlation spectroscopy.
Photon correlation spectroscopy (PCS) is a technique used for measuring the 
dynamic changes in light scattering associated with macromolecular and colloidal 
systems. Particles in solution undergo the random movement of Brownian motion, 
which occurs due to collisions with the smaller molecules of the continuous phase. 
The suspended particles are constantly in a state of motion, and hence undergo 
diffusion. Diffusion is governed by the average distance of travel before collision
158
with another molecule, which causes a diversion from the original path of motion. 
When a solution of macromolecules is illuminated, the light is scattered by the 
particles in Brownian motion, and the intensity of this light yields information 
regarding the molecular weight.
PCS analyses the constantly changing patterns of laser light scattered or 
diffracted by particles in solution, exhibiting Brownian motion. The rate of change of 
the scattered light during diffusion is monitored. The scattered light displays a 
spectrum of frequencies due to the Doppler effect. Fluctuations in the intensity arise 
because the centres of light scattering are constantly moving, producing different 
extents of interference. An autocorrelation function allows the intensity fluctuations 
to be characterised. The intensities are measured at short time intervals (5-10 p,s) over 
a longer time period of several minutes, and recorded digitally.
PCS allows estimation of the translational diffusion coefficient (D). D is 
related to the equivalent hydrodynamic radius of the particle by the Stokes-Einstein 
equation:
6/T77rh
where ks is the Boltzman constant, T is the absolute temperature (Kelvin), T| is the 
viscosity of the solvent and rh is the hydrodynamic radius.
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6.1.1.1. Analysis.
CONTIN analysis was used to fit the experimental intensity decay curve with a 
curve calculated assuming a distribution of decay rates. This method extracts a 
smoothed or regularised size distribution by matrix techniques. Larger particles 
produce a greater intensity of scattered light, and this may interfere with the intensity 
from smaller species. In extreme cases, the intensity of light scattered from small 
particles may be masked by the interference and intensity from only a tiny percentage 
of large particles within the population.
Solutions which contain more than one species require correction for the 
intensity interference problems. The correlation function contains the same number of 
terms as species in the sample, but each term is weighted by the intensity of light 
scattered from each species. The output from CONTIN analysis includes information 
about weight and number distribution within the sample.
6.1.2. Isothermal titration calorimetry.
Isothermal titration calorimetry measures the energetics of biochemical or 
molecular reactions, such as ligand-binding phenomena, at constant temperature. A 
heat change is an almost universal property of binding reactions, and the sensitivity of 
the equipment enables measurements to be made from nanomole quantities of 
reactants (Wiseman et al., 1989). This method allows the generation of a binding 
isotherm, which allows the binding saturation of the ligand to be determined. The 
experimental method involves titration of a reactant into the sample solution 
containing the other reactant. After the addition of each aliquot, the heat changes are 
monitored by the isothermal titration calorimeter.
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6.2. MATERIALS AND METHODS
6.2.1. Stability of polymer-DNA complexes in serum.
Complexes were prepared using 6  |ig of the plasmid pRSVlacZ, and sufficient 
polymer to produce a charge ratio (+/-) of 1.5, in a volume of 500 j l l I  HBS (section
3.4). The complexes were incubated at room temperature for 20 minutes before 
adding to 1.5 ml complete culture medium. This was incubated at 37°C for 4 hours, 
before removing a 40 |il aliquot, adding 10 pi of 5x loading buffer and mixing. A 15 
|il aliquot was loaded onto a 1 % horizontal agarose gel, which was run at a constant 
voltage (80V) for one hour. The gels contained ethidium bromide (0.5 |ng/ml), 
allowing visualisation of the DNA. The gels were then viewed and photographed 
over a UV light box, as described in section 2.10.
6.2.2. Toxicity of free polymer or DNA-polymer complexes.
Toxicity studies were performed on the polymers supplied by Sigma (Table 
3.1) using the MTT assay (section 2.19). B16 melanoma cells were seeded at 3000 
cells per well, and allowed to adhere in complete medium under standard incubation 
conditions for one hour. Free polymer toxicity was determined by the addition of 
aliquots of polymer stock solutions (0.05 pg/ml) to the wells over the concentration 
range 0 - 1 0  pg/ml. The cells were incubated under standard conditions for 4 hours, 
the supernatant removed, and MTT (1 mg/ml) in serum free medium added to each 
well. The remainder of the assay was performed as detailed in section 2.19, and the 
percentage of cell survival was determined compared to a control, to which no 
polymer had been added.
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The poly-L-lysine-DNA complex was assessed for toxicity in a similar 
manner. Complexes at a charge ratio (+/-) of 1.5 were produced using 6  pg plasmid 
DNA and the appropriate mass of polymer. The complex was incubated at room 
temperature for 2 0  minutes, before adding aliquots of the mixture to the wells, 
producing a concentration range of poly-L-lysine from 0 - 6  pg/ml. The incubation 
procedure and MTT assay were identical to that for the free polymers. A toxicity 
profile was prepared in parallel for free poly-L-lysine over the same range of 
concentrations for direct comparison between free and complexed poly-L-lysine.
6.2.3. Size analysis of polymer-DNA complexes.
Polymer-DNA complexes were sized by the method of photon correlation 
spectroscopy (section 6.1). Complexes were prepared as detailed in section 3.4 in 
water not HBS, using 6  jig plasmid DNA and varying quantities of polymer, to 
produce a variety of charge ratios (+/-). The complexes were incubated for 20 minutes 
at room temperature, then 1.5 ml distilled milliQ water was added, and then placed in 
sample bottles in the water-bath of a PCS 100SM (Malvern, UK) with a Coherent 
Innova 90 laser. This was connected to a B 1-9000 AT digital correlator (Brookhaven 
















F igu re  6.1 . Schem atic diagram o f  photon correlation spectroscopy system .
6.2.4. Thermometric activity monitoring .
A solution containing 0.5 mg DNA in 2.5 ml HBS was prepared and placed 
into the stainless steel ampoule of a 4 ml titration unit (Thermometric, Sweden), the 
ampoule was sealed and lowered in stages into the ThermoMetric 2277 Thermal 
Activity Monitor. A solution containing 10 mg/ml polylysine (Sigma. U.K.) in HBS 
was used to fill a 2 0 0  p,l graduated glass syringe linked to a canula, which was then 
inserted into the titration shaft. The polylysine solution was titrated into the DNA 
solution in 4 p i  aliquots at 15 minute intervals, while stirring at a rate of 10 rpm. This 
process was continued until a total volume of 2 0 0  p i  polylysine solution had been 
dispensed. A control was performed to calculate the heat associated with dilution of 
the DNA solution by the addition of 4 pi aliquots of HBS for a total of 200 p i
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6.2.5. Uptake of polypeptide-DNA complexes by B16 melanoma cells.
The uptake of DNA-polypeptide complexes by B16 melanoma cells was 
analysed using flow cytometry. FITC-labelled poly-L-lysine (Sigma, MW 11800) and 
standard poly-L-lysine (Sigma, MW 45700) were mixed with plasmid DNA to 
produce complexes according to the normal protocol (section 3.4). Complexes were 
prepared at charge ratios (+/-) of 1.5, 2.0, 2.5, and 5.0. The FTTC-polylysine 
component was kept constant while increasing the standard polylysine constituent. 
Cells were plated onto 6 -well plates 18-20 hours prior to transfection and the 
positively charged complexes were incubated with the cells for four hours (section 
3.6). The transfection medium was removed, and the cells were washed three times 
with ice-cold PBS. The adherent cells were removed from the plates with Trypsin- 
EDTA, and collected by centrifugation in a 1.5 ml microcentrifuge tube. The cells 
were washed two more times, before resuspension in 1.0 ml of PBS.
The fluorescence intensity of each sample was measured relative to a control 
population of cells using a FACS Vantage analyser (Becton Dickinson). The viability 
stain propidium iodide (100 ng/ml; Dako Ltd., U.K.) was added to each sample 
immediately prior to analysis, and the data collection (FL-1 emission spectrum) was 
gated for the live cells only. A minimum of 5000 cells were analysed per sample, and 
this was increased to 1 0 0 0 0  where cell viability was sufficiently high to allow for this. 
Comparative transfection studies by D. Milroy at 4°C and 37°C (unpublished results) 
have shown that there was little complex remaining adsorbed to the cell surface after 
the washing procedure.
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6.2.6. Effect of free polylysine on complex uptake by B16 melanoma cells.
The effect of free polylysine on the uptake of polylysine-DNA complexes by 
B16 melanoma cells was analysed using flow cytometry. Complexes were prepared 
from FITC-polylysine and plasmid DNA at a charge ratio of 1.5 (section 3.4). The 
complexes were added to the transfection medium of B16 cells in 6 -well plates, and 
unlabelled polylysine was added to the medium to produce an effective charge ratio of 
2.5, 5.0, 7.5, and 10.0. The cells were incubated with these systems for four hours, 
before washing with PBS and collecting the cells for FACS analysis as detailed in 
section 6.7. The cells were stained with propidium iodide (100 ng/ml) and the data 
collection was gated to analyse only the live cells in the population.
6.3. RESULTS
6.3.1. Stability of polycation-DNA complexes in serum.
Representative electrophoretic gels displaying the stability of complexes 
prepared from the various polycations and plasmid DNA are shown in Figures 6.2 and
6.3. The complexes were prepared at a charge ratio of 1.5 (+/-), as it was assumed that 
the plasmid DNA would be completely complexed by the polycations at this charge 
ratio. Figure 6.2 shows the homopolymers and co-polymers supplied from Sigma, as 
detailed in section 3.2.2. These included poly-L-lysine, poly-D-lysine, polyomithine, 
polyarginine, lysine-alanine (1:1), lysine-alanine (2:1) and lysine-alanine (3:1) in lanes 
5 - 1 1  respectively. Additionally, plasmid DNA incubated in HBS, serum alone and 
plasmid DNA incubated in serum are shown in lanes 2 - 4  respectively. Lanes 1 and 
12 contain the molecular weight marker X DNA with Hind III and EcoR I digests.
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F igu re 6.2. Agarose gel displaying stability o f  com plexes prepared using plasmid D N A  and the 
hom opolym ers and co-polymers supplied by Sigma (section 3.2.2). The com plexes were prepared in HBS 
as detailed in section 3.2.4, incubated in DMEM supplemented with 10% serum for 4 hours before 
loading onto a 1% agarose gel and running at 80V  for one hour. C om plexes prepared using poly-L-lysine, 
poly-D -lysine, polyornithine, polyarginine, lysine,alanine (1:1), lysine,alanine (2:1) and lysine,alanine 
(3:1) were loaded into lanes 5 - 1 1  respectively. Lanes 2 - 4 contain plasmid D N A  in HBS, serum, and 
plasmid D N A  incubated in serum respectively. Lanes 1 and 12 contain the molecular weight marker X 
D N A  with Hind III and EcoR I digests.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
F igu re 6.3. Agarose gel displaying stability o f com plexes prepared using plasmid D N A  and PEG-pLL  
(section 4 .1), H2oK25 and PEI (section 5.3). The com plexes were prepared in HBS as detailed in section  
3.2 .4 , incubated in DMEM supplemented with 10% serum for 4 hours before loading onto a 1% agarose 
gel and running at 80V  for one hour. Com plexes prepared using PEI and H20K25 were loaded into lanes 4 
and 5, while com plexes prepared using PEG-pLL 96-7 through to 96-15 were loaded in lanes 6 - 1 5  
respectively. Lanes 1 - 3 contain serum, plasmid D N A  in HBS, and plasmid D N A  incubated in serum  
respectively. Lane 8 contains the molecular weight marker X D N A  with Hind III and EcoR I digests.
All of the plasmid-DNA complexes remained in the wells during 
electrophoresis and no DNA smearing was observed, indicating that these systems 
were stable to the degradative nature of the serum enzymes. The plasmid DNA 
incubated in HBS (lane 2) exhibited no degradation, and the bands represent, from the 
bottom of the gel to the top, supercoiied and open circular conformations respectively. 
The free plasmid DNA incubated in serum was degraded, as indicated by the small 
fragments observed migrating rapidly through the gel causing smearing (lane 4). Lane 
3 contained serum alone, to demonstrate any background fluorescence due to the 
presence of various proteins contained in the serum.
A similar profile was observed when the stabilities of the PEG/pLL/DNA 
(section 4.1), H20K25/DNA and PEI/DNA (section 5.3) complexes were examined 
(Fig. 6.3). Serum was run in lane 1, plasmid DNA in HBS and plasmid DNA in 
serum were loaded into lanes 2 and 3 respectively. Complexes formed using PEI, 
H20K25 and the PEG-pLL polymers were loaded into lanes 4 to 15, with lane 8 
containing the molecular weight marker X DNA with Hind in and EcoR I digests. 
The PEG-pLL co-polymers 96-7 through to 96-15 were in lanes 6 - 1 5  respectively 
(except lane 8 ).
All of the DNA-polycation complexes were prepared at a charge ratio of 1.5 
(+/-) and remained in the wells of the gel. This indicated that the DNA was fully 
complexed with the polycations in each case, and the lack of smearing in the lanes 
showed that the DNA was protected from enzymatic degradation under the incubation 
conditions. The plasmid DNA incubated in serum (lane 3) showed the degraded 
fragments of DNA migrating at different rates through the gel, causing the
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characteristic smear. Lane 2 contained plasmid DNA in HBS, and the two bands 
represent open circular and supercoiled conformations moving from the well 
respectively. Lane 1 contained semm alone, and the fluorescence in this lane 
indicated any non-specific interaction of serum components with the ethidium 
bromide, for comparison with all of the other samples.
6.3.2. Polymer toxicity studies.
The comparative toxicities of the uncomplexed polycations were determined 
using the MTT assay (section 2.2.19) over the concentration range 0 - 1 0  jig/ml). The 
cationic homopolymers exhibited similar toxicities (Fig. 6.4A), each having an EC50 
of approximately 3 jLig/ml. The poly (lysine, alanine) co-polymers exhibited varying 
degrees of toxicity, which correlated with the ratio of alanine to lysine (Fig. 6.4B). 
The co-polymer containing the ratio of lysine : alanine 1:1 was considerably more 
toxic than either the 2:1 or 3:1 co-polymer. The lys,ala (1:1) co-polymer had a similar 
toxicity profile to that of polylysine, whereas the remaining two co-polymers were less 
toxic than polylysine at all of the concentrations studied.
The toxicity of the free polylysine was compared with that of polylysine 
complexed to plasmid DNA (Figure 6.5). At all of the concentrations examined ( 0 - 6  
jig/ml) the complexed polylysine was less toxic to B16 cells. The profiles exhibited a 
similar shape, but the curve for the complexed polylysine appeared to be displaced to 
the right of the curve for the free polylysine. No significant toxicity was observed for 
complexes at concentrations below 2 pg/ml. The estimated EC50 for the complexed 
polylysine was 4.5 |ig/ml, compared with 2.75 |LLg/ml for the free polylysine.
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F igu re  6 .4 . T oxicity  o f  free polym ers as determined using B 16 melanoma cells. B 16  cells w ere seeded  
at a concentration o f  3000  cells per w ell o f  a 96-w ell plate, and allowed to adhere in com plete m edium  
for 1 hour. Stock solutions o f  the polym ers (0 .05 |ig /m l) were prepared, and aliquots added to the w ells  
to produce concentrations in the range 0 - 1 0  |xg/ml. The cells were incubated under standard 
conditions for 4  hours, washed tw ice with serum free medium, and assayed using the M T T  assay  
(section  2 .19 ). C ell survival was determined by com parison with a control population o f  cells, w hich  
had been incubated in medium alone, using the ce ll number standard curve (appendix C). Data points 
represent mean ±  SEM  (n=4).
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F igu re  6 .5 . T oxicity o f  free poly-L-lysine on B 16 melanoma cells compared with the toxicity o f  poly- 
L -lysine-D N A  com plexes, as determined by M TT assay (section 2 .19). B 16  m elanom a cells were 
seeded at 3000  cells per w ell in a 96-w ell plate, and incubated for one hour in com plete medium to 
allow  cell adherence. Poly-L -lysine-D N A  com plexes were prepared at a charge ratio o f  1.5, using 6 |ig  
D N A  and the required mass o f  polymer, and incubated at room  temperature for 20 minutes. A liquots o f  
this mixture were added to the w ells, to provide concentrations o f  poly-L -lysine in the range o f  0 -6  
|ig /m l. Free poly-L-lysine was added to w ells to provide a similar range o f  poly-L -lysine  
concentrations. Cell survival was determined by comparison with a control population o f  cells, which  
had been incubated in medium alone, using the cell number standard curve (appendix C). The broken 
line represents the mean viability o f  B 16 cells in a replicate M TT for poly-L -lysine. Data points 
represent mean ±  SEM  (n=4).
6.3.3. Size analysis of polycation-DNA complexes.
6.3.3.1. Size analysis in water.
A representative histogram of the size distribution exhibited by polylysine- 
DNA complexes at a charge ratio of 1.0 is shown in Fig. 6 .6 , indicating that the size 
distribution was narrow. In general complexes were compared using the median 
diameter and the span of the distribution. The mean of the median diameter for three
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replicate experiments with polylysine-DNA complexes at the charge ratio 1.0 (+/-) was 
8 6  nm (S.D.of the median = 8.19).
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Figure 6.6. Representative histogram o f  size distribution o f  polylysine-D N A  com plexes, as determined 
by PCS. C om plexes were prepared using 6 p g  pRSVlacZ  and polylysine at a charge ratio o f  1.0 in a 
total volum e o f  0 .5  ml water. After incubation for 2 0  minutes at room temperature, the volum e was 
m ade up to 2 .0  m l with water, and the sam ples analysed im m ediately (section 6.2.3).
Table 6.1 shows the size of polylysine-DNA complexes prepared over the 
range of charge ratios (+/-) from 0 to 3.0. The complexes were incubated at room 
temperature for twenty minutes immediately after mixing, and were then diluted to 2 .0  
ml in water (section 6.2.3). The complexes maintained a similar size of 
approximately 100 nm over the range of charge ratios examined. The span of sizes 





0 .2 0.4 0.6 0 .8 1 .0 1.5 2 .0 2.5 3.0
Diameter
(nm)
77 105 132 83 83 8 8 119 92 117
Span 55- 79- 6 6 - 41- 45- 43- 8 6 - 45- 85-
(nm) 128 MO 264 165 173 258 228 270 224
Table 6.1. Size  analysis o f  polylysine-D N A  com plexes, as determined by PCS. C om plexes were 
prepared using 6 (ig  pR SV /acZ  and varying quantities o f  polylysine to produce a range o f  charge ratios, 
in a total volum e o f  0.5 ml water. After incubation for 20  minutes at room  temperature, the volum e was 
made up to 2 .0  m l with water and the sam ples analysed im m ediately (section 6 .2 .3 ). Data are 
representative o f  three replicate experiments.
The homopolymers and co-polymers supplied from Sigma (section 3.2) were 
used to prepare complexes at a charge ratio of 1.5, and sized in water. The effective 
diameters and the span of sizes measured within each population are displayed in 
Table 6.2. The diameters quoted were the medians, and for all of the systems tested 
except poly-D-lysine the sizes were approximately 100 - 150 nm, with spans routinely 
between 70 and 200 nm. The poly-D-lysine apparently produced complexes that were 
greater than 2 0 0  nm, and the span observed in the population was wider than for the 
other polymers tested (69 - 307 nm).
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Sample PLL PDL PLO PLA L,A 1:1 L,A 2:1 L,A 3:1
Diameter(nm) 95 231 145 93 145 139 1 0 1
Span (nm) 71-127 69-307 109-193 70-124 40-193 104-185 76-135
T a b le  6 .2 . Diam eter (nm ) o f  com plexes formed at a charge ratio o f  1.5 betw een the various polym ers 
and 6p.g o f  the plasm id pR SYlacZ. The com plexes were initially formed in 0.5 ml water, incubated at 
room  temperature for 20  minutes, and the volum e was made up to 2 .0  ml with water. T he com plexes  
w ere im m ediately analysed using PCS (section 6.2 .3) to establish the particle diameter.
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T ab le  6 .3 . Diameter and span o f  com plexes formed at a charge ratio o f  1.5 using the various PEG-pLL  
co-polym ers (Table 4 .1 ) and 6 |ig  pR SYlacZ. The com plexes were initially formed in 0 .5  ml water, 
incubated at room temperature for 20  minutes, and the volum e was made up to 2 .0  ml with water. The 
com plexes were im m ediately analysed using PCS (section 6.2 .3) to establish the particle diameter.
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Complexes prepared from the PEG-pLL co-polymers (section 4.1) and plasmid 
DNA at a charge ratio of 1.5 (+/-) were analysed in water, and the diameters are 
displayed in Table 6.4. The complexes had diameters of between 110 to 250 nm, and 
the spans observed ranged from 60 to 330 nm. The co-polymers with a high PEG:pLL 
ratio could not be sized using this method for reasons which were not established. No 











3.02.0 2.50.0 0.5 1.0 1.5
Charge Ratio (Polymer/DNA)
F igu re  6 .7 . R elationship between H2oK25 -DNA com plex diameter and charge ratio (+ /-). C om plexes 
were prepared using 6 |ig  pRSWlacZ and various quantities o f  H20K2 5 (section 5 .2). The com plexes 
were initially formed in 0 .5  ml water, incubated at room temperature for 20  minutes, and the volum e  
was made up to 2 .0  ml with water. The com plexes were im m ediately analysed using PCS (section  
6 .2 .3) to establish the particle diameter.
PCS was used to size complexes formed using H20K25 and DNA in water over 
a range of charge ratios (+/-) up to 3.0 (Fig. 6.7). The complexes were not able to be 
sized below a charge ratio of 0.4, but above this there was a rapid increase in size 
from 80 nm to 180 nm with charge ratio up to 1.0. Above this charge ratio, the size 
decreased back to approximately 80 nm at a charge ratio of 3.0. The span of size
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distributions observed within the populations ranged from 40 nm to 280 nm (Table
6.4), except at a charge ratio of 1.0, where the smallest particles within the population 
has a diameter of 130 nm. Above a charge ratio of 1.0, the largest particles within 
each population had diameters of approximately 250 nm.
Charge Ratio 0.4 0.6 0.8 1.0 1.5 2 2.5 3.0
Diameter (nm) 79 78 95 178 162 118 93 84
Span (nm) 40- 55- 59- 129- 81- 84- 30- 41-
159 219 127 341 236 236 281 247
T ab le  6 .4 . The diameter and span o f  com plexes prepared using 6p g  pR SVlacZ  and various quantities 
o f  H2oK25 (section  5 .3). The com plexes were initially formed in 0.5 ml water, incubated at room  
temperature for 20  minutes, and the volum e was made up to 2 .0  ml with water. The com plexes were 
im m ediately analysed using PCS (section 6 .2 .3) to establish the particle diameter.
63.3.2. Size analysis in buffers.
Complexes were prepared from polylysine and plasmid DNA in 0.5 ml water 
over the range of charge ratios 0 -3 .0 . They were then incubated at room temperature 
for 20 minutes before dilution to 2.0 ml with either water or the buffer opti-MEM. 
The particles were then immediately sized using PCS, and the comparative diameters 
are shown in Figure 6 .8 . The complexes formed in water maintained a constant size 
around 1 0 0  nm over the range of charge ratios examined, but this pattern was not 
exhibited by the complexes diluted in opti-MEM. The size of these complexes rapidly 
increased from 100 nm at a charge ratio (+/-) of 0.4 to approximately 700 nm at a 
charge ratio of 1.0. This instability was less pronounced when the charge ratio was 
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F ig u re  6 .8 . S ize analysis o f  po lylysine-D N A  com plexes, as determined by PCS. C om plexes were 
prepared using 6 |ig  pR SVlacZ  and varying quantities o f  polylysine to produce a range o f  charge ratios, 
in a total volum e o f  0 .5  ml water. After incubation for 20 minutes at room temperature, the volum e was 
made up to 2 .0  ml with water or opti-M EM , and the sam ples analysed im m ediately (section 6 .2 .3)  
(n=2).
HEPES concentration (mM) Diameter (nm) Span (nm)
1 0 97 51-134




T ab le  6 .5 . D iam eter o f  p o ly lysine-D N A  com plexes prepared in increasing concentrations o f  H epes 
buffer. T he com plexes w ere prepared at a charge ratio o f  1.0 using 6 |ig  D N A  and the necessary mass 
o f  poly lysine in 5 0 0  p i water containing the increasing concentrations o f  H epes. The com plexes were 
incubated at room  temperature for twenty minutes before diluting to 2 .0  m l in the respective H epes 
solutions. The sam ples were analysed im m ediately using PCS to establish the particle diameter.
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The effect of hepes buffer on the formation of polylysine-DNA complexes and 
their resultant size was examined over the concentration range of 10 - 50 mM Hepes. 
The complexes were prepared in the various concentrations of buffer, and the results 
are displayed in Table 6.5. The diameter of the complexes remained close to 100 nm 
for all of the buffer concentrations, and the range of sizes within each population was 
between 40 to 170 nm.
NaCl Concentration (M) Diameter (nm) Span (nm)
0.01 1512 154-274; 791-2090
0.025 790 269-1623
0.05 1 1 1 1 541-1795
0.075 335 251-447
0.1 283 305-541
0.125 1155 100-178; 1155-1778
0.15 257 140-846
T ab le  6 .6 . E ffect o f  N aCl on H2oK25 -DNA com plex size. C om plexes were prepared using 6 p g  DNA 
and sufficient mass o f  H20K25 to produce a charge ratio o f  1.0 (+/-). The com plexes w ere initially  
prepared in 500 p i N aCl solution o f  the appropriate concentration, incubated at room  temperature for 
twenty minutes, before dilution to 2.0 ml with NaCl solution. The com plexes were analysed  
im m ediately using PCS to establish the particle diameter.
The effect of sodium chloride (NaCl) on the formation and size of the 
complexes formed was investigated using polylysine-DNA and H20K25/DNA 
complexes at a charge ratio of 1.0 (+/-), which were formed in NaCl solutions of 
increasing concentrations from 0.01 to 0.15 M. The polylysine system was unable to 
be analysed due to large fluctuations in the counts detected, indicating a large degree 
of interference. The median diameters of the H20K25/DNA complexes at the different
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NaCl concentrations fluctuated from 280 nm to 1512 nm, but followed no pattern with 
increase in NaCl concentration (Table 6 .6 ). The range of particle sizes observed at 
each NaCl concentration was much wider than that observed for the complexes 
formed in water (129 nm - 341 nm, Table 6.4). In two cases, at 0.01 M and 0.125 M, 
two distinct populations were observed within the system. This indicated that the 
NaCl was affecting the complex formation, producing a more heterogeneous system 
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F igu re  6 .9 . E ffect o f  pH on particle size o f  com plexes containing H2oK25 and D N A  at charge ratios (+/- 
) o f  0 .5  and 0 .75. The com plexes were prepared using 6 |ig  D N A  and the necessary mass o f  H2oK25 to 
produce the required charge ratio in 500  |i l phosphate-citrate buffer at the different pH values. The 
com plexes were incubated at room  temperature for twenty minutes before diluting to 2 .0  ml in the 
appropriate buffer. Sam ples were analysed im m ediately using PCS to establish the particle diameter.
The effect of pH on the formation of complexes by H20K25 and plasmid DNA 
was examined using PCS, and the results are represented in Figure 6.9. The 
complexes were prepared at theoretical charge ratios (+/-) of 0.5, 0.75 and 1.0 in 
phosphate-citrate buffers at pH values of 4, 5, 6 , 7 and 8  and analysed immediately.
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The pattern for the complexes prepared at charge ratios of 0.5 and 0.75 showed a 
steady increase in size as the pH increased from 4 to 8 . The range of sizes within the 
populations observed were broad for the complexes at charge ratio 0.5, and were 
generally in the range 200 nm to 1000 nm. These complexes could not be sized at a 
pH of 8 .
The complexes at charge ratio 0.75 exhibited narrower ranges of particle sizes, 
but there was a shift towards larger particles as the pH was increased. At pH 4, 
particle sizes ranged from 91 - 552 nm, and at pH 8 the range was from 369 - 657 nm. 
Complexes prepared at a charge ratio of 1.0 could only be sized at a pH of 8 , and the 
median diameter was established as 482 nm.
6.3.4 Isothermal titration calorimetry.
The graphs shown in Fig. 6.10 represent the traces obtained from the 
thermometric analysis of the titration of polylysine (10 mg/ml) into a solution of 250 
p,g/ml pRSNlacZ. The control trace for the titration of HBS into the plasmid solution 
exhibited a very similar profile. Peaks from the corrected profiles were integrated 
automatically, providing energy values corresponding with the titration processes. 
There were problems encountered with precipitation inside the ampoule, and this was 
observed even at points where the charge ratio was as low as 0.4. Variation of the 
DNA concentration, the aliquot volume and the mixing speed had no effect on the 
precipitation problem. This indicated that this method of mixing and thermometric 
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Figure 6.10. Thermometric analysis o f  the formation o f com plexes from poly-L-lysine and pRSVlacZ. 
A polylysine solution (10  mg/ml) was titrated into a D N A  solution (250 |ig/m l pRSVlacZ) contained 
in a 4 ml stainless steel titration ampoule. Aliquots o f 4 pi o f polylysine solution were titrated into the 
D N A  at 15 minute intervals, while stirring at 10 rpm, until a total volum e o f 200 pi had been dispensed. 
A control was performed where HBS solution was titrated into the D N A  solution to calculate the heat o f  
dilution associated with the D NA . All measurements were performed using a Thermometric 2277  
Thermal Activity Monitor. Figure A shows the raw trace produced by the titration process, while B 
shows the corrected data, accounting for the lag time o f  the transfer o f thermometric measurements by 
the system compared with the actual temperature fluctuations. This was done automatically using the 
correction program supplied as part o f the system.
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6.3.5. Uptake studies of polylysine-DNA complexes.







F igure 6.11. Uptake studies o f  polylysine-DN A  com plexes in B16 melanoma cells. Com plexes were 
prepared over the range o f charge ratios (+/-) 1.5, 2.0, 2.5, and 5.0 using 6 pg pRSVlacZ, and a constant 
mass o f  FITC-polylysine and various quantities o f standard polylysine to produce the desired charge 
ratios (A). The com plexes were incubated with the cells for 4  hours at standard conditions, before 
analysis with FACS. Alternatively, com plexes were prepared from 6 pg pRS VlacZ  and FITC-polylysine 
at a charge ratio o f  1.5, and added to the culture medium. Standard uncom plexed polylysine was then 
added to the transfection medium to produce effective charge ratios o f 2.5, 5.0, 7.5 and 10.0 (B). The 
cells were incubated for four hours at standard conditions before FACS analysis. Figures C and D depict 
3-D  representations o f Figs. A  and B respectively. The profiles are representative o f two replicate 
experiments.
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The uptake of polylysine-DNA complexes in B16 melanoma cells was 
examined using FITC-labelled polylysine and FACS. Initially, the uptake of 
polylysine-DNA complexes of charge ratios (+/-) on the range 1.5 - 5.0 was examined 
(Figure 6.11, plates A and C). Cell viability was also determined by staining with 
propidium iodide immediately prior to FACS analysis. The grey line represented the 
negative control sample of cells which had not been incubated with any complex. The 
green, navy, pink and pale blue lines represent cells incubated with complexes at 
charge ratios of 1.5, 2.0, 2.5, and 5.0 respectively. The profiles for the different 
charge ratios were almost completely overlaid, but the 3-D histogram showed that the 
cell viability decreased with increasing charge ratio of the complexes.
Additional studies into the effect on complex uptake by free polylysine 
involved transfection using complexes of charge ratio 1.5, and the addition of free 
polylysine into the culture medium to produce an effective charge ratio in the medium 
of 2.5, 5.0, 7.5 and 10.0. Similar ranges of fluorescence were observed in all of the 
samples (Plates B and D), and the toxicity increased as the cationic charge and 
quantity of free polylysine in the medium was increased. Comparative cell viability of 
the polylysine-DNA complex at a charge ratio (+/-) of 5.0 and 1.5 with free polylysine 
up to a theoretical charge ratio of 5.0 were 76% and 44% respectively.
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6.4. DISCUSSION
6.4.1. Stability of complexes in serum.
The production of pharmaceutical products requires assessment of the stability 
of the formulation. A major limitation to the therapeutic application of gene therapy 
is the presence of nucleases in vivo and in vitro which can rapidly digest DNA. 
Complexation of DNA with polycations has been shown to enhance stability towards 
melting (Olins et a l, 1967), and chemical modification of oligonucleotides to produce 
phosphorothioates has also been shown to confer protection on the DNA from 
enzymatic degradation (Zobel et al., 1996). The assay used here was developed to 
establish the comparative stability of the complexes of various formulations to 
enzymatic degradation in serum. The polycation-DNA stability studies relied on the 
resolution of the complexes on agarose gels for visualisation of any degradation that 
had occurred. Electrophoresis of DNA requires that the molecules are negatively 
charged to effect migration. Beyond the point of charge neutralisation by 
complexation with polylysine, P. Lucas (1995) demonstrated that plasmid DNA 
remained in the well during electrophoresis. This method allowed DNA samples that 
had been degraded by the nucleases in serum to be identified, as non-degraded 
samples would remain in the wells, but smaller degraded fragments would migrate 
towards the cathode during electrophoresis.
All of the complexes were prepared at a charge ratio of 1.5, as this was the 
ratio used for transfection studies. The complexes were then incubated in the 
presence of complete tissue culture medium with 1 0 % foetal calf serum for four 
hours, to mimic the conditions of the transfection procedure. None of the complexes
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prepared from any of the polymers exhibited any degree of DNA degradation. There 
were no differences observed between all of the homopolymers, or the lysine,alanine 
co-polymers. Additionally, the PEG-pLL co-polymers all protected DNA to the same 
degree, as did H20K25 and PEI. Internal controls were included in the experiments and 
these behaved as expected, with uncomplexed DNA suffering degradation in serum 
but not in HBS. The serum alone revealed a band of fluorescence due to interaction of 
some of the proteins with the ethidium bromide, and this was observed in all of the 
samples. This band ran faster than the undegraded DNA, so did not interfere with the 
interpretation of the gel.
This assay demonstrated that the polymers all conferred a similar level of 
protection from degradation to the DNA. This assay does not allow quantification of 
the DNA, which could be done in parallel using radiolabelled DNA, as performed by 
Chiou et al. (1994). These results demonstrated that despite the observations of Olins 
et a l (1967)that different side-chains conferred varying degrees of stability on 
complexed DNA towards melting, all of the polycations were capable of protecting 
the DNA from nuclease degradation. Hence, these results illustrate that differences in 
transfection efficiencies of complexes prepared with the various polycations are 
unlikely to be due to degradation in the transfection medium. This indicates that the 
differences are either due to differential uptake or processes occurring distal to the cell 
membrane.
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6.4.2. Toxicity studies of the poly cations.
The cellular toxicity exhibited by the polymers studied would primarily be as a 
result of the concentration of cationic charge. All of the homopolymers demonstrated 
similar toxicity profiles, as would be expected from their similar molecular 
weight/charge ratios (Table 3.1). For ail the homopolymers, at a concentration of 4 
pg/ml, the cells were subjected to a cationic charge of 2xl0 ' 5 M. Hence it would 
appear that all of the homopolymers exerted cellular toxicity due to their cationic 
nature, and that the degree of toxicity was similar in all cases.
The lysine, alanine co-polymers produced a less homogeneous pattern of 
toxicity. The charge density of the co-polymers differed from each other and 
polylysine, and for lysine, alanine ratios of 1:1, 2:1, 3:1 and polylysine, the respective 
molar concentrations of lysine at 4 jig/ml were 1.43x1 O'5, 1.63x1 O'5, 1.72x1 O' 5 and 
2xl0 '5. If the cellular toxicity was solely due to the cationic charge then the 
decreasing order of toxicity of the polycation would be polylysine, then the co­
polymers of molar ratio 3:1, 2:1 and 1:1.
The lysine, alanine (1:1) co-polymer with the lowest charge density was the 
most toxic studied, followed by polylysine, then the 3:1 and the 2:1 co-polymers. The 
order of charge density-related toxicity was observed for polylysine, the co-polymers 
(3:1) and (2:1), but the (1:1) co-polymer did not fit into this pattern. This implies that 
there is another factor contributing to cellular toxicity with lysine, alanine (1:1). The
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neutral alanine component could be toxic to cells above a threshold concentration, and 
below this concentration the toxicity could be primarily due to the cationic charge 
effects. The molar concentrations of alanine in the co-polymers 1:1, 2:1 and 3:1 at 4 
pg/ml were 1.43xl0'5, 8.18xl0'6 and 5.73xl0 ' 6 respectively.
A molecular weight influence on toxicity has been reported by Wolfert and 
Seymour (1996), although they showed that higher molecular weights exerted greater 
toxicity. This is in contrast to the results presented here, as the lysine, alanine (3:1) 
co-polymer had a molecular weight of 31,000, whereas the other two lysine,alanine 
co-polymers, (1:1) and (2:1),had molecular weights of 50,000 and polylysine was
45,000.
Reduced toxicity was observed with DNA-polylysine complexes compared 
with free polylysine. If the cellular toxicity was due directly to the concentration of 
cationic charge, then complexation of the polycation with anionic DNA would serve 
to reduce this toxicity. The complexes routinely used for transfection had a charge 
ratio (+/-) of 1.5, so although they maintained an overall positive charge, interaction 
with the anionic DNA served to reduce the cellular toxicity. There may have been 
free polylysine available for interaction with the cells, as it could not be removed from 
the preparations before toxicity testing. In spite of this possibility, at the 
concentration used for transfection with polylysine-DNA complexes of 3.5 Jig/ml, the 
free polylysine produced approximately 40% viability compared with 75% for the 
polylysine-DNA complexes.
186
6.4.3. Size analysis of complexes.
The variation of in vitro transfection efficiencies observed between complexes 
formed with the different cationic polymers, and at different charge ratios have been 
shown in an earlier part of this study (section 6.2.3). One postulation to account for 
this was that the complexes formed were of different sizes, which would result in 
differential uptake into cells. The size analysis of complexes formed from DNA and a 
variety of polycations, at a range of charge ratios and in different conditions was 
performed to investigate this possibility.
The size analysis studies of the polycation-DNA complexes demonstrated that 
all of the complexes were between 100 - 150 nm diameter when prepared in water. 
The experiment required that the equipment was very clean from contaminating 
particles. This was because even one large particle could sway the mean considerably, 
due to intensity interference. To reduce the effect of this, the median diameter was 
taken for comparison, as this was a measure of the diameter of the majority of 
particles within the population. An idea of the range of sizes was also included (the 
span) for comparative purposes. The reproducibility of the measurements was 
initially demonstrated using the polylysine-DNA system at a charge ratio of 1.0 in 
triplicate. Due to severe time restrictions using the equipment, many of the 
subsequent measurements were performed either once or in duplicate.
6 .4.3.1. PCS o f complexes in water.
The polylysine-DNA complexes were all shown to be about 100 nm if formed 
in water at charge ratios (+/-) of between 0-3 .0 .  Analysis was initially attempted in 
HBS, but there was considerable interference with the light scattering pattern, and the
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correlation program was unable to interpret the data. The complexes were then 
prepared in water, which allowed analysis to be performed, but clearly these 
conditions did not mimic the normal procedure for complex preparation, or the 
environment during transfection.
Sizing of complexes prepared from the various cationic polymers did not 
demonstrate any differences between them which correlated with the pattern of 
transfection efficiency. The system did not mimic the normal transfection procedure 
conditions very strongly, so further size analysis focused on the properties of 
complexes prepared in electrolyte solutions, to identify any differences due to 
constituents of the buffer system used.
The PEG-pLL complexes were sized in water as between 110 - 250 nm, with 
spans ranging from 60 to 330 nm. The complexes formed from the co-polymers with 
a high PEG : pLL ratio were unable to be sized. This could be due to the large mass 
of PEG relative to the polylysine causing a heterogeneity in the conformation of the 
complexes. If the PEG was producing a mantle enclosing a hydrophobic core in a 
controlled manner, then the particles would be quite likely to have a spherical shape. 
In cases where the PEG : pLL ratio was high, the particles could be less spherical, 
causing variable light scattering patterns, which the computer programme would have 
difficulty interpreting.
Analysis of H 2 0 K2 5 -DNA complexes in water demonstrated a maximum size 
of 180 nm at a charge ratio of 1.0. Below this charge ratio the complexes were close 
to 80 nm, and above 1 .0 , particle size fell gradually back to approximately 80 nm at a 
charge ratio of 3.0. The range of sizes observed within the populations was shown to
increase above a charge ratio of 1.0. The maximum size at electroneutrality can be 
accounted for due to the complexes at this point exhibiting no overall charge. Hence, 
no electrostatic repulsion would be expected to occur between the complex molecules, 
and particle aggregation could occur.
6.4.3.2.. PCS o f complexes in buffers.
The size of polylysine-DNA complexes over the range of charge ratios (+/-) 
from 0 - 3 . 0  showed no differences in water, but in the buffer system opti-MEM (pH 
7.4), a peak of 700 nm was observed at 1.0, beyond which the size fell once again to 
150 nm. This indicated that components contained in opti-MEM were affecting the 
complex formation, as the complexes were much larger when formed in this system 
than in water. Also, the change in size with alteration of the charge ratio, with a 
maximum at the charge neutralisation point, demonstrated aggregation of the 
complexes at this point due to reduced repulsion between the individual particles. 
This pattern was not mimicked in water as the system was probably very sensitive to 
the mixing method.
The polylysine-DNA complexes were sized at a charge ratio (+/-) of 1.0 in 
Hepes buffer at concentrations in the range 10-50 mM to try to explain the differences 
observed between complex formation in water and opti-MEM. The complexes all 
sized at roughly 100 nm, with a narrow range of size distributions at each Hepes 
concentration. It was concluded that the Hepes was not the component in the buffer 
system that was altering the complex formation compared with the water system.
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Complex formation was affected considerably by the presence of NaCl. 
Polylysine-DNA complexes could not be analysed when formed at any of the NaCl 
concentrations studied. The controlled formation of co-operative complexes has 
previously been shown to be dependent upon the NaCl concentration (Leng and 
Felsenfeld, 1966; Shapiro et al.. 1969). The mixing process used by these groups 
involved a more controlled process than the flash mixing used for complex formation 
throughout this study. The ionic concentration of the solvent is likely to affect the 
electrostatic interaction between the anionic DNA and the polycations. The stability 
of the polycation-DNA complexes is an important consideration in the production of 
these systems as pharmaceutical products, and the effect of NaCl on the various 
formulations will require attention in the future. Some means of stabilisation will be 
required if these systems are to be used in vivo.
The H20K25-DNA complexes were sized in various concentrations of NaCl. 
There was considerable fluctuation in size and a wide span of sizes within each 
population, although no pattern emerged relating complex size to the ionic 
concentration of the solvent. At some charge ratios, more than one population of 
particles with distinct size distributions were observed. This indicated that the 
complex formation was being affected by the presence of the NaCl. The process 
appeared to produce a more heterogeneous population of particles when the 
complexes were formed in NaCl solution. The susceptibility of complexes to the 
effects of NaCl over time would provide an indication of the comparative stability of
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each system, and this could have been monitored using PCS to detect size distribution 
fluctuations within populations of particles. The main limitation within the present 
study was the availability of a laser with sufficient power to allow sizing of DNA 
particles at 10 Jig/ml DNA.
6.4.33. pH effects on H2 0K25 -DNA complexes.
The effect of pH variation on the complexes formed between plasmid DNA 
and H20K25 were examined because of the proposed pH-dependent DNA release 
mechanism from the endosome (section 5.1.1). The charge ratio at each pH was 
calculated assuming that only the polylysine component was contributing to the 
cationic effect and a constant mass of polymer was used at each pH. However, at the 
lowest pH of 4.0; approximately 99% of the polyhistidine would also have been 
positively charged; at a pH of 8.0, approximately 0.99% of the polyhistidine would 
have been protonated. Therefore, at the theoretical charge ratio of 0.5 the actual 
charge ratios at pH 4, 5, 6 , 7 and 8  would have been 0.9, 0.86, 0.7, 0.53 and 0.5 
respectively. Similarly, at the theoretical charge ratio of 0.75 the actual charge ratios 
at pH 4, 5, 6 , 7 and 8  would have been 1.34, 1.29, 1.05, 0.81 and 0.76.
A size increase was observed with rise in pH, which could now be attributed to 
a charge ratio effect. The presence of a neutral component within the block co­
polymer would provide steric hindrance to the formation of a highly compact species. 
A situation similar to the formation of a PEG mantle (section 4.1.1) could exist. As 
the percentage of protonation of the neutral polymer increased, the particle
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morphology would be affected. The increase in heterogeneity observed within 
populations as the degree of polymer ionisation decreased supported the hypothesis 
that more disorganised systems were formed when the polyhistidine remained 
unprotonated.
6.4.4. Isothermal titration calorimetry.
The technique of titration calorimetry has been shown to be highly sensitive, 
allowing binding constants and heats of binding to be established for enzyme- 
substrate systems (Wiseman et al., 1989). The enthalpy for binding of repressors to 
DNA operator sites have also been established using calorimetry (Merabet and 
Ackers, 1995). This method was chosen to establish comparative binding enthalpies 
for the different cationic polymers with DNA. This information might have been 
expected to provide an indication of the relative strengths of association between 
polymer and DNA for the complexes. Systems with high binding enthalpies would be 
more stable but also more resistant to dissociation inside the cell. This would possibly 
affect the availability of the DNA for uptake into the nucleus and subsequent 
transcription and expression.
There were several drawbacks to the use of this technique for analysis of 
polycation/DNA complexes. The mixing process during titration of small aliquots of 
highly concentrated polylysine (10 mg/ml) into a concentrated DNA solution (250 
|ig/ml) bore little resemblance to the flash mixing of the two dilute solutions (15 
jig/ml and 6  jig/ml for polylysine and DNA respectively). The concentrations of both 
components had to be increased to produce measurable enthalpy changes, and the
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aliquots were small so that the titrant was still thermostatically controlled. An 
alternative model of the calorimeter has two chambers which contain the two 
reactants. The reactants are mixed by removal of the dividing partition, and the 
enthalpy of the whole association can be established (batch calorimetry). This would 
have been a better system for measuring and comparing the different polycation-DNA 
interactions. Unfortunately there was no accessibility to the batch calorimeter for this 
study, and this work was therefore terminated since the titration calorimeter was not 
an appropriate instrument.
6.4.5. Uptake studies in B16 melanoma cells.
Basic polyamino-acids have been demonstrated to enhance the uptake of 
protein molecules (Ryser, 1967) and DNA (Farber et a i, 1975) into certain cell lines. 
It would appear that a mechanism exists for the association of these complexes with 
the cell membrane, leading to internalisation. It was postulated in section 3.12 that 
the differences observed in transfection efficiency between complexes prepared at 
different charge ratios were due to selective or differential uptake. It has been 
demonstrated that the complex diameter does not correlate with transfection efficiency 
(section 6.3.3), so another characteristic appears to govern the activity. The lack of 
transfection activity below a charge ratio (+/-) of 1 .0  was attributed to the necessity for 
association with the negatively charged cell membrane. It was postulated that 
observation of peak efficiency at charge ratio 1.5, and subsequent decrease in 
expression with increase in charge ratios, was due to uncomplexed polylysine 
inhibiting either complex uptake or dissociation inside the cell (section 3.12).
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The uptake of polylysine-DNA complexes of charge ratios from 1.5 to 5.0 
were examined to assess any correlation between uptake and the optimum transfection 
charge ratio of 1.5. The lack of difference observed in uptake profiles demonstrated 
that the peak in transfection activity was not related to a differential uptake profile. 
The similarity in fluorescence levels observed at the different charge ratios implied 
that the complexes incorporated all of the polylysine into their structure on formation. 
If this was not the case, then as more non-fiuoresceinated polylysine was used for 
mixing with the constant mass of FITC-polylysine, the relative proportion of FITC- 
polylysine incorporated into the complex would be decreased. This would produce a 
resultant decrease in fluorescence associated with the complex. The washing 
procedure has been shown to successfully remove any complexes not internalised (D. 
Milroy, personal communication), so that the fluorescence observed provided an 
accurate indication of complex uptake. This showed that the uptake mechanism was 
non-selective for complexes with different overall positive charges.
The competition of free polylysine for either uptake or dissociation after 
internalisation was studied by the addition of uncomplexed polylysine to transfection 
medium already containing polylysine-DNA complexes of charge ratio (+/-) 1.5. If the 
uptake mechanism had been saturated, a reduction in fluoresceinated complex uptake 
would be observed as the quantity of free polylysine increased. No difference in 
uptake profiles was observed, although the levels of cellular toxicity observed in the 
experiments with free polylysine were considerably higher than with the complexes 
alone (44% and 76% viability respectively). The toxicities observed were similar to
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those seen with the MTT assay comparing polylysine with DNA-polylysine 
complexes (section 6.3.2). These results demonstrated that for complexes of charge 
ratios (+/-) greater than 1.5, the excess polylysine appeared to be associated with the 
complex, and did not remain uncomplexed.
These results therefore disprove the theory that the polylysine used to form 
complexes at high charge ratios (+/-) did not all associate with the complexes, 
inhibiting complex uptake or dissociation within the cell. It appeared that the 
differences observed with in vitro transfection activities both for complexes formed at 
different charge ratios and using various polycations were due to characteristics which 
affected the processes distal to cellular uptake.
6 .6 . SUMMARY
The physical characteristics of delivery systems require investigation prior to 
optimisation and development into a pharmaceutical product. Preliminary studies 
have revealed that all of the cationic polymers used for plasmid DNA complexation 
conferred similar levels of protection on the DNA from the enzymatic degradation of 
nucleases present in serum. Polylysine-DNA complexes were shown to be less toxic 
to B16 melanoma cells than free polylysine. No correlation was observed between 
complex size and the transfection efficiency, and sodium chloride was shown to affect 
complex formation considerably, compared with complex production in water. This 
appeared to be a critical effect for establishing the stability of the complexes. The 
uptake of positively charged complexes was unaffected by increases in charge or the 
presence of free polylysine, indicating that the mechanism of uptake was non-selective
195
and not saturated at the levels tested. The toxicity of the complexes increased with 
positive charge, but remained lower than the toxicity due to free polylysine. Further 
investigations should include electron microscopy attempting to visualise the uptake 
and transport processes distal to the cell membrane. Other aspects of importance 
include determination of the relative dissociation of the various complexes, and 
whether this process must occur prior to nuclear localisation.
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CHAPTER 7. Concluding discussion.
The therapeutic applications of gene therapy are reliant on both identification of 
the genetic causes of a disease and ways of overcoming them, plus efficient delivery of 
the gene into the target cells. It has rapidly been realised that gene therapy can be used 
not only for replacement of genetically defective genes as in cystic fibrosis, but also for 
multifactorial diseases such as cancer and inflammatory disorders. Ideally, gene 
expression would be restricted to the target cell population, whether achieved via 
selective delivery or transcription, courtesy of tissue-specific promoters. Additionally, 
the gene must access the nucleus once inside the cell, ultimately allowing gene 
expression.
Despite the lack of progress exhibited with the immunotherapeutic approach 
detailed in this study, many investigations are currently concentrating on the generation 
of tumour-specific immunity. The potential for targeting exogenous antigen into the 
phagocytic pathway, resulting in presentation by MHC class I molecules, has been 
investigated by Falo et al. (1995). In vivo studies confirmed the generation of tumour 
rejection and protection from subsequent challenge both with tumours presenting the 
antigen previously used, plus other antigens expressed by the tumour. Alternatively, 
several of the MAGE antigens (restricted to melanoma cells) have been transfected into 
tumours, subsequently eliciting anti-tumour immunity via both CD4+ and CD8 + T cells 
(H. Bueler, personal communication). Co-expression of GM-CSF or B7-1 enhanced 
this anti-tumour effect during in vivo murine studies.
197
The lack of reliability demonstrated by the Trp-1 promoter system in these 
studies has also been observed in other investigations (Dr. R. Vile, personal 
communication). Current interest on melanoma-specific promoter activity centres on 
the tyrosinase promoter (section 1.4.1). This has been used to induce melanoma- 
specific expression of B7, resulting in an in vivo antitumour effect in immunocompetent 
mice (Chong et al., 1996). Substitution of the Trp-1 promoter with the tyrosinase 
promoter would therefore seem natural in the progression of this study.
Optimisation of delivery vectors for gene therapy involves characterisation of the 
interactions of the DNA with the vector. It is desirable that pharmaceutical products are 
well-characterised and reproducible in their effects. While much interest has centred on 
the use of attenuated viruses for clinical trials, it is widely accepted that these will 
ultimately be replaced with safer, non-viral vectors. The use of cationic polypeptides 
for binding DNA has been widely acknowledged, but more efficient vectors require 
additional characteristics to ensure transport of the DNA from outside the cell 
membrane to the nucleus.
The particulate nature of polycation-DNA complexes has been well documented 
by Olins et al. (1967). In the present study, modification of the chemical nature of the 
polycation was shown to have little effect on the 1:1 stoichiometry for DNA 
condensation with respect to charge ratio. The charge density of the various cations 
affected the mass ratio of interaction, which was most noticeable with the co-polymers 
containing neutral components.
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The relationship between overall ionic charge of the complexes and in vitro 
biological activity initially described for polylysine by Lucas (1996) was demonstrated 
to apply to complexes formed using a variety of cationic polymers and co-polymers. 
Reporter gene expression was effected after non-specific uptake in these studies, and 
this was observed only when the complexes were positively charged. The lack of in 
vitro biological activity observed below a charge ratio (+/-) of 1.0 indicated that the 
particulate systems formed by the flash mixing method used in this study were not co­
operative. This was in contrast to observations by Manning (1980) where the conditions 
for mixing and complex preparation were very closely regulated. The lack of activity 
below charge ratio (+/-) 1.0 suggested that no active complexes were formed below this 
ratio. Hence, the flash mixing appears to cause even distribution of the polycations 
throughout the population of DNA molecules. A co-operative interaction would infer 
that the initial interaction between a DNA molecule and a cation would favour further 
binding of cations to the same DNA molecule. This would result in a heterogeneous 
population of DNA molecules, each associated with various numbers of cations.
The complexes prepared using co-polymers containing a neutral component to 
reduce toxicity exhibited reduced transfection efficiency compared with polylysine. 
This was believed to result from differences in complex stability, uptake or endosomal 
release. Recently, Mislick and Baldeschwieler (1996) have reported that polycation- 
DNA complexes achieve cell-entry via interaction of the cation with anionic sulfated 
proteoglycans, found in basement membranes and the extracellular matrix. Restriction
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of direct interaction of the cations with the proteoglycans would serve to reduce uptake. 
This may account for the reduced activity profile observed for complexes prepared from 
PEG-polylysine co-polymers and DNA, due to the formation of a PEG mantle around 
the core containing the polycation and DNA.
The cell-specific prerequisite for chloroquine to effect transfection using 
poiycation-DNA complexes demonstrated that these systems are unsuitable for delivery 
in vivo. One theory to account for the differences observed between the B16 and the 
293 cells suggested that endosomes in different cell lines may exhibit variation in 
membrane integrity or internal endosome conditions. The erythroleukaemic cell line K- 
562 has been shown to exhibit increased transfection after treatment with chloroquine 
far in excess of that observed with other cell lines. This was established to be due to the 
presence of an unregulated acidified endosomal environment (Wagner et al, 1992).
Production of a co-polymer containing polylysine and polyhistidine attempted to 
combine DNA-binding with the capacity for protonation within the endosome. This 
‘proton sponge’ effect has been attributed to a lysosomotropic action (Stenseth and 
Thyberg, 1989). The lack of transfection activity with this system indicated that a 
greater membrane-disruption activity was required. High levels of activity have been 
produced from the use of synthetic peptides similar to those used by viruses for cell- 
entry (Gottschalk et al., 1996; Fominaya and Weis 1996). Wilke et al. (1996) have 
demonstrated gene delivery using a similar multifunctional vector. This group 
established the necessity for a mitotic event, in addition to efficient delivery, to produce 
high levels of transfection in vitro.
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These studies established no difference in uptake of polylysine-DNA complexes 
of increasing charge ratio (+/-). This profile contrasted with the decrease observed in 
gene expression above a charge ratio (+/-) of 1.5, indicating that the uptake of complexes 
was not the limiting step for in vitro biological activity. No differences were observed 
in the stability of complexes to the enzymatic degradation associated with incubation in 
serum. These results infer that the differential expression observed with the various 
formulations of complexes occur due to processes distal to cellular uptake.
There has been considerable interest in the cell-specific activity profiles 
observed by the various vectors currently used for gene therapy. Several reports have 
indicated that free plasmid DNA can transfect several tissues in vivo (Wolff et al., 1992; 
Yang and Huang, 1996), which are profiles not mimicked in vitro. Due to the lack of 
correlation observed between in vitro and in vivo activity profiles, there is currently a 
move away from the use of in vitro transfection data in the evaluation of gene therapy 
vectors.
Since these systems were colloidal in nature, properties including the particle 
size and physical stability were assessed. Precipitation of complexes at the bottom of 
the cell culture wells has been suggested as a reason for the unsuitability of in vitro 
uptake and expression studies. This would cause localised high concentrations of 
complexes, altering the distribution patterns within the transfection medium, and hence 
affecting the cellular uptake patterns. The particles were initially sized in water and 
shown to be between 100 - 250 nm. Further analysis in buffers mimicking those used
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for transfection established that electrolytes increased both the particle size and 
heterogeneity of the population of particles. The electrical properties of the complexes 
will induce the formation of an electrical double layer in the presence of positive and 
negative ions in aqueous solution. The presence of these ions during the formation of 
the complexes will affect the interaction between the DNA and the polycations. These 
studies also showed that addition of ions after complex formation in water generated 
larger particles with a less homogeneous population. There was no direct correlation 
observed between complex size and transfection efficiency, although the effect of ions 
on complex preparation is recognised as a critical factor in the physical stability of these 
systems.
Further work.
Further work involving the therapeutic aspects of this study would involve the 
use of the tyrosinase promoter for the restricted expression of genes capable of 
enhancing the immune response towards cancer cells. The development of an in vivo 
murine model to establish the degree of immunostimulation achieved with different 
systems would provide a closer correlation between the experimental outcome and the 
therapeutic profile. Ultimately, the therapeutic study would also involve the use of an 
optimised non-viral vector for the gene delivery.
This study has demonstrated the need for further investigations into the stability 
of the polycation-DNA complexes, both over prolonged time periods, and in biological 
buffers. It would appear that these profiles could be affected by the formulation and the 
method of preparation. The degree of flocculation observed within the systems would
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be likely to affect both the stability and the efficiency of cellular uptake, and hence 
expression.
The physico-chemical properties of the complexes require optimisation for 
cellular uptake. The mechanisms of DNA transport to the nucleus have yet to be fully 
elucidated. Gold labeling of the DNA would allow visualisation using electron 
microscopy during the cellular processing, after internalisation. Parallel labeling of the 
polycation would enable the point of dissociation to be established.
The importance of multifunctional peptides, capable of binding the DNA and 
membrane disruption is becoming more apparent. The design and synthesis of peptides 
incorporating these characteristics plus a nuclear localisation sequence would provide 
invaluable evidence about vector optimisation.
A crucial factor for consideration of the development of gene therapy vectors is 
that many of the effects observed thus far exhibit a large degree of cell-specificity. 
Additionally, a great divide exists between the activity profiles observed in vitro 
compared with in vivo. While, the expense and difficulty of performing mechanistic in 
vivo studies are very large, future work should attempt to concentrate, or at least attempt 
to correlate these two profiles more closely.
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Appendix A. Media and Solutions.
Where appropriate, media and solutions were sterilised by autoclaving for 20 minutes 
at 15 lbs/sq. inch (121 °C) on a liquid cycle. Unless specified, all reagents were 
obtained from Sigma Biochemicals.
B u ffer  P I: 100 pg/m l R Nase A , 50  mM Tris-HCl, 10 mM EDTA , pH 8.0.
B u ffer  P2: 200  mM  NaO H , 1% w/v  SDS.
B u ffer  P3: 3 .0  Potassium  acetate. pH 5.5.
B u ffer  Q B T : 750  mM  NaCl, 50  m M  M OPS, 15% 7 v  ethanol, 0.15%  7 v  Triton X -100 .
B u ffer  QC: 1.0 M  NaCl, 50  m M  M OPS, 15% 7 v  ethanol.
B u ffer  Q F: 1.25 M  N aCl, 50  m M  Tris-HCl, 15% 7 v  ethanol.
C h loro form :isoam yl a lcohol: Chloroform m ixed with isoam yl alcohol 24:1 (A m resco). 
C itra te-P h osp h ate  buffer: 0.1 M  citric acid, 0 .2  M  disodium  phosphate. Ratios varied according to 
pH, as detailed in Table A .I . The pH was adjusted as necessary with HC1 or NaOH.
pH V olum e 0.1M  citric acid (m l) V olum e 0.2M  disodium  phosphate (m l)
4 61.45 38.55




D N A  load in g  buffer: 50  mM  ED T A , 0.2% SD S, 0.05%  w/v  bromophenol blue, 50% glycerol. 
E lectro p o ra tio n  buffer: 25 mM  Hepes, 140 mM KC1, 10 mM N aCl, 2  mM  M gC l2 . 0.5%  Ficoll. 
Filter sterilise using 0 .2  pM  filter.
E th id iu m  B rom ide: 1 m g/m l in double distilled water.
H ep es B u ffered  S a lin e  (H BS): 20  mM Hepes, 150 m M  NaCl, pH 7.4.
L B  m ed iu m  (Luria-Bertani medium): (per litre) lOg Bacto tryptone (D ifco ), 5g  B acto yeast extract 
(D ifco ) and lOg NaCl, pH adjusted to 7 .0  with NaOH. LB plates were prepared from  1 litre o f  LB 
m edium  plus 20g  agar (D ifco).
L o w ry  A: 5% w/v  N a2C 0 3 in double distilled water.
L o w ry  B: 0.5%  w/v  C u S 0 4.5H 20  /  1% NaK  tartrate solution.
O N P G  (2X ) assay  buffer: 1.35 mg/ml o-nitrophenylgalactopyranoside, 2 mM  M gC l2, 100 mM  2- 
m ercaptoethanol, 200  m M  sodium  phosphate, pH 7.3).
P B S: 15 m M  sodium  phosphate, 150 mM sodium  chloride (pH 7.3).
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P en o l/ch loro form : Tris P h e n o l: Chloroform : Isoam yl alcohol 25:24:1 (A m resco).
SO C : 2% B acto tryptone (D ifco), 0.5%  Bacto yeast extract (D ifco), 10 mM NaCl, 2.5 mM  KC1, 10 
m M  M g S 0 4, 20  m M  glucose.
S o d iu m  P h osp h ate  b u ffer  (pH  7.4): 77 .4  ml 1M N a2H P 0 4 solution , 22 .6  m l 1M N aH 2P 0 4 solution. 
S o lu tio n  I (m in ipreps): 50  mM  glucose, 25 mM  Tris, 10 m M  EDTA .
S o lu tio n  II (m in ipreps): 0 .2  N  NaOH, 1% SDS; freshly prepared aseptically from 10 N  N aO H  and 
10% SD S stocks.
S o lu tio n  III (m in ipreps): (per 100 m l) 60  ml 5 M potassium  acetate, 11.5 ml glacial acetic acid, 
ddH 20  28.5  ml.
S T O P  B uffer: 300 mM  glycine, 15 mM  EDTA , pH 11.2.
T B E  ( lx ):  10.8g Tris base, 5 .5g  boric acid, 0 .93g  N a2E D T A .H 20  pH 8.3.
T B S: 150 m M  NaCl, 20  m M  Tris HC1. pH 7.5.
TE: 10 m M  Tris-HCl, 1 m M  E D T A  pH 7.0.
X -G a l so lu tion: 0.2%  X -G al (M elford laboratories), 1 mM M gC l2, 150 mM N aC l, 3 .3  m M  
K4 F e(C N )6, 3.3 mM  K3F e(C N )6.
Z  B uffer: 100 mM  sodium  phosphate, 10 m M  KC1, 1 m M  M gC l2, pH 7.0 .
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Appendix B. Molecular Weight Markers.
For agarose gel electrophoresis, markers consisted of EcoRl/HindlH-cut lanbda DNA 
(Northumbria Biologicals). The digest consists of DNA fragments of the following 
sizes (base pairs):
1: 21226 8: 1584
2: 5148 9: 1375
3: 4973 10: 947
4: 4268 11: 831
5: 3530 12: 564
6: 2027 13: 125
7: 1904
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Appendix C: Calibration curves for quantitative assays.
C.l. MTT assay for K1735 cell number.
Cells were plated at densities ranging from 2.5x103 to 40x103 into 96-well 
plates. The cells were allowed to adhere for 1 hour before assay using the standard 
MTT protocol. A linear Beer-Lambert plot for absorbance (540 nm - 690 nm) was 
obtained (Fig. C.l) with the following linear regression analysis:
Slope = 2.06xl0'2 Intercept =8.64xl0'2 r = 0.996
0.8
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F ig u re  C .l .  Calibration curve for the M TT assay for K 1735 cell number. Each point represents mean 
absorbance value (540  nm - 690  nm) ±  SEM  (n=8). The data are representative o f  tw o experim ents.
C.2. MTT assay for viability of K1735 cells.
The K1735 cells were seeded at a density of 3xl03 cells/well and allowed to 
adhere in complete medium for 4 hours before the addition of 0-5 mg/ml G418, or 0- 
40 |ig/ml puromycin. The cells were assayed after 3 days to establish viability using
rI* 
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the MTT assay, and the cell number determined using the MTT calibration curve for 
K1735 cells (section C.l). The minimum concentration to inhibit cell growth was 
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F igu re  C .l.  K ill curves for the treatment o f  K1735 melanoma cells with the antibiotics G 418 (A ) and 
purom ycin (B ), to establish concentrations required for selection o f stable transfectants.
C.3. MTT assay for B16 cell number.
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Cells were plated at densities ranging from 2.5x103 to 40x103 into 96-well 
plates. The cells were allowed to adhere for 1 hour before assay using the standard 
MTT protocol. A linear Beer-Lambert plot for absorbance (540 nm - 690 nm) was 
obtained (Fig. C.3) with the following linear regression analysis:
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F igu re  C .3 . Calibration curve for the M TT assay for B 16 cell number. Each point represents mean 
absorbance value (540  nm - 690  nm) ±  SEM  (n=8). This data is representative o f  three experim ents.
C.4. Lowry protein assay for cell extracts for ONPG analysis.
A series of BSA solutions in 0.1 M sodium phosphate buffer were prepared 
over the range 0-1.2 mg/ml. The samples were then assayed by the method described 
in section 2.2.20.3. A linear Beer-Lambert plot was obtained for absorbance at 750 
nm (Fig. C.4) with the following linear regression analysis.
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F ig u re  C .4 . Standard curve for Lowry protein assay. Calibration was performed using bovine serum  
album in in 0.1 M  sodium  phosphate buffer at increasing concentrations and measuring the absorbance 
at 7 5 0  nm (section  2 .2 .20 .3).
C.5. ONPG assay for (3-galactosidase activity in cell extracts.
A series of p-galactosidase solutions were prepared in 0.1 M sodium 
phosphate buffer over the range 0-12 milliunits of activity. The stock solution 
contained 1.06 units/ml). The samples were assayed as detailed in section 2.2.20.2. 
A linear Beer-Lambert plot was obtained for absorbance at 420 nm (Fig. C.5) with 
the following linear regression analysis.







S  0.3- 
d)
o
|  0.2 - 
o
CO
<  0.1 -
0.0
0 2 4 86 10 12
p-galactosidase (milliunits)
F ig u re  C .5 . Calibration curve for absorbance at 420  nm versus p-galactosidase activity. The ON PG  
assay reagent (appendix A ) was incubated with increasing quantities o f  P-galactosidase enzym e  
(section  2 .2 .20 .2 ). A bsorbance was measured after 30 minutes.
C.6. Lowry protein assay for cell extracts for MUG analysis.
A series of BSA solutions in Z buffer (appendix A) were prepared over the 
range 0-1.2 mg/ml. The samples were then assayed by the method described in 
section 2.2.20.3. A linear Beer-Lambert plot was obtained for absorbance at 750 nm 
(Fig. C.4) with the following linear regression analysis.
Slope = 0.2194 Intercept = 0.0324 r = 0.995
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F ig u re  C .6 . Standard curve for Lowry protein assay. Calibration was perform ed using bovine serum  
album in in Z  buffer at increasing concentrations and measuring the absorbance at 7 5 0  nm (section  
4 .2 .5 ).
C.l.  MUG assay for p-galactosidase activity in cell extracts.
A series of p-galactosidase solutions were prepared in Z buffer over the range 
0-100 milliunits of activity. The stock solution contained 1.06 units/ml. The 
samples were assayed as detailed in section 4.2.4. A linear Beer-Lambert plot was 
obtained for fluorescence over the range 0-70 milliunits of activity (XeX 350 nm,
450 nm; Fig. C.l) with the following linear regression analysis.
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F igu re  C .7 . F luorescence associated with P-galactosidase activity (A,em 350  nm, Xex 4 5 0  nm). 
Increasing concentrations o f  P-galactosidase enzym e (1 .06 units/ml) w ere incubated with a 30 |il 
aliquot o f  3 mM M U G  assay reagent, as described in section 4 .2 .4 . The fluorescence was measured  
after incubation at 37°C  for 90  minutes.
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Appendix D. Amino acids.
Amino acid. Abbreviation, 
(hydrophilicity).
Code Letter. Mass. Properties
Alanine Ala A 89.09 Neutral, (-0.5)
Arginine Arg R 174.2 Basic, (3.0)
Asparagine Asn N 132.1 Neutral, (0.2)
Aspartic acid Asp D 133.1 Acidic, (3.0)
Cysteine Cys C 121.12 Neutral, (-1.0)
Glutamic acid Glu E 147.13 Acidic, (3.0)
Glutamine Gin Q 146.15 Neutral, (0.2)
Glycine Gly G 75.07 Neutral, (0.0)
Histidine His H 155.16 Basic, (-0.5)
Isoleucine lie I 131.17 Neutral, (-1.8)
Leucine Leu L 131.17 Neutral, (-1.8)
Lysine Lys K 146.19 Basic, (3.0)
Methionine Met M 149.21 Neutral, (-1.3)
Phenylalanine Phe F 165.19 Neutral, (-2.5)
Proline Pro P 115.13 Neutral, (0.0)
Serine Ser S 105.09 Neutral, (0.3)
Threonine Thr T 119.12 Neutral, (-0.4)
Tryptophan Trp W 204.22 Neutral, (-3.4)
Tyrosine Tyr Y 181.19 Neutral, (-2.3)
Valine Val V 117.15 Neutral, (-1.5)
Hydrophilicity value according to Hopp and Woods (1981)
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